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Chapter 1
General introduction
Adapted from:  
Lafeber HN, van de Lagemaat M, Rotteveel J, van Weissenbruch MM 
Timing of nutritional interventions in very low birth weight infants: 
optimal neurodevelopment compared with the onset of the metabolic 
syndrome
Am J Clin Nutr. 2013;98:556S-560S
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General introduction
Of the 177,713 infants born in The Netherlands in 2008, 13,649 (7.7%) newborns were 
born preterm (gestational age <37 weeks), 2,637 (1.5%) newborns were born very 
preterm (gestational age <32 weeks), and 2,456 (1.4%) newborns had a very low birth 
weight (VLBW; birth weight <1,500 gram) [1]. Preterm infants experience the third 
trimester in an extrauterine environment and have a different postnatal growth pattern 
compared to the fetus in utero or the term infant after birth. Postnatal growth patterns 
of preterm infants are, among other factors, related to the availability of nutrients and 
may be associated with long-term metabolic and cardiovascular consequences.
PrenaTaL and PosTnaTaL growTh In PreTerM InfanTs
endocrine regulation of prenatal and postnatal growth
In contrast to growth regulation during infancy and childhood, the endocrine regulation 
of prenatal growth is not growth hormone (GH) dependent. Although fetal GH levels 
are high, GH has little effect on the fetal insulin-like growth factor (IGF) axis [2]. This is 
supported by studies on congenital GH deficiency in humans [3-4] and rodents [5] as 
well as by studies on fetal GH overproduction in mice [5]. These studies demonstrate a 
similar size at birth in subjects with GH deficiency or GH overproduction compared to 
their healthy peers [3-5].
During the first half of pregnancy, several animal models [6-7] as well as associations 
between serum insulin-like growth factor type II (IGF-II) and the degree of fetal growth 
retardation or fetal overgrowth in humans [8-9] indicate that IGF-II is the dominant fac-
tor for fetal growth. IGF-II signal transduction leads to mitogenic and anti-apoptotic ef-
fects and to some cell differentiation via the IGF type I receptor [2]. However, in a mouse 
model, deletion of the IGF-II gene results in growth retardation with a weight 40% lower 
than normal, deletion of the IGF type I receptor gene results in a weight 55% lower 
than normal, whereas combined deletion of the IGF-II and the IGF type I receptor genes 
results in a weight 70% lower than normal [7]. This suggests that, at least in a mouse 
model, IGF-II may also have a growth-promoting effect via another receptor, possibly 
the insulin receptor [10]. Embryonic and early fetal growth is independent of nutrient 
supply because the influence of nutrition on IGF-II is limited [11-12]. The role of IGF-II for 
fetal growth diminishes with advancing gestation and IGF-II is no longer an important 
growth regulator after birth [2]. 
During the second half of pregnancy, there is a shift from IGF-II towards insulin-like 
growth factor type I (IGF-I) as the dominant factor for growth, as supported by animal 
models [6-7] and genetic abnormalities in humans [13-15]. IGF-I exerts its growth-
promoting action by binding to the IGF type I receptor [2, 11] and in part by binding to 
the insulin receptor [10]. The IGF type I receptor has a higher affinity for IGF-I than for 
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IGF-II and the insulin receptor binds IGF-I with an affinity of 1% of the affinity for insulin 
[16]. In contrast to growth regulation by IGF-II during the first half of pregnancy, IGF-I 
and fetal growth are strongly related to nutrition during the second half of pregnancy 
[11-12]. 
Hepatic IGF-I production and secretion are regulated by thyroid hormones, gluco-
corticoids, nutrient supply, and insulin secretion [11-12]. Thyroid hormones directly 
affect IGF-I via modulation of the hepatic IGF-I production [5, 12, 16]. Glucocorticoids 
and nutrient supply influence IGF-I levels, at least to some extent, via insulin. Increased 
endogenous or exogenous fetal glucocorticoids suppress insulin actions and decrease 
IGF-I expression [12]. Furthermore, the availability of nutrients and the resultant insulin 
concentration influence hepatic IGF-I production and secretion. Placental glucose trans-
fer maintains fetal glucose levels, which enhance insulin secretion; insulin stimulates 
hepatic IGF-I production [12]. Thus, in addition to optimal thyroid hormone and gluco-
corticoid levels, adequate insulin concentrations and nutrient supply are necessary to 
maintain fetal growth during the second half of gestation.
Nutrient availability may be compromised by maternal malnutrition, placental dys-
function, impaired uterine blood flow, and impaired fetal nutrient uptake and this may 
result in intrauterine growth restriction (IUGR). The impact of IUGR developed under 
these circumstances (i.e. a nutrient deprived intrauterine environment) is that the fetus 
does not has the ability to grow to its maximal genetic potential [11]. Other factors 
may also influence intrauterine growth, such as genetic factors, parity, maternal age, 
maternal smoking, and gender of the fetus [17].
After birth, fetal growth regulatory mechanisms remain dominant during the first six 
postnatal months [11]. Thereafter, growth regulation shifts from nutrition/insulin/IGF-I 
dependency towards IGF-I/GH dependency due to an increase in GH receptors [2]. GH 
acts on the GH receptors in the liver to stimulate the release of IGF-I, a process that 
is potentiated by insulin [16]. IGF-I acts by binding to the IGF type I receptor and to 
some extent to the insulin receptor to increase somatic growth [10]. IGF-I/GH dependent 
growth allows the individual to attain its full genetic growth potential, while nutrition/
insulin/IGF-I dependent growth allows the influence of the environment, which may 
limit growth.
It has been suggested that preterm infants have a fetal growth regulation during the 
extrauterine third trimester that under optimal circumstances leads to adequate growth 
[12]. However, many postnatal conditions that preterm infants are exposed to, such as 
morbidity and insufficient nutrient availability, may adversely influence growth. More-
over, little is known about the timing of the shift from nutrition/insulin/IGF-I dependent 
growth towards IGF-I/GH dependent growth in preterm infants. As long as growth 
regulation is nutrition dependent, increased nutrient supply stimulates insulin and IGF-I 
release and enhances growth in preterm infants. Insulin primarily enhances adipogen-
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esis [11-12] and the effect on lean mass is mediated through IGF-I [11]. The quantity 
and quality of tissue accretion in early infancy is important with regard to metabolic 
consequences in later life. 
Intrauterine growth patterns
The pattern of intrauterine growth determines the size of the infant at birth. Based on 
weight and length at birth, preterm infants may be born appropriate-for-gestational-age 
(AGA) or small-for-gestational-age (SGA). AGA defines infants that are born with a birth 
weight and a birth length within two standard deviations scores (SDS) of the population 
mean for gestational age (birth weight and birth length ≥-2 SDS and ≤+2 SDS); SGA 
defines infants that are born with a birth weight and/or a birth length at least two SDS 
below the population mean for gestational age (birth weight and/or birth length <-2 
SDS) [18]. In the general population, between 2.3% and 10% of infants are born SGA [17-
18]. In very preterm infants (gestational age <32 weeks), 6.3-26.7% have a birth weight 
below -2 SDS [19-20] and 7% have a birth weight and/or a birth length below -2 SDS [21]. 
Being SGA does not reflect the intrauterine growth pattern but the size at birth of the 
infant compared to the general population [18] because birth weight and birth length 
of an individual infant are interpreted in relation to birth weight and birth length of the 
population. In contrast, IUGR refers to a decline in fetal growth as a result of an underly-
ing pathological process that prevents the fetus to achieve its genetic growth potential 
[17]. Being SGA may be a result of fetal, maternal, or placental causes [18, 22] that lead to 
IUGR; however, SGA also includes infants that are constitutionally small and have a lower 
genetic growth potential. This emphasizes that SGA and IUGR are not synonymous [18]: 
an infant may be born SGA without IUGR and an infant may experience IUGR and be 
born AGA. This difference suggests that an accurate assessment of the reason for being 
SGA is needed by relating the size at birth to the fetal growth potential, which is, among 
other factors, determined by the maternal and parental size, maternal parity, and ethnic-
ity [23]. Although birth weight and birth length are important surrogate markers of the 
intrauterine condition that the fetus was exposed to, these parameters remain indirect 
measures of the growth potential of the fetus [22]. To determine if being small (SGA) 
at birth is a result of a lower genetic growth potential or a consequence of IUGR, fetal 
growth needs to be evaluated by serial ultrasonographic measurements. An SGA infant 
that is small throughout pregnancy is likely to have a lower genetic growth potential, 
whereas an SGA infant that demonstrates a deflection of intrauterine growth at some 
point may be classified as IUGR. The distinction between being constitutionally small 
or having IUGR may be important because it has been suggested that IUGR, even with 
a resultant birth weight within the normal limits, is associated with an increased risk of 
long-term cardiovascular and metabolic consequences, whereas constitutional small-
ness is not [22].
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extrauterine growth patterns
Preterm infants experience the third trimester, when most of the fetal growth takes place, 
in an extrauterine environment. During this extrauterine third trimester, preterm infants 
direct their nutrient expenditure towards surviving several postnatal complications of 
preterm birth at the expense of postnatal growth [24]. Postnatal morbidity increases the 
nutritional demands, which usually are not reached because of limited feeding possibili-
ties. Among these limitations are gut immaturity and limited amounts of total parenteral 
nutrition that are tolerated without complications. In addition, even higher nutritional 
intakes are needed to achieve growth during the third trimester. 
As a result, the disequilibrium between nutrient requirement and nutrient supply leads 
to extrauterine growth restriction (EUGR) of preterm infants during the third trimester. 
Lemons et al. show that up to 97% of VLBW preterm infants have EUGR at discharge 
[25]. During infancy and childhood, preterm infants with early EUGR (i.e. EUGR before 
term age) and SGA preterm infants have a similar growth pattern [17, 24]. At 4-5 years 
of age, approximately 10% of very preterm infants have height <-2 SDS [24] compared 
to a similar percentage of SGA preterm infants [17-18]. As a consequence of the similar 
growth patterns in the early postnatal period and during infancy, it has been hypoth-
esized that preterm infants with EUGR and SGA preterm infants have a comparable risk 
for the development of cardiovascular and metabolic consequences in later life [21, 24].
consequences of PreTerM bIrTh
Prematurity, IUGR, and EUGR are associated with long-term metabolic and cardio-
vascular consequences [26-28]. Furthermore, preterm infants are at risk of decreased 
bone mass [29], deficits in macronutrients and micronutrients, and impaired cognitive 
development [22, 30].
Long-term cardiovascular and metabolic consequences
The ‘developmental origins of adult health and disease’ (DoHaD) concept suggests that 
early life events can alter the risk of diseases in later life, such as diabetes, hypertension, 
and cardiovascular disease. The DoHaD concept originates from the epidemiological ob-
servations that birth weight is inversely related to the risk of cardiovascular disease [31] 
and type 2 diabetes [32]. These associations imply that fetal growth restriction during 
middle and late pregnancy results in disproportional growth and permanent changes 
in body structures and functions that predispose to chronic diseases in adulthood, as 
stated by the ‘fetal origins of disease’ hypothesis [31]. However, the associations are not 
based on a low birth weight per se, as similar relations are found in subjects with a birth 
weight within the normal range [31]. This suggests that a mismatch between the actual 
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size at birth, as a proxy of the growth pattern in utero, and the genetic growth potential 
may explain the increased risk of chronic adult diseases [33].
The changes in body structures and functions may be an adaptive mechanism of the 
fetus and young infant to a nutrient deprived environment. This concept suggests that 
if nutrient availability is decreased, the fetus reduces growth and insulin sensitivity and 
redistributes its blood flow in order to reduce its anabolic demands and to promote 
short-term survival [22, 33]. Thus, the fetus adapts to a nutrient deprived environment. 
After this early adaptation, a mismatch between the predicted future nutrient deprived 
environment and the actual nutrient rich postnatal environment that the infant is ex-
posed to may lead to accelerated growth [34] with increased fat accumulation and the 
infant may develop insulin resistance and cardiovascular disease, as demonstrated in 
animal models [35]. This concept is described by the ‘thrifty phenotype hypothesis’ [36] 
or ‘accelerated growth hypothesis’ [37-38]. 
During the first year of life, increased fat deposition as a result of rapid growth is 
demonstrated in term infants [39-40] and preterm infants [41]. In addition, rapid 
growth during infancy is associated with increased fat deposition and an increased risk 
of adiposity during childhood [42-43] and adulthood [42, 44] in term subjects as well 
as with increased body fat during adulthood in preterm subjects [45]. This may be a 
consequence of tracking of fat mass from infancy to childhood and adulthood [46-47], 
which may be associated with insulin resistance and cardiovascular disease. These 
findings suggest that increased fat accumulation during an early critical window may 
be related to the development of long-term metabolic consequences, such as obesity, 
insulin resistance, increased blood pressure, and cardiovascular disease [48]. Neverthe-
less, although intrauterine as well as early postnatal growth appear to affect the risk of 
long-term cardiovascular and metabolic consequences, the exact critical window for the 
influence of growth and nutrient availability remains unclear [49].
decreased bone accretion
The risk of suboptimal bone mass is increased in preterm infants because they lack the 
intrauterine third trimester when 80% of calcium, vitamin D, and bone accumulation 
takes place [29, 50-51]. Moreover, decreased intrauterine growth may result in even 
lower bone accretion in utero and may explain the lower bone mass in SGA compared 
to AGA preterm infants at birth [52]. Thus, prematurity as well as being SGA is related to 
a bone mass deficit at birth.
Bone accretion can be divided into bone formation and bone mineralization. The 
bone formation phase requires a sufficient supply of amino acids for the synthesis of 
collagen type I that results in bone matrix formation [53]; the bone mineralization phase 
requires a sufficient supply of calcium, phosphorus, and vitamin D to maintain intestinal 
mineral absorption and to add minerals to the bone matrix [29]. During the extrauterine 
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third trimester, it is nearly impossible to achieve protein, mineral, and vitamin D intakes 
that are adequate to reach a bone accretion rate similar to that achieved in utero. As a 
consequence, the bone deficit of preterm infants is further aggravated after birth. This 
is highlighted by lower bone accretion during infancy and childhood in preterm infants 
compared to their term born peers [54-56]. Decreased bone mass in preterm infants is 
related to lower peak bone mass in adulthood [57-59], which is subsequently associated 
with a higher risk of osteoporosis [60]. 
Postnatal deficits in macronutrients and micronutrients
During the extrauterine third trimester, preterm infants have high nutritional require-
ments in order to survive postnatal morbidity and to achieve adequate postnatal 
growth. However, preterm infants encounter several feeding difficulties that limit the 
administration of an adequate amount of nutrients and this results in postnatal deficits 
of macronutrients and micronutrients. During the first postnatal weeks, no or limited 
enteral nutrition is tolerated due to immaturity of the gut and an increased risk of necro-
tizing enterocolitis [61] and, in fact, the nutritional supply in this crucial period depends 
predominantly on total parenteral nutrition. Unfortunately, the amount of nutrients 
that can be administered safely via total parenteral nutrition is also limited. As a conse-
quence, the suboptimal early nutritional intake may result in major cumulative deficits 
of energy and macronutrients, especially of protein, during the first postnatal months. 
Hence, these deficits lead to severe EUGR [62].
In addition to deficits of macronutrients, the limitations of nutritional supply also 
result in deficits of various micronutrients during early postnatal life, such as calcium, 
phosphorus, vitamin D, iron, and long-chain polyunsaturated fatty acids (LC-PUFAs). 
An adequate nutritional supply of calcium, phosphorus, and vitamin D is necessary for 
bone accretion in preterm infants but is difficult to attain. Human milk is low in calcium, 
phosphorus, and vitamin D [63] and, therefore, human milk fortifier is added to increase 
the intake of these micronutrients in preterm infants. Nevertheless, preterm infants fed 
human milk often have lower bone accretion compared to those fed preterm formula 
during the first months of life [64-65], which may be due to persistently lower calcium, 
phosphorus, and vitamin D intakes. 
Furthermore, preterm infants are at risk of iron deficiency because they are deprived 
of the fetal iron accretion of the third trimester and are born with low iron stores [66-67]. 
Postnatally, preterm infants have increased iron requirements as a result of a strongly 
activated erythropoiesis, a shorter life span of fetal and preterm red blood cells, frequent 
blood sampling, and rapid postnatal growth [68]. However, due to inadequate dietary 
iron intake, 25-85% of preterm infants develop iron deficiency during the first year of 
life [68-70]. Prevention of iron deficiency is necessary to maintain erythropoiesis but 
may also be beneficial for growth and neurodevelopment [71-72]. Iron is a key factor in 
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the defense against infections and iron deficiency has been associated with impaired 
cell-mediated immunity and bactericidal function by in vitro studies. However, these 
findings remain controversial as no significant benefits of iron supplementation on 
immunity and infection reduction have been demonstrated in vivo [73]. In addition, 
virtually all pathogens, such as bacteria, protozoa, and viruses, depend on iron for their 
growth [74] and this might suggest that higher dietary iron intake increases the risk of 
infection in preterm infants. On the other hand, several studies have demonstrated that 
an increased dietary iron intake is safe with regards to severe infections [75]. The low 
iron stores of preterm infants at birth are usually depleted six to eight weeks after birth. 
Therefore, to prevent iron deficiency in preterm infants, an elemental iron intake of 2-4 
mg/kg/d is recommended between 6 weeks and 12 months postnatal age [76], which 
can be achieved with iron-fortified formulae or with enteral iron supplementation.
Similar to iron, LC-PUFAs are important for central nervous system development [77-
78] and possibly for growth [79], although the effect on growth remains controversial 
[80-81]. In particular, the LC-PUFAs docosahexaenoic acid (DHA) and arachidonic acid 
(AA) are important. LC-PUFA stores of preterm infants are low at birth because the 
intrauterine third trimester when most of the LC-PUFA accretion occurs is lacking [67]. 
To prevent LC-PUFA deficiency, the European Society of Paediatric Gastroenterology 
Hepatology and Nutrition (ESPGHAN) recommends 0.25-0.45 g% DHA and 0.38-0.64 g% 
AA in preterm formula [82-83]. Nevertheless, the dietary supply of LC-PUFAs during the 
first postnatal months is usually insufficient, which results in an increasing deficit that 
may be associated with reduced postnatal growth and impaired neurodevelopmental 
outcome. 
nuTrITIonaL InTervenTIons In PreTerM InfanTs
With regard to the postnatal deficits in macronutrients and micronutrients that contrib-
ute to EUGR, decreased bone accretion, and impaired neurological outcome, in-hospital 
as well as postdischarge nutritional interventions in preterm infants should aim to 
prevent and correct these postnatal deficits. Furthermore, such interventions should 
lead to adequate growth during a critical window, while they prevent excessive fat ac-
cumulation that is associated with cardiovascular and metabolic disease in later life.
In-hospital nutritional interventions
During the first postnatal weeks, when no or only limited enteral nutrition is tolerated 
by preterm infants, total parenteral nutrition has a key role in preventing nutritional 
deficits. To prevent hypoglycemia and to enable energy utilization, intravenous glucose 
administration is initiated immediately after birth [84]. Controversy exists on the time of 
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initiation and the dose of intravenous protein and lipids because of fear of complications. 
Whereas some studies demonstrate that early high parenteral protein administration to 
preterm infants leads to uraemia [85-86], others advocate that early administration of 
an improved amino acid composition of total parenteral nutrition prevents postnatal 
growth restriction in preterm infants [87-88] without the development of hyperam-
monaemia or uraemia [89-90]. A recent study demonstrates that improved growth 
is achieved when preterm infants receive total parenteral nutrition with a relatively 
high protein content directly after birth [62]. With this early high protein administra-
tion, cumulative protein deficits are prevented [62]. Similarly, a recent meta-analysis 
demonstrates that early initiation of intravenous lipids is safe and well-tolerated [91]. 
After several days, enteral nutrition is initiated and gradually increased, while it is still 
supported by parenteral nutrition until enteral nutrition is adequate and can be used as 
the sole source of nutrition [61]. 
The recommendations for energy and nutrient intake aim to achieve a postnatal 
weight gain of preterm infants similar to weight gain in utero. This can be achieved with 
an energy intake of >100 kcal/kg/d, a protein intake of >3 g/kg/d, and a protein-energy 
ratio of 3 g protein per 100 kcal [82]. In addition, the supply of energy and protein needs 
to compensate the cumulative energy and protein deficits that are observed in almost 
all preterm infants, and, therefore, an energy intake of 110-135 kcal/kg/d and a protein 
intake of 3.5-4.0 g/kg/d are recommended [82]. Carbohydrates are a major source for 
energy synthesis as well as for de novo synthesis of fatty acids and nonessential amino 
acids. For preterm infants, a carbohydrate intake of 11.6-13.2 g/kg/d is recommended 
[82]. Furthermore, adequate administration of lipids is necessary to provide energy, 
essential LC-PUFAs, and lipid soluble vitamins. The minimum fat intake is estimated at 
3.8-4.8 g/kg/d to meet the daily intrauterine fat deposition as well as the fat loss from 
malabsorption and conversion. To compensate for a cumulative deficit that might al-
ready have developed in preterm infants in early life, a lipid intake of 4.8-6.6 g/kg/d is 
advised with a DHA intake of 12-30 mg/kg/d, an AA intake of 18-42 mg/kg/d, and a DHA/
AA ratio between 1.0 and 2.0 [82]. 
In addition to an adequate macronutrient intake, in-hospital nutritional interventions 
should aim to achieve sufficient micronutrient administration. During early postnatal 
life, this is achieved by mineral and vitamin supplementation via total parenteral nutri-
tion. When enteral nutrition is the sole nutritional source, minerals and vitamins are 
available from either human milk fortifier or preterm formula. Calcium, phosphorus, and 
vitamin D are important micronutrients for bone accretion in preterm infants. To ensure 
adequate bone mineralization, a calcium retention of 60-90 mg/kg/d is necessary [29]. 
This requires a calcium intake of 120-140 mg/kg/d and a phosphorus intake of 60-90 mg/
kg/d in preterm infants based on a calcium absorption of 50-65%, a phosphorus absorp-
tion of 90%, and a calcium/phosphorus ratio between 1.5 and 2.0 [82]. Several studies 
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demonstrate that vitamin D improves calcium absorption [92] and, therefore, a vitamin 
D intake of 800-1000 IU/d is recommended for preterm infants [82]. Furthermore, as 
stated previously, an elemental iron intake of 2-4 mg/kg/d from iron-fortified formulae 
or enteral iron supplementation is recommended between 6 weeks and 12 months 
postnatal age to prevent iron deficiency in preterm infants [76]. To date, however, cumu-
lative deficits of macronutrients and micronutrients as well as EUGR and decreased bone 
accretion cannot be fully prevented with the in-hospital feeding regimens used [93]. 
nutritional interventions after discharge
After hospital discharge, adequate nutrition is important to achieve an optimal body 
composition and to prevent further deficits in macronutrients and micronutrients 
that contribute to growth faltering and insufficient bone accretion [93]. Human milk is 
preferred for preterm infants after discharge because it has several beneficial effects, 
for example on immune status and on weight gain composition, which results in lower 
fat mass in later life. However, when human milk is not available, the ESPGHAN recom-
mends the use of specialized postdischarge nutrition in preterm infants until at least 
40-52 weeks postconceptional age [94] and advises that this postdischarge nutrition 
contains 72-74 kcal/100 ml, 1.8-1.9 g protein/100 ml (2.5 g/100 kcal), and 70-80 mg 
calcium/100 ml [94].
Some studies show that preterm infants fed high-energy, high-protein postdischarge 
formulae (per 100 ml: energy 72-81 kcal, protein 1.85-2.3 g) have better growth during 
infancy compared to those fed standard term formulae (per 100 ml: energy 55-68 kcal, 
protein 1.4-1.7 g) [95-98]. However, this may be attributed to increased fat deposition 
during the first six months post-term [96, 99], which may be directly related to the higher 
energy intake [100-101]. In contrast, a recent study [102] as well as a recent Cochrane 
meta-analysis, which included 15 trials (1128 preterm infants) [103], demonstrate no 
clear benefit of high-energy, high-protein postdischarge formulae (per 100 ml: energy 
>72 kcal, protein >1.7 g) on growth and body composition during infancy. These incon-
sistent results may be due to differences in methodology and patient cohorts between 
the included studies. In addition, the high-energy, high-protein postdischarge formulae 
used in the studies did not only differ in energy and protein content but also in the 
composition of other macronutrients and micronutrients, such as fat, minerals, and 
vitamins [95-98, 102-103]. The differences in these other nutrients may, at least to some 
extent, explain the inconsistent effects of postdischarge formulae on growth and body 
composition.
Postdischarge nutrition that, in addition to energy and protein, is supplemented with 
calcium, phosphorus, and vitamin D may also improve bone accretion. After discharge, 
some studies show that preterm infants fed high-energy, protein- and mineral-enriched 
formulae reach a higher bone mineral content (BMC) compared to preterm infants fed 
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standard term formulae [96, 104-105], whereas others did not find a positive effect 
of such formulae on bone accretion [64, 106]. This controversy may be related to dif-
ferences in formula composition and patient cohorts. Moreover, although a positive 
effect of an isocaloric, protein- and mineral-enriched formula on bone accretion has 
been demonstrated before term age [107], it remains to be elucidated if an isocaloric, 
protein- and mineral-enriched postdischarge formula has a similar beneficial effect on 
bone accretion after term age. 
In addition, postdischarge nutrition is fortified with iron to provide an adequate iron 
intake to preterm infants. If preterm infants are fed human milk, iron supplementation is 
advised until 12 months of age according to the current guidelines [76]. The exact iron 
content of postdischarge formula that is needed to prevent iron deficiency in preterm 
infants remains controversial, as iron absorption from formula is problematic due to 
decreased intestinal resorption of iron from formula. A previous study demonstrated 
that a formula fortified with 0.5-0.9 mg iron/100 ml leads to iron deficiency in 2.5% of 
the infants at two months post-term and in 14.3% of the infants between two and six 
months post-term [108]. This might suggest that a postdischarge formula with a higher 
iron content prevents iron deficiency even further if the solubility of iron within the for-
mula as well as the intestinal absorption of iron from the formula is taken into account, 
although both are influenced by several other factors.
concLusIon
Early optimal nutritional intake may prevent deficits in macronutrients and micronu-
trients that are related to growth faltering, decreased bone mineral accretion, iron 
deficiency, and neurological impairment as well as to increased fat accumulation and 
concomitant long-term cardiovascular and metabolic consequences. Nevertheless, as 
long as nutrition cannot be optimized in all preterm infants during the first months of 
life, specialized postdischarge nutrition has a key role in the nutritional management of 
preterm infants after discharge in order to prevent further EUGR and to limit fat accumu-
lation, which is associated with long-term cardiovascular and metabolic consequences. 
However, the extent to which specialized postdischarge nutrition compensates the bone 
and micronutrient deficits of preterm infants remains to be elucidated. Furthermore, a 
better understanding of the effect of the prenatal and the early postnatal trajectory on 
growth, bone accretion, and body composition acquisition of preterm infants during the 
first six months post-term is important because SGA preterm infants and preterm infants 
with early EUGR may benefit from specialized postdischarge nutrition. 
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Objective and aims
This thesis focuses on the effects of the prenatal growth trajectory, the early postnatal 
growth trajectory, and postdischarge nutrition on growth, body composition, and bone 
accretion of preterm infants during the first half of infancy. It is based on a single-blinded 
randomized controlled trial in preterm infants entitled “Study Towards the Effects of 
Postdischarge nutrition on growth and body composition of infants born ≤32 weeks 
gestational age and/or ≤1,500 gram birth weight (STEP)” [1]. This chapter describes the 
design and main results of the STEP as well as the aims and outline of this thesis.
sTudy Towards The effecTs of PosTdIscharge nuTrITIon (sTeP)
The hypothesis of the STEP was that a postdischarge formula with a similar energy 
content and a higher protein, mineral, and vitamin content compared to standard term 
formula improved the quality of growth by preventing increased fat deposition because 
protein intake is associated with lean mass accretion [2]. The STEP evaluated the effect 
of postdischarge formula (PDF), standard term formula (TF), and human milk (HM) on 
growth and body composition between term age (i.e. 40 weeks postmenstrual age) and 
six months corrected age (CA) [1].
study design
Between 2003 and 2006, infants born at a gestational age of 32 weeks or less and/or 
with a birth weight of 1,500 gram or less were considered eligible for the STEP (Figure 
2.1). Exclusion criteria were congenital malformations or conditions known to affect 
growth or body composition. At term age, 152 preterm infants were included and at six 
months CA, 139 preterm infants (52 PDF, 41 TF, and 46 HM fed infants) completed the 
study (Figure 2.1).
Between birth and term age, preterm infants were fed 150 ml/kg/d preterm formula or 
fortified human milk (Figure 2.1 and Figure 2.2). The type of feeding between birth and 
term age could not be determined in two infants due to missing data. At term age, 102 
formula fed infants were randomized to PDF or TF and were fed the study formulae until 
six months CA (Figure 2.1 and Figure 2.2). PDF provided a similar quantity of energy and 
a higher quantity of protein, minerals, vitamins, and LC-PUFAs compared to TF (Appen-
dix A). Fifty preterm infants that were fed predominantly (>80%) HM at term age were 
considered to be HM fed and were supplemented with 200 IU vitamin D per day. If HM 
was insufficiently available, HM fed infants were fed TF additionally. Supplements that 
provided additional energy were limited before term age and were not allowed thereaf-
ter. The introduction of complementary feeding was discouraged until five months CA 
and was limited to fruit and vegetables. Between term age and six months CA, parents 
recorded their infant’s weight (g), volume intake (ml/d), the type of intake (PDF, TF, or 
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HM), any supplements, and any changes in their infant’s daily intake in a diary once per 
week. In PDF and TF fed infants, total volume intake (ml/kg/d), energy intake (kcal/kg/d), 
and protein intake (g/kg/d) were calculated based on the infant’s weight, volume intake, 
and the formula composition (Appendix A).
ELIGIBLE:
450 infants 
(GA ≤32 wk and/or BW ≤1,500 g)
298 infants not included
 77 did not meet inclusion criteria
 150 no informed consent
 52 deceased
 19 other reasons
RANDOMIZATION:
102 formula fed infants
50 human milk (HM)
INCLUDED:
152 preterm infants
Did not follow study protocol:
 1 insufficient HM
 1 renal insufficiency
 1 failure to thrive
 1 hydrocephalus
46 HM fed infants 
completed study protocol
41 TF fed infants 
completed study protocol
52 PDF fed infants 
completed study protocol
2 did not follow study protocol:
 2 withdrawal informed consent
7 did not follow study protocol:
 2 withdrawal informed consent
 4 deviation feeding protocol
 1 renal insufficiency
54 postdischarge formula (PDF) 48 standard term formula (TF)
BIRTH
TERM AGE
6 MONTHS CA
NOT RANDOMIZED:
50 human milk fed infants
65 Preterm formulaa 80 Fortified human milkb7 missing data 
(1 TF and 1 HM)
figure 2.1. STEP subject recruitment and inclusion
BW: birth weight; CA: corrected age; GA: gestational age; HM: human milk; PDF: postdischarge formula; TF: term 
formula. a 39 PDF- and 26 TF-fed infants; b 13 PDF-, 18 TF-, and 49 HM-fed infants.
Fortified human milk
Preterm formula
Preterm formula Postdischarge formula
Term formula
Human milk
Birth Term age 3 months 
corrected age
6 months 
corrected age
figure 2.2. Study design of the STEP
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Gestational age at birth was extracted from the infant’s medical record. At birth, term 
age, three and six months CA, weight, length, and head circumference were measured 
and expressed as standard deviation scores (SDS) based on references for preterm 
infants at birth and term age [3] and based on references for Dutch infants at three and 
six months CA [4]. At term age and six months CA, lean mass (LM; g) and fat mass (FM; g) 
were measured by dual-energy x-ray absorptiometry (DXA; Hologic QDR 4500A, Hologic 
Inc., Bedford, MA, USA) and analyzed by Infant Whole Body Software version 12.3.3.
Main results
At birth and term age, weight, length, head circumference, and body composition were 
not different between PDF and TF fed infants (Table 2.1 and Table 2.2). Between term age 
and six months CA, protein intake was higher in PDF compared to TF fed infants (Figure 
2.3), whereas volume intake and energy intake were similar. At six months CA, PDF fed 
infants had similar weight SDS, length SDS, and head circumference SDS compared to TF 
fed infants (Chapter 8, Figure 8.2). However, PDF fed infants had a lower %FM compared 
to TF fed infants (Table 2.2). During the first six months post-term, PDF fed infants gained 
more LM and less FM compared to TF fed infants (Table 2.2). In addition, post-hoc analy-
ses indicated that boys and preterm infants with EUGR benefited from PDF, as they had a 
lower gain in FM during the first six months post-term when fed PDF compared to TF [1].
Table 2.1. Characteristics of PDF, TF, and HM fed infants at birth and term age
PDF
(n=52)
TF
(n=41)
HM 
(n=46)
Boys1 51.9% 56.1% 45.7%
Birth
Postmenstrual age (wk) 30.7 (1.5) 30.9 (2.3) 30.0 (1.9)
Weight (g) 1344 (483) 1394 (262) 1345 (605)
Length (cm) 38.0 (4.0) 38.3 (3.0) 38.0 (3.5)
Head circumference (cm) 27.9 (2.5) 28.0 (2.1) 28.0 (2.8)
Term age
Postmenstrual age (wk) 40.6 (1.1) 40.3 (0.9) 40.6 (0.7)
Weight (g) 3173 (699) 3090 (603) 3158 (734)
Length (cm) 49.0 (3.0) 48.5 (3.0) 48.3 (2.6)
Head circumference (cm) 35.9 (1.4) 35.8 (1.6) 35.8 (2.3)
Values expressed as median (interquartile range), unless specified otherwise. Linear regression adjusted for 
gender and gestational age showed no significant differences between PDF, TF, and HM fed infants. 1 frequency 
(%); chi-square test showed no significant differences between PDF, TF, and HM fed infants. HM: human milk; 
PDF: postdischarge formula; TF: term formula. 
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conclusion
It was concluded that preterm infants fed the isocaloric, protein- and mineral-enriched 
PDF used in the STEP have similar growth with less fat mass gain and more lean mass 
gain during the first six months post-term compared to preterm infants fed TF [1].
aIMs of ThIs ThesIs
The first aim of this thesis was to study the effects of the prenatal and early postnatal 
growth trajectory on growth, body composition, and bone accretion during the first 
Table 2.2. Body composition of PDF and TF fed infants between term age and six months CA
PDF 
(n=43)
TF 
(n=34)
PDF vs. TF1
Term age
LM (kg) 3.04 ± 0.43 3.07 ± 0.41 n.s.
FM (kg) 0.24 (0.12;0.45) 0.30 (0.18;0.46) n.s.
%FM 6.8 (4.5;11.9) 8.3 (5.5;12.4) n.s.
6 months CA
LM (kg) 5.78 ± 0.62 5.64 ± 0.62 n.s.
FM (kg) 1.85 (1.32;2.28) 2.01 (1.63;2.42) n.s.
%FM 23.6 ± 7.1 26.8 ± 6.2 0.043
Term age-6 months CA
Gain in LM (g/kg/d) 2.00 ± 0.39 1.81 ± 0.31 0.022
Gain in FM (g/kg/d) 1.08 (0.84;1.34) 1.14 (1.02;1.53) 0.050
Values expressed as median ± SD or median (P25;P75). 1 P-value of unpaired t-test. CA: corrected age; FM: fat 
mass; HM: human milk; LM: lean mass; n.s.: not significant; PDF: postdischarge formula; TF: term formula. 
figure 2.3. Protein intake (g/kg/d) between term age and six months corrected age in postdischarge 
formula (PDF; white) and term formula (TF; grey) fed infants
Tukey boxplots. PDF: postdischarge formula; TF: term formula. For all weeks, Mann-Whitney U test showed higher 
protein intake in PDF compared to TF fed infants, P<0.05 [unpublished data].
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Objective and aims
half of infancy (Part I). The regulation of postnatal growth of preterm infants by the 
endocrine growth regulators IGF-I and insulin was investigated in relation to nutrient 
intake during the first six months post-term. In addition, the effect of being SGA (birth 
weight, birth length, or both <-2 SDS) on growth, body composition, and bone accretion 
between term age and six months CA was evaluated and it was investigated if this effect 
was modified by nutritional intake or the type of postdischarge nutrition. The second 
aim of this thesis was to study the effects of postdischarge nutrition on growth, LC-PUFA 
status, bone accretion, vitamin D status, and the incidence of iron deficiency of preterm 
infants between term age and six months CA (Part II).
ThesIs ouTLIne
The thesis outline is summarized in Figure 2.4. Part I (chapter 3-6) focuses on the ef-
fects of the prenatal and postnatal growth trajectory. chapter 3 reports on the role of 
IGF-I and insulin in growth regulation of preterm infants during the first half of infancy. 
chapter 4 describes the body composition between term age and six months CA of 
SGA preterm infants and AGA preterm infants with EUGR and without EUGR before term 
age. chapter 5 reports on the bone accretion of SGA compared to AGA preterm infants 
during the first six months post-term. chapter 6 shows the relation between growth, 
bone accretion, and procollagen type I N-terminal peptide (PINP), a marker of collagen 
type I synthesis, in SGA and AGA preterm infants between term age and six months CA.
Part II (chapter 7-10) focuses on the effects of postdischarge nutrition. chapter 
7 demonstrates the effects of PDF, TF, and HM on bone accretion during the first six 
months post-term. chapter 8 describes LC-PUFAs in relation to growth of preterm 
infants between term age and six months CA. chapter 9 shows the effects of PDF, TF, 
and HM on vitamin D status of preterm infants during the first six months post-term. 
Preterm birth 
1st trimester 
Term age 6 months 
corrected age 
3rd trimester 
In-hospital nutrition 
Postnatal (growth) trajectory Postdischarge nutrition 
Growth 
Body composition 
Bone accretion 
Intrauterine (growth) trajectory 
LC-PUFA Vitamin D 
2nd trimester 
figure 2.4. Thesis outline
LC-PUFA: long-chain polyunsaturated fatty acid
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chapter 10 reports on the incidence of iron deficiency in PDF, TF, and HM fed preterm 
infants during the first half of infancy. 
chapter 11 discusses the findings and implications of this thesis in relation to the 
current literature and provides suggestions for future research. chapter 12 summarizes 
the findings of this thesis in English and Dutch, respectively.
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Prenatal and postnatal growth 
of preterm infants
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Chapter 3
Growth in preterm infants until six months 
post-term: the role of insulin and IGF-I
Monique van de Lagemaat, Joost Rotteveel, Annemieke C. Heijboer, 
Harrie N. Lafeber, Mirjam M. van Weissenbruch
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absTracT
background/aims
Since insulin-like growth factor type I (IGF-I) and insulin regulate growth in term infants, 
they were studied in relation to nutrient intake and growth until 6 months corrected age 
(CA) in preterm infants.
Methods
In 138 preterm infants (51% male, gestational age [expressed as median (IQR)] 30.6 
(1.9) weeks, birth weight 1368 (389) g), weight SDS, length SDS, IGF-I, and insulin were 
measured at term age, 3 and 6 months CA.
results
IGF-I and insulin at term age were associated with weight SDS and length SDS at term 
age and 3 months CA. IGF-I and insulin at 3 months CA were associated with weight 
SDS and length SDS at 3 and 6 months CA. IGF-I and insulin at term age were negatively 
associated with gain in weight SDS and gain in length SDS between term age and 6 
months CA (IGF-I: β=-1.03, 95% CI -1.65;-0.41, p=0.001 and β=-0.78, 95% CI -1.32;-0.23, 
p=0.005; insulin: β=-0.19, 95% CI -0.37;-0.01, p=0.044 and β=-0.18, 95% CI -0.35;-0.01, 
p=0.035). Nutrient intake was not associated with IGF-I or insulin.
conclusions
The present study suggests that IGF-I and insulin are important growth regulators in 
preterm infants until 6 months CA, independent of nutrient intake.
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InTroducTIon
Postnatal growth restriction is common in preterm infants and is usually explained by 
postnatal morbidity in combination with insufficient nutrient intake. Postnatal growth 
is mainly regulated by nutrients, insulin, and insulin-like growth factor type I (IGF-I). Suf-
ficient nutrient supply and adequate insulin action are important for fetal IGF-I produc-
tion, indicating a linkage between growth and nutrient availability [1-2]. In term infants, 
IGF-I levels are associated with postnatal growth and protein intake during infancy [3-8].
In preterm infants, IGF-I levels are associated with protein intake until term age (40 
weeks postmenstrual age) [9-13] and with postnatal growth until 6 months corrected 
age (CA) [14]. Little attention has been devoted to IGF-I and insulin in relation to growth 
and nutrient intake in preterm infants after term age. We hypothesized that IGF-I levels 
and insulin levels were positively related to nutrient intake and growth until 6 months 
CA in preterm infants. Therefore, the present study investigated IGF-I levels and insulin 
levels between term age and 6 months CA in relation to nutrient intake and growth 
between birth and 6 months CA in preterm infants.
MeThods
subjects
The present study was an observational analysis within a randomized controlled trial 
that evaluated the effects of postdischarge formula, term formula, and human milk on 
growth and body composition of preterm infants, as described in detail elsewhere [15]. 
In short, 152 infants with a gestational age ≤32 weeks and/or a birth weight ≤1,500 g 
were included shortly after birth [15]. The present study combined nutritional data with 
anthropometry, serum IGF-I levels, and serum insulin levels. The infants attended our 
outpatient clinic at term age (40.3 ± 0.7 weeks postmenstrual age), 3 months CA (53.0 ± 
0.5 weeks postmenstrual age), and 6 months CA (66.0 ± 0.5 weeks postmenstrual age). 
At 6 months CA, 139 preterm infants completed the study. 13 infants did not complete 
the study for different reasons (withdrawn by parents (n=4), incorrect feeding protocol 
(n=5), renal disease (n=2), failure to thrive (n=1), and hydrocephalus (n=1)). In 1 infant, 
length at 6 months CA was not measured due to a body cast for developmental hip 
dysplasia. Therefore, 138 infants were included in the analyses of the present study (51% 
boys, gestational age [expressed as median (interquartile range)] 30.6 (1.9) weeks (range 
25.3-32.9 weeks), birth weight 1,368 (389) g (range 710-2,065 g)).
The study protocol was approved by the ethics committee of VU University Medical 
Center, Amsterdam, The Netherlands. All the parents of the participating children gave 
written informed consent.
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anthropometry and severity of illness
At birth, term age, and 3 and 6 months CA, a single research nurse measured weight 
(g) with a digital scale to the nearest 1.0 g, length (cm) with a length board to the 
nearest 0.1 cm, and head circumference (cm) with a non-stretchable measuring tape 
to the nearest 0.1 cm, as described previously [15]. To adjust for postmenstrual age and 
gender, weight, length, and head circumference were expressed as standard deviation 
score (SDS) based on Swedish references for preterm infants at birth and term age [16] 
and as SDS based on Dutch references at 3 and 6 months CA [17]. Unfortunately, Dutch 
references for weight, length, and head circumference of preterm infants at birth and 
term age were not available. Gain, expressed as ΔSDS, in weight, length, and head 
circumference was calculated for the following intervals: birth-term age, birth-3 months 
CA, birth-6 months CA, term age-3 months CA, term age-6 months CA, 3-6 months CA. 
During hospital admission, the Neonatal Therapeutic Intervention Scoring System was 
used to evaluate severity of illness. The Neonatal Therapeutic Intervention Scoring Sys-
tem has a maximum score of 130 and is a valid indicator of severity of illness in neonates, 
independent of birth weight [18].
hormone level analyses
At term age and at 3 and 6 months CA, fasting venous blood samples were collected for 
IGF-I and insulin level analyses and mean fasting duration was recorded as the interval 
between blood sampling and the last feed before blood sampling. Mean fasting duration 
was 3.4 ± 0.7 h at term age, 3.6 ± 0.7 h at 3 months CA, and 3.5 ± 0.7 h at 6 months CA. 
Serum was stored at -80oC and serum IGF-I and insulin level analyses were performed at 
two time-points.
IGF-I concentrations (nmol/l) were measured using two different methods as the lo-
cal assay changed. In 80 infants, IGF-I levels were determined using one immunoassay 
(Advantage, Nichols Diagnostics, Capistrano, Calif., USA) with an intra-assay variation of 
<6%, an inter-assay variation of <8% for the whole range, and a lower limit of quantifica-
tion of 2 nmol/l. In 59 infants, IGF-I levels were measured using another immunoassay 
(Immulite 2500, Siemens Diagnostics, Deerfield, IL., USA) with an intra-assay variation of 
<5%, an inter-assay variation of <8% for the whole range, and a lower limit of quantifica-
tion of 3.2 nmol/l. All measurements were performed at the Endocrine Laboratory of 
VU University Medical Center, Amsterdam, The Netherlands. Since a comparison of the 
two methods by regression analysis, as described by Passing and Bablok [19], resulted 
in the following formula: Immulite=0.99*Advantage+1.2 and showed a correlation coef-
ficient of 0.99, we decided that IGF-I levels measured by both methods were comparable 
and could be analyzed together in the present study. IGF-I levels were available from 
129 preterm infants at term age, 132 preterm infants at 3 months CA, and 126 preterm 
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infants at 6 months CA. The difference in IGF-I levels was calculated for the following 
intervals: term age-3 months CA and 3-6 months CA.
Insulin concentration (pmol/l) was measured using an automated immunoassay (Ad-
via Centaur, Siemens Medical Solutions, USA) with an intra-assay variance of <4% and 
an inter-assay variance of <8% for the whole range. At 3 and 6 months CA, 1 infant was 
excluded from the insulin level analysis, because blood samples were collected within 2 
h after feeding. Insulin levels were available from 135 preterm infants at term age, 134 
preterm infants at 3 months CA, and 134 preterm infants at 6 months CA.
nutritional intake
Between birth and term age, infants were fed preterm formula (n=61) or fortified human 
milk (n=75) and in 2 infants the type of diet could not be classified due to missing data. 
Between term age and 6 months CA, infants were fed postdischarge formula (n=51), 
term formula (n=41), or human milk (n=46) [15]. Complementary feeding was not in-
troduced before 5 months CA. If it was introduced between 5 and 6 months CA, it was 
limited to fruits and vegetables once a day.
Between birth and discharge, details on enteral and parenteral intake were col-
lected from the daily log in each infant’s medical record by one single person. Between 
discharge and 6 months CA, parents recorded their child’s intake in a diary. Between 
discharge and term age, parents recorded their child’s intake daily; between term age 
and 6 months CA, they recorded their child’s intake 1 day per week and indicated if the 
amount of formula given per day changed at any time during the week. The medical 
records and parental diaries provided information about type and amount of intake 
(ml). Before term age, human milk fed infants were predominantly bottle-fed and of 
these infants the amount of enteral intake was recorded. After term age, human milk 
fed infants were breast-fed and their exact enteral intake was unknown. The available 
information on the amount of intake was used to calculate total parenteral and enteral 
volume intakes (ml/kg/day) between birth and 6 months CA. The mean intakes of energy 
(kcal/kg/day), carbohydrate (g/kg/day), fat (g/kg/day), and protein (g/kg/day) between 
birth and 6 months CA were calculated based on the total volume intake (ml/kg/day), 
the composition of parenteral fluids and infant formulas, an estimated composition of 
unfortified human milk (per 100 ml: 68 kcal, 1 g protein, 4 g fat, 7 g carbohydrates), and 
the composition of breast milk fortifier (per 100 g: 361 kcal, 19 g protein, 71.5 g carbohy-
drates) [20]. Between birth and term age, energy, fat, and protein intakes were available 
from 135 infants (61 preterm formula fed infants and 74 fortified human milk fed infants) 
and carbohydrate intake was available from 127 infants (56 preterm formula fed infants 
and 71 fortified human milk fed infants). Energy, fat, protein, and carbohydrate intakes 
were available from 90 formula-fed infants between term age and 3 months CA and 
from 91 formula-fed infants between 3 and 6 months CA.
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statistics
Gestational age, severity of illness, IGF-I levels, insulin levels, and nutritional intake 
were natural log transformed and described as median with IQR. The other variables 
were normally distributed and described as mean ± SD. Changes in weight SDS, length 
SDS, and head circumference SDS were evaluated by generalized estimating equations 
adjusted for gender and gestational age for the following intervals: birth-term age, term 
age-3 months CA, 3-6 months CA, term age-6 months CA. Changes in insulin levels and 
IGF-I levels were evaluated by generalized estimating equations adjusted for gender 
and gestational age for the following intervals: term age-3 months CA, 3-6 months CA, 
and term age-6 months CA. Associations between insulin levels, IGF-I levels, growth, 
and nutrient intake were evaluated by linear regression analyses, adjusted for gender 
and gestational age. Insulin levels were adjusted for mean fasting duration. P<0.05 was 
considered significant. All statistical analyses were performed in SPSS 17.0 for Windows 
(SPSS, Inc., Chicago, Ill., USA).
resuLTs
growth, Igf-I levels, and insulin levels
Weight SDS and length SDS decreased between birth and term age and increased 
between term age and 3 months CA, and length SDS showed an additional increase 
between 3 and 6 months CA (Figure 3.1). Head circumference SDS increased between 
birth and term age and decreased between term age and 3 months CA (Figure 3.1). IGF-I 
levels and insulin levels increased between term age and 3 months CA and IGF-I levels 
showed a further increase between 3 and 6 months CA (Figure 3.2).
figure 3.1. Weight SDS (A), length SDS (B), and head circumference SDS (C) between birth and 6 months 
CA
Tukey boxplots. Differences in weight SDS, length SDS, and head circumference SDS between time-points were 
evaluated by generalized estimating equations adjusted for gender and gestational age; similar letters indicate a 
significant difference between time-points, P<0.01.
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associations between Igf-I levels, insulin levels, and growth parameters at 
term age, 3 and 6 months ca
IGF-I levels and insulin levels were associated with weight SDS and length SDS at term 
age and at 3 and 6 months CA (Table 3.1 and Table 3.2). Insulin levels were associated 
with IGF-I levels at term age and at 3 months CA (β=0.12, 95% CI 0.06-0.18, p<0.001 and 
β=0.20, 95% CI 0.08-0.31, p=0.001, respectively), but not with IGF-I levels at 6 months 
CA. The associations between insulin and IGF-I levels at term age and 3 months CA 
remained significant after adjustment for severity of illness, type of diet, and nutritional 
intake (data not shown).
figure 3.2. IGF-I (nmol/l) (A) and insulin levels (pmol/l) (B) between term age and 6 months CA
Tukey boxplots. Differences in IGF-I and insulin levels between time-points were evaluated by generalized 
estimating equations adjusted for gender and gestational age; similar letters indicate a significant difference 
between time-points, P<0.01.
Table 3.1. IGF-I levels in relation to growth parameters at term age, 3 and 6 months CA
IGF-I Term IGF-I 3 m IGF-I 6 m
β 95% CI β 95% CI β 95% CI
Weight SDS
Term 1.99a 1.35-2.59
3 m 1.57a 0.84-2.29 1.39a 0.84-1.94
6 m 0.83d 0.13-1.54 1.18a 0.66-1.70 0.75b 0.25-1.26
Length SDS
Term 1.77a 1.07-2.48
3 m 1.40a 0.75-2.05 1.06a 0.55-1.58
6 m 0.83a 0.16-1.51 1.08a 0.59-1.58 0.60c 0.12-1.07
Head circumference SDS
Term 0.98b 0.43-1.53
3 m 0.57 -0.01;1.15 0.60b 0.16-1.04
6 m 0.31 -0.32;0.94 0.53d 0.05-1.0 -0.04 -0.50;0.42
Term: term age; m: months corrected age. Linear regression with log transformed IGF-I levels adjusted for gender 
and gestational age; a P<0.001, b P<0.01, c P<0.02, d P<0.05.
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Igf-I levels and insulin levels in relation to preceding growth 
IGF-I levels at term age, 3 and 6 months CA were associated with preceding weight SDS 
gain and length SDS gain between birth and term age, birth and 3 months CA, and birth 
Table 3.2. Insulin levels in relation to growth parameters at term age, 3 and 6 months CA
Insulin Term Insulin 3 m Insulin 6 m
β 95% CI β 95% CI β 95% CI
Weight SDS
Term 0.30c 0.06-0.53
3 m 0.27d 0.02-0.53 0.42d 0.01-0.83
6 m 0.10 -0.14;0.35 0.38d 0.0-0.76 0.59a 0.31-0.87
Length SDS
Term 0.37b 0.12-0.63
3 m 0.31c 0.07-0.54 0.44d 0.06-0.81
6 m 0.16 -0.06;0.39 0.41d 0.05-0.78 0.44b 0.18-0.71
Head circumference SDS
Term 0.13 -0.07;0.33
3 m 0.04 -0.16;0.24 0.05 -0.28;0.38
6 m -0.07 -0.28;0.15 0.12 -0.23;0.47 0.20 -0.06;0.46
Term: term age; m: months corrected age. Linear regression with log transformed insulin levels adjusted for 
gender, gestational age, and mean fasting duration; a P<0.001, b P<0.01, c P<0.02, d P<0.05.
Table 3.3. IGF-I and insulin levels in relation to preceding weight and length gain
Term age
IGF-I Insulin
β 95% CI β 95% CI
Birth-term age
ΔWeight SDS 0.20a 0.13;0.27 n.s.
ΔLength SDS 0.07c 0.02;0.13 n.s.
3 months CA
β 95% CI β 95% CI
Birth-3 months CA
ΔWeight SDS 0.19a 0.12;0.25 0.12d 0.01;0.22
ΔLength SDS 0.11b 0.04;0.17 0.11d 0.004;0.22
6 months CA
β 95% CI β 95% CI
Birth-6 months CA
ΔWeight SDS 0.13a 0.07;0.20 0.20b 0.08;0.32
ΔLength SDS 0.12b 0.05;0.18 n.s.
Δ: gain; CA: corrected age. Linear regression analysis with log transformed IGF-I and insulin levels adjusted for 
gender and gestational age (and mean fasting duration for insulin levels); a P<0.001, b P<0.01, c P<0.02, d P<0.05.
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and 6 months CA, respectively (Table 3.3). Insulin levels at 3 months CA were associated 
with preceding weight SDS gain and length SDS gain between birth and 3 months CA 
(Table 3.3). Insulin levels at 6 months CA were associated with preceding weight SDS 
gain between birth and 6 months CA (Table 3.3). These associations were not influenced 
by severity of illness, the type of diet, or nutritional intakes. After adjustment for current 
weight or length, the associations between IGF-I levels at term age, 3 and 6 months CA 
and preceding weight SDS gain between birth and term age, birth and 3 months CA, 
and birth and 6 months CA, respectively remained significant, whereas those between 
IGF-I levels at term age, 3 and 6 months CA and preceding length SDS gain and the 
associations between insulin levels at 3 and 6 months and preceding weight SDS gain 
and length SDS gain disappeared.
Igf-I levels and insulin levels in relation to subsequent growth
IGF-I levels and insulin levels at term age, adjusted for growth between birth and term 
age, were negatively associated with weight SDS gain and length SDS gain between 
term age and 6 months CA (IGF-I: β=-1.03, 95% CI -1.65;-0.41, p=0.001 and β=-0.78, 95% 
CI -1.32;-0.23, p=0.005; insulin: β=-0.19, 95% CI -0.37;-0.01, p=0.044 and β=-0.18, 95% CI 
-0.35;-0.01, p=0.035). These associations were not influenced by severity of illness, the 
type of diet, or nutritional intakes. IGF-I levels and insulin levels at 3 months CA were not 
associated with weight SDS and length SDS gain between 3 and 6 months CA.
figure 3.3. Protein (g/kg/d) (A), energy (kcal/kg/d) (B), fat (g/kg/d) (C), and carbohydrate (g/kg/d) (D) 
intake between birth and six months CA
Tukey boxplots.
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Igf-I levels and insulin levels in relation to nutrient intake
Protein (g/kg/d), energy (kcal/kg/d), fat (g/kg/d), and carbohydrate (g/kg/d) intake 
decreased between birth and 6 months CA (Figure 3.3). Mean energy, protein, fat, and 
carbohydrate intake between birth and term age, between term age and 3 months 
CA, and between 3 and 6 months CA were neither associated with IGF-I levels nor with 
insulin levels at any point in time.
dIscussIon
The present study suggests that IGF-I and insulin are important factors in growth 
regulation of preterm infants during the first 6 months post-term, as demonstrated by 
the relation between serum IGF-I and insulin levels, preceding growth, current growth 
parameters, and subsequent growth. The associations between IGF-I and insulin levels 
and current growth parameters are in accordance with previous studies of term infants 
at similar postmenstrual age [3-6] and with studies of preterm infants [9-11, 13-14]. Fur-
thermore, the associations between IGF-I and insulin levels at term age and subsequent 
growth until 6 months CA, independent of growth before term age, are in line with the 
results of Chellakooty et al. and Madsen et al. in term infants at 3 months and 9 months 
of age, respectively [5, 8]. We hypothesize that the inverse association between IGF-I and 
insulin levels at term age and subsequent growth in the present study may reflect that 
most preterm infants experienced decreased growth between birth and term age, which 
resulted in lower IGF-I and insulin levels at term age, followed by accelerated growth 
after term age. If preterm infants experience the largest decrease in growth between 
birth and term age, they may demonstrate the most growth after term age. Thus, the 
findings of the present study may imply that IGF-I and insulin levels are regulators of 
post-term growth in preterm infants.
Previous studies have demonstrated that IGF-I levels are related to nutrient intake, in 
particular to protein intake, in term infants during late infancy [7] and in preterm infants 
before term age [12]. In contrast, other investigators did not find a direct association 
between nutrient intake and IGF-I levels in term infants at 9 months of age [8]. In the 
present study, IGF-I levels were not associated with nutrient intake in preterm infants af-
ter term age. We hypothesize that IGF-I levels in preterm infants might be independent 
of nutritional intake. In addition, IGF-I levels may be genetically determined.
On the other hand, the lack of association between IGF-I levels, insulin levels, and 
nutrient intake may be due to the insufficient data on the exact nutritional intake in the 
human milk fed infants. Between birth and term age, the composition of human milk was 
estimated based on average analytical information on the composition of human breast 
milk from the literature [20], while there is a large inter-individual and intra-individual 
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variation as well as a gradual change over time in the composition of human milk. In 
addition, between term age and 6 months CA, most human milk fed infants were breast-
fed and, therefore, the exact amount and composition of their nutritional intake was 
unknown. Thus, we can only suggest that, with the post-term nutritional regimen used 
in the present study, nutrient intake does not play an essential role for IGF-I production 
in formula-fed infants. 
During the third trimester of pregnancy, IGF-I is an important factor for fetal growth. 
During this phase, IGF-I is primarily controlled by the glucose/insulin axis that allows 
rapid responses to changes in nutrient intake [10]; insulin, in turn, may link nutrient 
intake to IGF-I. In the present study, insulin levels were positively related to IGF-I levels 
at term age and 3 months CA. This suggests that the post-term growth regulation in 
preterm infants shares similarities with the fetal growth regulation during the third 
trimester. Therefore, it is interesting to note that insulin levels were related to IGF-I levels 
at term age and at 3 months CA, but not at 6 months CA. In term infants, major changes 
in growth regulation occur with a shift from insulin/nutrition dependency at term age 
towards GH dependency at 6 months postnatal age [1]. The lack of association between 
IGF-I and insulin levels at 6 months CA in the present study may be due to this gradual 
maturation of the GH/IGF-I axis. 
In addition, insulin is important for direct stimulation of postnatal growth, in particu-
lar body composition [21-23]. In our study, insulin levels were associated with preced-
ing weight gain and subsequent growth but to a smaller extent than IGF-I. This might 
indicate that insulin mainly exerts a permissive role on the production of IGF-I instead 
of a direct enhancing role on postnatal growth and that insulin production is stimulated 
by gain in body weight.
This study had some limitations. A limitation of the present study is the small sample 
size. It should be considered that the number of subjects was too small to show signifi-
cant associations between nutrient intake and IGF-I levels. In addition, this paper reports 
on post-hoc analyses, whereas the power analysis of the main randomized controlled 
trial was based on the primary objective of the complete study, notably differences in 
growth and body composition between preterm infants fed postdischarge formula, 
term formula, and human milk with the earlier mentioned limitations [15]. The lack of 
association between nutrient intake and IGF-I levels, therefore, needs to be interpreted 
with caution. Moreover, since this paper reports on post-hoc analyses, it can only sug-
gest that IGF-I levels, insulin levels, and growth are associated. Within the design of the 
present study, causal relations between IGF-I levels, insulin levels, and growth cannot be 
established.
Furthermore, according to the study protocol of the randomized controlled trial, 
infants in the present study were fed different feeding regimes, e.g. postdischarge for-
mula, term formula, or human milk. This type of feeding did not influence or explain any 
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of the associations found in the present study; however, the influence of the diet on any 
of the associations cannot be excluded completely.
In conclusion, this study suggests that IGF-I may play an important role in the regula-
tion of growth in preterm infants during the first 6 months post-term, which shares simi-
larities with the regulation of fetal growth and growth of term infants during infancy, 
and that insulin may exert a permissive role on the production of IGF-I. Similar to term 
infants, a shift from insulin dependent towards GH dependent growth regulation may 
occur in preterm infants at 6 months CA. In contrast to findings in term infants, our data 
could only permit to suggest that IGF-I levels in preterm infants until 6 months CA are 
not dependent on type of nutrition per se. 
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absTracT
background/objectives
Early growth restriction followed by accelerated growth may result in metabolic disease 
in later life. This study compared growth, body composition, and nutritional intake 
between birth and six months post-term between appropriate-for-gestational-age 
preterm infants with and without growth restriction at term age (AGA GR+ and AGA GR-, 
respectively) and small-for-gestational-age (SGA) preterm infants.
subjects/Methods
Eighty-three AGA GR-, 15 AGA GR+, and 33 SGA preterm infants were included. At term 
age and six months post-term, weight (g), length (cm), and head circumference (cm) 
were measured and expressed as standard deviation scores (SDS) and lean mass (LM; g) 
and fat mass (FM; g) were measured by whole-body dual-energy x-ray absorptiometry 
(Hologic QDR4500A). Between term age and six months post-term, gain (Δ) in weight, 
LM, and FM and intake of protein (g/kg/day) and energy (kcal/kg/day) were calculated.
results
Higher protein and energy intake during the first six months post-term resulted in 
higher Δweight SDS, higher ΔLM, and lower ΔFM in AGA GR+ and SGA compared to 
AGA GR- preterm infants (Δweight SDS [expressed as mean ± SD]: 1.34 ± 0.93 and 0.97 ± 
1.04 versus 0.45 ± 0.99 SDS; respectively, P<0.05; ΔLM [expressed as median (IQR)]: 2898 
(587) and 3055 (581) versus 2552 (618) g, respectively, P≤0.05; ΔFM: 1263 (834) and 1441 
(772) versus 1722 (764) g, respectively, P≤0.07).
conclusions
During the first six months post-term, AGA GR+ and SGA preterm infants restore their 
LM without excessive FM despite higher energy and protein intake compared to AGA 
GR- preterm infants.
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InTroducTIon
Adequate prenatal and postnatal growth without excessive fat accumulation is impor-
tant for metabolic health of preterm infants in later life. Body composition is affected by 
prenatal [1-2] as well as by early postnatal growth. As a result of their extrauterine third 
trimester, preterm infants are extremely susceptible for disruption of this early postnatal 
growth phase. Preterm infants born appropriate-for-gestational-age (AGA) are at risk 
of growth restriction at term age (AGA GR+; weight, length, or both at term age <-2 
SDS), since postnatal nutrient supplies are directed towards survival at the expense of 
postnatal growth [3-4]. Similar to small-for-gestational-age (SGA) preterm infants, AGA 
GR+ preterm infants demonstrate catch-up growth during early infancy [3-4], which is 
associated with adiposity during infancy [5] and adolescence [6]. Adiposity, in turn, has 
been related to metabolic consequences in later life, including insulin resistance and 
cardiovascular disease.
Growth and body composition of preterm infants are influenced by nutritional intake. 
Some studies demonstrate that energy and protein intake enhance fat mass (FM) 
accumulation of preterm infants during infancy [7-8], whereas others do not [9-10]. 
Adequate growth without increased FM accumulation may be especially important for 
infants that are prone for accelerated growth during infancy, such as AGA GR+ and SGA 
preterm infants [3, 11]. Recently, Roggero et al. showed that growth and FM accumula-
tion was similar in SGA preterm infants fed an energy- and protein-enriched formula 
compared to those fed a standard term formula during the first six months post-term 
and they suggest that SGA preterm infants have either a delay in FM restoration or a 
lower genetic potential [12]. However, another explanation for their findings may be 
that energy (kcal/kg/d) and protein intake (g/kg/d) were comparable between SGA 
and AGA preterm infants [12], as it has been suggested that SGA and AGA GR+ preterm 
infants may benefit from a higher nutrient intake [13-14]. Moreover, few studies have 
focused on body composition of AGA GR+ preterm infants in relation to their nutritional 
intake during early infancy. We hypothesized that, similar to SGA preterm infants, AGA 
GR+ preterm infants have catch-up growth, as a result of higher nutrient supply, that 
results in increased FM accumulation. Therefore, the present study compared growth, 
body composition, and nutritional intake until six months post-term between AGA 
preterm infants with and without growth restriction at term age (AGA GR+ and AGA GR-, 
respectively) and SGA preterm infants.
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subjecTs and MeThods
The present study was an observational analysis within a randomized controlled trial 
that evaluated the effects of an isocaloric, protein- and mineral-enriched postdischarge 
formula, term formula, and human milk on growth and body composition of preterm 
infants until six months post-term, as described in detail previously [13]. In short, 152 
preterm infants with a gestational age of 32 weeks or less, a birth weight of 1,500 gram 
or less, or both were included shortly after birth. Preterm infants with congenital malfor-
mations or conditions known to affect growth or body composition were not included. 
One-hundred-and-thirty-nine preterm infants completed the randomized controlled 
trial at six months post-term (Figure 4.1). The present study included 131 preterm infants 
with available data on growth, body composition, and nutritional intake until six months 
post-term (Figure 4.1). These infants visited our outpatient clinic at term age (40.3 ± 
INCLUDED:
152 preterm infants 
(GA ≤32 wk and/or BW ≤1,500 g)
102 formula fed infants
50 human milk (HM)
152 preterm infants
4 did not follow study protocol:2 did not follow study protocol 7 did not follow study protocol
54 postdischarge formula (PDF) 48 standard term formula (TF)
BIRTH
TERM AGE 50 human milk fed infants
46 HM fed infants 
completed study
52 PDF fed infants 
completed study
6 MONTHS 
POST-TERM
41 TF fed infants 
completed study
RANDOMIZATION NO RANDOMIZATION
65 Preterm formulaa 80 Fortified human milkb7 missing data 
(1 TF and 1 HM)
CLASSIFIED 
AND INCLUDED 
IN ANALYSES
31 AGA GR-
3 AGA GR+
11 SGA
29 AGA GR-
9 AGA GR+
12 SGA
23 AGA GR-
3 AGA GR+
10 SGA
2 missing birth length 5 missing birth length 1 missing birth length
figure 4.1. Flow chart of subject recruitment, inclusion and randomization of the original randomized 
controlled trial
AGA GR-: appropriate-for-gestational-age infants without growth restriction at term age; AGA GR+: appropriate-
for-gestational-age infants with growth restriction at term age; BW: birth weight; GA: gestational age; HM: 
human milk; PDF: postdischarge formula; SGA: small-for-gestational-age infants; TF: term formula. a 35 AGA GR-, 
8 AGA GR+, and 15 SGA preterm infants; 3 preterm infants did not follow study protocol, 4 preterm infants had 
missing birth length. b 48 AGA GR-, 7 AGA GR+, and 18 SGA preterm infants; 3 preterm infants did not follow 
study protocol, 4 preterm infants had missing birth length.
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0.7 weeks postmenstrual age), three months post-term (53.0 ± 0.5 weeks postmenstrual 
age), and six months post-term (66.0 ± 0.5 weeks postmenstrual age). This study was 
conducted according to the guidelines laid down in the Declaration of Helsinki and all 
procedures involving patients were approved by the ethics committee of VU University 
Medical Center, Amsterdam, The Netherlands. Written informed consent was obtained 
from the parents of all participating children.
Between birth and term age, infants were fed preterm formula (per 100 ml: 80 kcal, 
2.2-2.5 g protein, 4.3-4.4 g fat, 7.6-8.2 g carbohydrates) or fortified human milk (Figure 
4.1). At term age, formula fed infants were randomized to isocaloric postdischarge for-
mula (per 100 ml: 67 kcal, 1.7 g protein, 3.5 g fat, 7.0 g carbohydrates) or standard term 
formula (per 100 ml: 67 kcal, 1.47 g protein, 3.5 g fat, 7.2 g carbohydrates) (Figure 4.1), as 
described previously [13], and were fed this diet until six months post-term. Infants that 
were fed >80% human milk at term age were considered to be human milk fed. If human 
milk was insufficiently available, infants were fed standard term formula additionally. If 
complementary feeding was introduced between five and six months post-term, it was 
limited to fruit or vegetables once a day.
Details on enteral and parenteral intake, including volume intake (ml/d) and type of 
diet, were extracted from the infant’s medical record between birth and discharge by 
a single person. Between discharge and six months post-term, parents recorded their 
infant’s formula intake (ml/d), intake of supplements, and any changes in their infant’s 
diet in a diary (per day between discharge and term age; once per week between term 
age and six months post-term). Human milk fed infants were predominantly fed human 
milk with fortifier by bottle before term age. In these infants, the volume of human milk 
intake was recorded and the composition of human milk was estimated (per 100 ml: 68 
kcal, 1 g protein, 4 g fat, 7 g carbohydrates [15]). After term age, human milk fed infants 
were breast-fed and their exact intake was unknown. The available data on volume, type, 
and composition of intake and weight was used to calculated the mean intake of energy 
(kcal/d and kcal/kg/d), protein (g/d and g/kg/d), fat (g/d and g/kg/d), and carbohydrates 
(g/d and g/kg/d) between birth and term age in all infants and between term age and 
six months post-term only in formula fed infants. As previously demonstrated, between 
term age and six months post-term, growth was similar, gain in LM was higher and gain 
in FM was lower in preterm infants fed postdischarge formula compared to those fed 
term formula or human milk [13].
Weight (g) was measured with a digital scale to the nearest 1 gram, length (cm) was 
measured with a length board to the nearest 0.1 cm, and head circumference (cm) was 
measured with a non-stretchable measuring tape to the nearest 0.1 cm by a single 
research nurse at birth, term age, three months post-term, and six months post-term, 
as described previously [13]. Weight, length, and head circumference at birth and term 
age were expressed as standard deviations scores (SDS) based on Swedish references for 
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preterm infants [16]. Weight, length, and head circumference at three and six months 
post-term were expressed as SDS based on Dutch references [17]. Adapted from Rog-
gero et al. and Finken et al. [3, 18], infants were classified as AGA GR- if weight and length 
at birth and term age were -2 SDS or above, as AGA GR+ if weight and length at birth 
were -2 SDS or above and weight, length, or both at term age were below -2 SDS, and 
as SGA if weight, length, or both at birth were below -2 SDS. Gain (Δ) in absolute and 
relative (SDS) weight, length, and head circumference between term age and six months 
post-term was calculated.
As length was included in the classification of preterm infants (AGA GR-, AGA GR+, 
or SGA), the influence of parental height was considered as a proxy of the genetic 
growth potential. Maternal height (cm) and paternal height (cm) were acquired through 
parental questionnaires. Target height was calculated as follows: target height boys 
(cm)=44.5+0.376*paternal height (cm)+0.411*maternal height (cm) and target height 
girls (cm)=47.1+0.334*paternal height (cm)+0.364*maternal height (cm) [19]. In ad-
dition, target height SDS was calculated as follows: target height SDS boys=(target 
height-183.8)/7.1 and target height SDS girls=(target height-170.7)/6.3 [19].
The severity of illness during hospital admission was evaluated by the Neonatal 
Therapeutic Intervention Scoring System, which has a maximum score of 130. It is a valid 
indicator of severity of illness in neonates, independent of birth weight [20].
Lean mass (LM; g) and fat mass (FM; g) were measured by whole-body dual-energy 
x-ray absorptiometry (DXA; Hologic QDR4500A, Hologic, Bedford, MA, USA) at term age 
and six months post-term and analyzed by Infant Whole Body Software version 12.3.3. 
[13]. FM was expressed as percentage FM (%FM) as follows: FM (g)/weight (g)*100%. One 
expert radiologist evaluated the DXA scan quality and was blinded for the study groups 
or the type of diet. Scans that were incomplete or that had severe movement artifacts 
were excluded. Good quality DXA scans were available from 110 preterm infants at term 
age (68 AGA GR-, 14 AGA GR+, and 28 SGA), from 102 preterm infants at six months 
post-term (66 AGA GR-, 12 AGA GR+, and 24 SGA), and from 84 preterm infants both at 
term age and six months post-term (52 AGA GR-, 11 AGA GR+, and 21 SGA).
statistical analyses
The distribution of gender and type of diet were expressed as frequencies and were 
compared between AGA GR-, AGA GR+, and SGA infants by logistic regression. Ges-
tational age, absolute growth parameters, LM and FM as well as energy and protein 
intakes between birth and term age were normally distributed after log transformation 
and were expressed as median (IQR). Relative growth (SDS), severity of illness, target 
height SDS, fat and carbohydrate intakes between birth and term age and nutritional 
intakes between term age and six months post-term were normally distributed and 
were expressed as mean ± SD. Gestational age, growth, target height SDS, nutritional 
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intakes, LM, and FM were compared between AGA GR-, AGA GR+, and SGA infants by 
regression analyses with the between-group comparisons as dummy variables adjusted 
for gender and gestational age (the comparison of gestational age was only adjusted 
for gender). In addition, all analyses were adjusted for type of diet and severity of ill-
ness score. A P value of 0.05 was considered significant and P values were two-sided. 
All statistical analyses were performed with SPSS 17.0 for Windows (SPSS Inc., Chicago, 
IL, USA).
resuLTs
This study included 83 AGA GR-, 15 AGA GR+, and 33 SGA preterm infants (Figure 4.1). 
SGA infants were more often boys than AGA GR- and AGA GR+ infants (73% versus 43% 
and 40%, P<0.05) and had a higher gestational age than AGA GR- infants (Table 4.1). All 
SGA infants had a birth length below -2 SDS and 10 SGA infants also had a birth weight 
below -2 SDS (30.3%). Severity of illness score and target height SDS were not different 
Table 4.1. Gestational age and absolute growth parameters in AGA GR-, AGA GR+, and SGA infants
Characteristics
AGA GR- 
(n=83)
AGA GR+ 
(n=15)
SGA 
(n=33)
Birth
Gestational age (wk) 30.1 (2.0)† 30.7 (1.4) 31.1 (1.6)
Weight (g) 1465 (371)*,† 1182 (220)‡ 1160 (468)
Length (cm) 39.0 (3.5)*,† 38.0 (2.0)‡ 36.0 (3.5)
HC (cm) 28.0 (2.5)*,† 27.5 (4.0)‡ 27.5 (2.6)
Term age
Weight (g) 3230 (465)*,† 2641 (300) 2736 (574)
Length (cm) 49.5 (2.0)*,† 47.5 (3.0)‡ 46.5 (3.5)
HC (cm) 36.0 (1.4)*,† 34.9 (2.2) 35.0 (2.4)
3 months post-term
Weight (g) 5860 (980)*,† 4925 (420) 4990 (1240)
Length (cm) 60.0 (3.0)*,† 57.5 (3.0)‡ 57.0 (3.5)
HC (cm) 40.8 (1.3)*,† 40.6 (2.1) 40.5 (2.9)
6 months post-term
Weight (g) 7460 (1300)*,† 6840 (1503) 6625 (1560)
Length (cm) 67.0 (3.0)*,† 66.0 (3.5)‡ 64.0 (4.0)
HC (cm) 44.0 (1.8)*,† 43.4 (1.2) 43.8 (2.4)
Values as median (IQR). AGA GR-: appropriate-for-gestational-age without growth restriction at term age; 
AGA GR+: appropriate-for-gestational-age with growth restriction at term age; SGA: small-for-gestational-age; 
HC: head circumference. Differences compared by regression analyses adjusted for gender and gestational age;
* AGA GR- versus AGA GR+, P<0.02; † AGA GR- versus SGA, P<0.02; ‡ AGA GR+ versus SGA, P<0.05.
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between AGA GR-, AGA GR+, and SGA infants (severity of illness score: 21.4 ± 8.3, 23.4 
± 8.2, and 21.3 ± 7.8; target height SDS: -0.26 ± 0.60, -0.34 ± 0.56, and -0.33 ± 0.84; 
respectively; all P≥0.05). The distribution of the type of diet was not different between 
the three groups (Figure 4.1; P≥0.05).
Anthropometric measurements were lower in AGA GR+ and SGA infants compared 
to AGA GR- infants at all time-points (Table 4.1 and Figure 4.2). Gain in weight SDS and 
gain in length SDS between term age and six months post-term were higher in AGA GR+ 
and SGA infants compared to AGA GR- infants (Table 4.2). Gain in head circumference 
figure 4.2. Weight SDS (A), length SDS (B), and head circumference SDS (C) between birth and six months 
post-term in AGA GR-, AGA GR+, and SGA infants
Tukey box plots. AGA GR-: appropriate-for-gestational-age infants without growth restriction at term age; 
AGA GR+: appropriate-for-gestational-age infants with growth restriction at term age; SDS: standard deviation 
scores; SGA: small-for-gestational-age infants. Differences between AGA GR-, AGA GR+, and SGA infants were 
compared by linear regression adjusted for gender and gestational age; ** AGA GR- versus AGA GR+, P<0.001; 
* AGA GR- versus AGA GR+, P<0.05; † AGA GR- versus SGA, P<0.001; ‡ AGA GR- versus SGA, P<0.05; § AGA GR+ 
versus SGA, P<0.05.
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SDS between term age and six months post-term was higher in SGA infants compared 
to AGA GR- infants (Table 4.2).
With respect to nutrition, AGA GR+ and SGA infants had higher protein, energy, and fat 
intake per kilogram per day compared to AGA GR- infants between birth and term age as 
well as between term age and six months post-term (Table 4.3). However, absolute total 
protein, energy, and fat intake per day between birth and term age was lower in AGA 
GR+ and SGA infants compared to AGA GR- infants (Table 4.3).
With respect to body composition, AGA GR+ and SGA infants had lower LM, FM, and 
%FM at term age and lower FM and %FM at six months post-term compared to AGA 
GR- infants (Figure 4.3). Between term age and six months post-term, AGA GR+ and SGA 
infants had higher gain in LM and lower gain in FM compared to AGA GR- infants (Table 
4.2).
The differences in growth, nutritional intakes, LM, and FM between the three groups 
remained unchanged after adjustment for severity of illness score and for type of diet 
(i.e. preterm formula or fortified human milk between birth and term age; postdischarge 
formula, term formula, or human milk between term age and six months post-term).
Table 4.2. Absolute and relative (SDS) growth and gain in lean mass and fat mass in AGA GR-, AGA GR+, 
and SGA infants between term age and six months post-term
Term age-6 months post-term
AGA GR- 
(n=83)
AGA GR+ 
(n=15)
SGA 
(n=33)
Growth
ΔWeight gram 4075 (1135) 4235 (1390) 3985 (1120)
SDS 0.45 ± 0.99*,† 1.34 ± 0.93 0.97 ± 1.04
ΔLength cm 18.0 (2.5) 18.0 (4.0) 18.0 (2.8)
SDS 0.64 ± 0.80*,† 1.24 ± 1.02 1.28 ± 1.04
ΔHC cm 8.0 (1.0)† 8.5 (2.0) 8.5 (1.2)
SDS -0.49 ± 0.73† -0.10 ± 0.89 -0.23 ± 0.65
Body composition
ΔLM gram 2552 (618)#,† 2898 (587) 3055 (581)
ΔFM gram 1722 (764)§,† 1263 (834) 1441 (772)
Values as mean ± SD or median (IQR). AGA GR-: appropriate-for-gestational-age without growth restriction 
at term age; AGA GR+: appropriate-for-gestational-age with growth restriction at term age; SGA: small-for-
gestational-age; Δ: gain; SDS: standard deviation score; HC: head circumference; LM: lean mass; FM: fat mass. 
Differences compared by regression analyses adjusted for gender and gestational age; * AGA GR- versus AGA 
GR+, P<0.02; # AGA GR- versus AGA GR+, P=0.05; § AGA GR- versus AGA GR+, P=0.07; † AGA GR- versus SGA, 
P<0.05.
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Table 4.3. Protein, energy, fat, and carbohydrate intake between birth and six months post-term in 
formula-fed AGA GR-, AGA GR+, and SGA infants
AGA GR- AGA GR+ SGA
Birth-term age
Protein intakea g/kg/d 2.63 (0.48)† 2.72 (0.98) 2.75 (1.55)
g/d 8.85 (2.39)*,† 7.51 (0.90) 7.84 (2.01)
Energy intakea kcal/kg/d 116.4 (89.5)*,† 125.4 (24.2) 128.4 (14.2)
kcal/d 379.7 (68.7)*,† 342.8 (63.9) 357.4 (83.8)
Fat intakea g/kg/d 5.48 ± 0.90† 5.90 ± 0.64 5.93 ± 0.82
g/d 18.5 ± 3.5*,† 15.8 ± 2.4 16.3 ± 3.0
Carbohydrate intakeb g/kg/d 13.2 ± 2.0 12.9 ± 1.8 12.8 ± 1.4
g/d 44.5 ± 8.0*,† 34.7 ± 6.0 34.8 ± 5.8
Term age-6  months post-term
Protein intakec g/kg/d 2.38 ± 0.25*,† 2.66 ± 0.27 2.58 ± 0.39
g/d 18.2 ± 2.5 18.4 ± 2.6 18.1 ± 2.5
Energy intakec kcal/kg/d 99.8 ± 7.5*,† 109.6 ± 10.0 106.9 ± 13.5
kcal/d 760.9 ± 94.0 758.2 ± 101.1 753.1 ± 83.9
Fat intakec g/kg/d 5.21 ± 0.38*,† 5.65 ± 0.54 5.56 ± 0.68
g/d 39.7 ± 4.8 39.1 ± 5.0 39.2 ± 4.7
Carbohydrate intakec g/kg/d 10.7 ± 0.9*,† 11.8 ± 1.2 11.5 ± 1.6
g/d 81.4 ± 10.7 81.7 ± 11.8 80.7 ± 8.9
Values as mean ± SD or median (IQR). AGA GR-: appropriate-for-gestational-age without growth restriction 
at term age; AGA GR+: appropriate-for-gestational-age with growth restriction at term age; SGA: small-for-
gestational-age a 80 AGA GR-, 15 AGA GR+, and 33 SGA infants included; b 78 AGA GR-, 15 AGA GR+, and 30 SGA 
infants included; c 52 AGA GR-, 12 AGA GR+, and 21 SGA infants included. Differences compared by regression 
analyses adjusted for gender and gestational age; * AGA GR- versus AGA GR+, P<0.05; † AGA GR- versus SGA, 
P<0.05.
figure 4.3. Lean mass (g) (A), fat mass (g) (B), and percentage fat mass (%) (C) between term age and six 
months post-term in AGA GR-, AGA GR+, and SGA infants
Tukey box plots. AGA GR-: appropriate-for-gestational-age infants without growth restriction at term age; 
AGA GR+: appropriate-for-gestational-age infants with growth restriction at term age; SGA: small-for-gestational-
age infants. Differences between AGA GR-, AGA GR+, and SGA infants were compared by linear regression (with 
natural log transformed variables) adjusted for gender and gestational age; ** AGA GR- versus AGA GR+, P<0.001; 
* AGA GR- versus AGA GR+, P<0.05; † AGA GR- versus SGA, P<0.001.
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dIscussIon
The present study shows that, compared to AGA GR- infants, higher weight gain in AGA 
GR+ and SGA infants consists of higher LM accretion and lower FM accretion during the 
first six months post-term. It has been demonstrated that FM accumulation of preterm 
infants is positively related to energy and protein intake after term age [7-8] as well as 
to weight gain during early infancy [5]. Therefore, it was remarkable in the present study 
that FM accretion was lower in AGA GR+ and SGA preterm infants while they had higher 
weight gain, energy intake (kcal/kg/d), and protein intake (g/kg/d) compared to AGA 
GR- infants between term age and six months post-term.
The lower FM deposition in AGA GR+ and SGA preterm infants may be a consequence 
of deficits in macronutrients that developed before term age and were not corrected 
thereafter, as may be suggested by the lower total nutritional intake between birth and 
term age in these infants. After term age, persisting deficits of fat and carbohydrates 
may delay fat mass restoration [21]. It has been suggested that AGA GR+ and SGA pre-
term infants may benefit from increased nutritional intakes to achieve adequate growth 
and body composition during infancy [13-14]. With respect to fat mass accretion, our 
findings might support the conceptual premise that AGA GR+ and SGA infants may 
benefit from even higher nutritional intakes than that were achieved with the current 
feeding regimen during infancy. On the other hand, not the absolute amount of fat but 
the higher rate of fat accumulation in AGA GR- infants may have adverse metabolic 
consequences in later life [22].
Another explanation for the lower FM accretion and adequate LM restoration in AGA 
GR+ and SGA preterm infants may be the fact that LM replenishment has lower energy 
requirements than FM accretion [23] and, therefore, precedes FM restoration during 
postnatal growth of preterm infants [24-25]. This may imply that the lack of FM restora-
tion of AGA GR+ and SGA preterm infants in the present study is a consequence of the 
timing of body composition measurement and that complete FM restoration may occur 
later in life.
In addition to nutritional intake, body composition acquisition may depend on the 
genetic growth potential. A genetically smaller body size of AGA GR+ and SGA preterm 
infants may explain the lower FM accumulation during the first six months post-term 
[26]. However, in the present study, target height SDS of AGA GR+ and SGA preterm 
infants was not different than that of AGA GR- preterm infants.
The present study had several limitations. A limitation was that the sample size was 
relatively small, in particular after subgroup classification. The original randomized 
controlled trial investigated growth and body composition of preterm infants fed three 
different feeding regimens during the first six months post-term. The distribution of 
the type of diet was similar in the three groups and the differences between AGA GR-, 
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AGA GR+, and SGA infants persisted after adjustment for the type of diet. However, the 
influence of the nutritional regimen cannot be excluded completely. Another limitation 
was that the first body composition measurement occurred at term age and not a birth. 
This was a consequence of the design of the randomized controlled trial, which focused 
on the effects of a nutritional intervention between term age and six months post-term. 
Thus, the differences in body composition between AGA GR-, AGA GR+, and SGA infants 
could not be adjusted for differences in body composition at birth.
In addition, in the present study, SGA was used as a proxy for fetal growth restriction. 
Several studies in term infants suggest that customized fetal growth curves should be 
used to define SGA [27-29], as infants with fetal growth restriction are at increased risk of 
perinatal morbidity and chronic adult disease, such as insulin resistance, hypertension, 
and cardiovascular disease [27-28], whereas constitutionally small infants are not [28]. 
However, others suggest that SGA is justified as a proxy for fetal growth restriction after 
early preterm birth, since perinatal morbidity of SGA infants declines with advancing 
gestational age [26]. Furthermore, the composition of human milk that was used to cal-
culate the nutritional intake between birth and term age was estimated [15]. However, 
there is a large inter-individual and intra-individual variation as well as a gradual change 
over time in the composition of human milk. Therefore, the comparison of nutritional 
intake between birth and term age needs to be interpreted with caution.
In conclusion, compared to AGA GR- preterm infants, SGA and AGA GR+ preterm 
infants restore their LM without excessive FM accumulation at six months post-term 
despite a higher nutritional intake per kilogram per day between birth and six months 
post-term. Nevertheless, it remains controversial if higher nutritional intakes that may 
potentially increase FM accretion are desirable in AGA GR+ and SGA infants, as the 
higher FM accumulation in AGA GR- preterm infants may even have adverse metabolic 
consequences. Therefore, it is recommended to carefully monitor early postnatal effects 
of specific nutritional intakes on body composition in preterm infants in order to prevent 
excessive FM accretion that is associated with a higher risk of adiposity and metabolic 
consequences in later life.
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Small-for-gestational-age preterm-born 
 infants already have lower bone 
mass during early infancy
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absTracT
background
In preterm-born infants, low birth weight and diminished bone accretion deteriorate 
peak bone mass. Whether low birth weight is already associated with decreased bone 
mass during infancy is unknown.
objective
To study the effect of birth weight on bone accretion between term age (40 weeks 
postmenstrual age) and six months post-term in preterm-born infants.
design
In 139 preterm-born infants (51% male, gestational age 30.3 ± 1.5 weeks, birth weight 
1341 ± 288 g) weight and whole-body bone mineral content (BMC, g) were measured 
at term age and six months post-term. At birth, infants were small-for-gestational-age 
(SGA, n=33, weight and/or length <-2 SDS) or appropriate-for-gestational-age (AGA, 
n=98, weight and length ≥-2 SDS).
results
At term age and six months post-term, BMC adjusted for gender and gestational age 
was lower in SGA than AGA infants (term age: 38.1 ± 9.5 versus 48.6 ± 10.1 g, β=-0.26, 
95%CI -0.37;-0.16, p<0.001; six months: 130.1 ± 25.7 versus 145.4 ± 22.9 g, β=-0.16, 
95%CI -0.25;-0.08, p<0.001). At six months post-term, BMC remained lower in SGA in-
fants after adjustment for actual weight and length. Between term age and six months 
post-term, BMC gain adjusted for gender and gestational age was lower in SGA than 
AGA infants (91.7 ± 22.8 versus 98.2 ± 20.7 g; β=-0.12, 95%CI -0.24;-0.003, p=0.044). BMC 
gain remained lower in SGA infants after adjustment for weight and length gain.
conclusion
The first six months post-term, SGA preterms have lower bone accretion, independent of 
body size, suggesting that prenatal conditions for bone accretion cannot be replicated 
postnatally.
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InTroducTIon
Preterm-born infants are prone to suboptimal bone mass. Preterm birth is frequently 
preceded by intra-uterine growth retardation, which is associated with inadequate 
intra-uterine bone formation and a smaller skeleton at birth. In addition, preterm-born 
infants are deprived of the intra-uterine third trimester, which is essential for 80% of the 
total bone mass of the newborn [1]. During the postnatal extra-uterine third trimester, 
mineral intake of preterm-born infants is insufficient for bone mass accretion, which 
aggravates the already present bone mineral deficit. During infancy and childhood, 
preterm-born children have lower bone mass accretion compared to their term-born 
peers [2-5]. This decreased bone mass tracks from infancy to adulthood resulting in 
lower peak bone mass in preterm-born adults [6-8], which is associated with a higher 
risk of osteoporosis [9].
During infancy, bone mass accretion can to a certain extent be modified by feeding 
and growth. The type of feeding provided during early infancy influences bone mass 
accretion, as emphasized by lower bone mineral content (BMC) in preterm-born infants 
fed human milk compared to formula [10-12] and by higher BMC in preterm-born infants 
fed nutrient-enriched formula compared to standard formula [13-15].
Bone mass accretion can also be modified by prenatal and postnatal growth trajecto-
ries. In term-born infants, fetal growth and low birth weight, as a proxy of intra-uterine 
growth, are associated with lower bone mass and decreased estimated bone strength 
at adult age [16-19]. In preterm-born infants, low birth weight is associated with de-
creased bone mass at term age and with lower bone mineral density (BMD) at 20 years 
of age [7, 20]. In particular, preterm-born infants that are small-for-gestational-age have 
decreased bone size and lower BMD at 20 years of age [7, 21]. In both term-born and 
preterm-born infants, growth during infancy and childhood determines bone mass in 
childhood and adulthood [17, 22-28].
Whether low birth weight in preterm-born infants is already associated with decreased 
bone mass during early infancy is unknown. Therefore, we studied the effect of birth 
weight on bone mass accretion between term age (40 weeks postmenstrual age) and six 
months post-term in preterm-born infants and investigated if this relation was modified 
by post-term growth and type of feeding.
subjecTs and MeThods
subjects
The present study was part of a randomized controlled trial that evaluated the effect of 
postdischarge formula, term formula, and human milk on growth and body composition 
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of preterm-born infants. The design of the randomized controlled trial has been de-
scribed in detail elsewhere [29]. In short, 152 infants with a gestational age of 32 weeks 
or less and/or a birth weight of 1,500 gram or less were included shortly after birth. 
Infants with congenital malformations or conditions that affected growth and body 
composition were not included. The present study aimed to investigate size at birth in 
relation to prospectively collected anthropometry and bone mass between term age 
and six months post-term and included all infants with available data on anthropometry 
and bone mass between these time-points. Infants were evaluated at our outpatient 
clinic at term age (40.3 ± 0.7 weeks postmenstrual age), at three months post-term 
(53.0 ± 0.5 weeks postmenstrual age) and at six months post-term (66.0 ± 0.5 weeks 
postmenstrual age). At six months post-term, 139 preterm-born infants completed the 
randomized controlled trial (51% boys, gestational age 30.3 ± 1.5 weeks, birth weight 
1341 ± 288 g) (Figure 5.1). Thirteen infants did not complete the randomized controlled 
trial for various reasons (Figure 5.1).
The study protocol was approved by the ethics committee of VU University Medical 
Center, Amsterdam, The Netherlands. All the parents of the participating children gave 
written informed consent.
Included infants 
n=152 
Completed RCT  
at 6 months corrected 
age  
n=139 
Withdrawal by parents (n=4) 
Incorrect protocol (n=5) 
Renal disease (n=2) 
Failure to thrive (n=1) 
Hydrocephalus (n=1) 
DXA measurement 
n=139 
Good quality DXA 
Term age 
n=116 
6 months CA 
n=106 
Both 
n=87 
AGA n=82 
SGA n=28 
Missing n=6 
AGA n=78 
SGA n=24 
Missing n=4 
AGA n=63 
SGA n=21 
Missing n=3 
figure 5.1. Flow diagram of study subject recruitment
N: number of infants; AGA: appropriate-for-gestational-age (weight and length ≥-2 SDS); SGA: small-for-
gestational-age (weight and/or length <-2 SDS); missing: not classified as AGA or SGA due to unknown birth 
length.
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Methods
Anthropometry, severity of illness, and type of diet
At birth, at term age, and at three and six months post-term, weight (gram) was mea-
sured with a digital scale, length (cm) was measured with a length board, and head 
circumference (cm) was measured with a non-stretchable measuring tape [29]. At birth, 
weight, length, and head circumference were expressed as standard deviation score 
(SDS) based on Swedish references for preterm-born infants, which adjusted for gender 
and gestational age [30]. Infants were classified as small-for-gestational-age (SGA) if 
birth weight and/or length were below -2 SDS and as appropriate-for-gestational-age 
(AGA) if birth weight and length were -2 SDS or above. The relative gain in weight and 
length between term age and six months post-term was calculated as follows: (gain 
between term age and six months post-term)/measurement at term age*100%.
The Neonatal Therapeutic Intervention Scoring System was used to evaluate severity 
of illness during hospital admission. The Neonatal Therapeutic Intervention Scoring 
System has a maximum score of 130 points and is a valid indicator of severity of illness 
in neonates, independent of birth weight [31]. In the present study, infants were fed 
different feeding regimens between term age and six months post-term according to 
the study protocol of the randomized controlled trial, namely postdischarge formula, 
term formula, or human milk [29].
Dual-energy x-ray absorptiometry (DXA)
At term age and at six months post-term, bone mass was measured with whole-body 
dual-energy x-ray absorptiometry (DXA; Hologic QDR4500A, Hologic Inc, Bedford, MA, 
USA), as described previously [29]. In short, naked infants were swaddled in a cotton 
sheet and placed in supine position on the scanning area. Infants were not sedated 
and were scanned after feeding when the infant was settled. A research nurse was in 
attendance during the scanning procedure to ensure an adequate position of the infant. 
Scan analysis was performed with Infant Whole Body Software, version 12.3.3 and 
provided bone area (BA; cm2), bone mineral content (BMC; g), and bone mineral density 
(BMD; g.cm-2). Since body weight was a main determinant of bone mineral content in 
previous studies [32-33], the proportion BMC/weight (%) was calculated as follows: BMC 
(g)/weight (g)*100%. The relative gain in BA, BMC, and BMD between term age and six 
months post-term was calculated as follows: (gain between term age and six months 
post-term)/measurement at term age*100%.
DXA scan quality was evaluated by one expert radiologist who was blinded for the 
size at birth and the type of diet of the infants. Incomplete scans and scans with severe 
movement artifacts, as described by Koo et al. [34], were excluded from the analyses in 
the present study. Good quality DXA scans were available from 116 infants at term age, 
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from 106 infants at six months post-term, and from 87 infants at both term age and six 
months post-term (Figure 5.1).
statistics
All parameters were normally distributed at all time-points. Values were expressed as 
mean ± standard deviation (SD), unless indicated otherwise. Cross tabulation and logis-
tic regression analyses were used for between-group comparisons (AGA versus SGA) of 
gender and type of diet.
Multivariate regression analyses were used for between-group comparisons of ges-
tational age, severity of illness, and growth with AGA versus SGA as the independent 
variable and gestational age, severity of illness, and growth as the dependent variables. 
Growth was adjusted for gender, gestational age, and postmenstrual age. Multivariate 
regression analyses were also used for between-group comparisons of bone mass with 
AGA versus SGA as the independent variable and bone mass parameters as the depen-
dent variables. BA, BMC, BMC/weight, BMD, and covariates were natural log transformed 
to increase the power of the analyses [35]. BA, BMC, and BMD were adjusted for gender, 
gestational age, weight, length, and type of diet, and BMC/weight was adjusted for 
gender, gestational age, and type of diet. In addition, BMC was adjusted for gender, ges-
tational age, weight, length, and bone area, as recommended by Prentice et al. [35]. A P 
value of less than 0.05 was considered significant. All statistical analyses were performed 
using SPSS 17.0 for Windows (SPSS Inc., Chicago, IL, USA).
resuLTs
study population
Ninety-eight infants were classified as AGA and 33 infants as SGA. Eight infants could not 
be classified as AGA or SGA due to unknown birth length. Of the SGA infants, 10 infants 
had a birth weight as well as a birth length below -2 SDS and 23 infants had a birth length 
below -2 SDS and a birth weight of -2 SDS or higher (mean birth weight SDS -1.13 ± 0.45).
The SGA group comprised more boys than the AGA group (72.7% versus 42.9%, 
OR=3.6, 95%CI 1.5-8.4, p=0.004). Gestational age was lower in AGA than SGA infants 
(30.1 ± 1.5 versus 31.1 ± 1.1 weeks, p<0.001). Postmenstrual age at term age and at 
three months and six months post-term was not different between AGA and SGA infants 
(term age: 40.5 ± 0.7 versus 40.6 ± 0.9 weeks; three months: 52.9 ± 0.5 versus 52.9 ± 
0.7 weeks; six months: 66.1 ± 0.8 versus 66.2 ± 0.8 weeks; all p≥0.05). Type of diet and 
severity of illness did not differ between AGA and SGA infants (severity of illness: 21.8 ± 
8.3 versus 21.3 ± 7.8 points, p=0.78). Of the AGA infants, 38.8% was fed postdischarge 
formula, 26.5% term formula, and 34.7% human milk. Of the SGA infants, 36.4% was fed 
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postdischarge formula, 30.3% term formula, and 33.3% human milk. If only infants with 
a good quality DXA at term age and six months post-term were compared, similar results 
were found in AGA and SGA infants.
aga and sga infants: growth between term age and six months post-term
Weight, length, and head circumference were lower in SGA than AGA infants at birth, at 
term age, and at three and six months post-term, after adjustment for gender, gestational 
age, and postmenstrual age (Table 5.1). These differences were not explained by severity 
of illness or the type of diet (e.g. postdischarge formula, term formula, or human milk).
Gain in weight, length, and head circumference between term age and six months 
post-term was not different between AGA and SGA infants after adjustment for gender 
and gestational age (Table 5.1). If only infants with a good quality DXA at term age and 
six months post-term were compared, similar results were found in AGA and SGA infants.
Table 5.1. Growth between birth and six months post-term in AGA and SGA infants 
AGA 
(n=98)
SGA 
(n=33)
mean ± SD range mean ± SD range P
Birth
Weight (g) 1394 ± 283 710-2065 1158 ± 254 760-1577 <0.001
Length (cm) 38.9 ± 2.6 32-45 35.5 ± 2.2 31-39 <0.001
Head circumference (cm)1 27.9 ± 1.9 22.2-32 27.0 ± 1.7 24-30.5 <0.001
Term age
Weight (g) 3262 ± 439 2395-4260 2751 ± 447 2035-3540 <0.001
Length (cm) 49.2 ± 1.9 44.5-54 46.4 ± 2.3 42-50.5 <0.001
Head circumference (cm) 35.9 ± 1.3 33-39.6 35.2 ± 1.5 31.7-38.4 <0.001
3 months post-term
Weight (g) 5755 ± 778 2395-4260 5102 ± 862 3680-7050 <0.001
Length (cm) 59.6 ± 1.9 44.5-54.0 57.0 ± 2.6 51.0-64.0 <0.001
Head circumference (cm) 40.9 ± 1.4 37.5-45.5 40.5 ± 1.5 37.6-42.7 0.002
6 months post-term
Weight (g) 7509 ± 101 5520-11030 6872 ± 100 5070-8865 <0.001
Length (cm) 67.1 ± 2.6 61-75 64.8 ± 2.9 59.5-72.5 <0.001
Head circumference (cm) 44.0 ± 1.5 40-49.4 43.7 ± 1.5 40.7-46.8 0.023
Term age-6 months post-term
ΔWeight (g) 4247 ± 828 2900-7165 4121 ± 808 2500-5680 n.s.
ΔLength (cm) 17.9 ± 2.0 13.7-24.0 18.4 ± 2.3 14.5-26.0 n.s.
ΔHead circumference 8.0 ± 1.0 4.7-10.4 8.5 ± 1.0 6.8-10.9 n.s.
AGA: appropriate-for-gestational-age (weight and length at birth ≥-2 SDS); SGA: small-for-gestational-age 
(weight and/or length at birth <-2 SDS); Δ: gain. Multivariate regression analyses for between-group differences 
adjusted for gender, gestational age, and postmenstrual age. 1 HC at birth was missing in two AGA infants.
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aga and sga infants: bone mass at term age and six months post-term
At term age and at six months post-term, all bone mass parameters were lower in SGA 
than AGA infants after adjustment for gender and gestational age (Table 5.2 and Figure 
5.2). BA, BMC, and BMD at term age were not lower in SGA than AGA infants after ad-
ditional adjustment for actual weight and length. BMD at six months post-term was also 
not lower in SGA than AGA infants after additional adjustment for actual weight and 
length. However, BA and BMC at six months post-term remained lower in SGA than AGA 
infants after additional adjustment for actual weight and length (BA: β=-0.03, 95%CI 
-0.06;-0.01, p=0.013; and BMC: β=-0.06, 95%CI -0.12;-0.01, p=0.014). 
BMC at term age and at six months post-term was not different between AGA and SGA 
infants after adjustment for gender, gestational age, weight, length, and bone area (data 
not shown). The differences in bone mass parameters at six months post-term between 
AGA and SGA infants were not explained by severity of illness or the type of diet. If only 
infants with a good quality DXA at term age and six months post-term were compared, 
similar results were found in AGA and SGA infants.
Table 5.2. Bone mass in AGA and SGA infants between term age and six months post-term
AGA SGA AGA versus SGA
n mean ± SD n mean ± SD β 95% CI P
Term age
BA (cm2) 82 322.0 ± 39.1 28 274.0 ± 34.1 -0.17 -0.23;-0.12 <0.001
BMC (g) 82 48.6 ± 10.1 28 38.1 ± 9.5 -0.26 -0.37;-0.16 <0.001
BMD (g.cm-2) 82 0.15 ± 0.02 28 0.14 ± 0.02 -0.09 -0.15;-0.03 0.003
BMC/weight (%) 82 1.37 ± 0.18 28 1.28 ± 0.17 -0.07 -0.13;-0.01 0.033
6 months post-term
BA (cm2) 78 627.3 ± 59.8 24 582.5 ± 50.2 -0.10 -0.15;-0.05 <0.001
BMC (g) 78 145.4 ± 22.9 24 130.1 ± 25.7 -0.16 -0.25;-0.08 <0.001
BMD (g.cm-2) 78 0.23 ± 0.02 24 0.22 ± 0.03 -0.07 -0.12;-0.01 0.012
BMC/weight (%) 78 1.84 ± 0.15 24 1.73 ± 0.18 -0.07 -0.12;-0.02 0.003
Term age-6 months
ΔBA (cm2) 63 309.5 ± 55.2 21 312.7 ± 40.6 n.s.
ΔBMC (g) 63 98.2 ± 20.7 21 91.7 ± 22.8 -0.12 -0.24;-0.003 0.044
ΔBMD (g.cm-2) 63 0.082 ± 0.026 21 0.083 ± 0.027 n.s.
ΔBMC/Δweight (%) 63 2.30 ± 0.30 21 2.07 ± 0.28 -0.11 -0.18;-0.03 0.007
AGA: appropriate-for-gestational-age (weight and length ≥-2 SDS); SGA: small-for-gestational-age (weight and/
or length <-2 SDS); BA: bone area; BMC: bone mineral content; BMD: bone mineral density; Δ: gain. Multivariate 
regression analyses with AGA versus SGA as independent categorical variable (AGA as reference category) and 
natural log transformed bone mass parameters as dependent variables, adjusted for gender and gestational age. 
The negative beta coefficient (β) indicates lower bone mass in SGA than AGA infants.
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aga and sga infants: gain in bone mass between term age and six months 
post-term
All bone mass parameters increased in AGA and SGA infants between term age and 
six months post-term (Table 5.2 and Figure 5.2). Gain in BA and BMD was not different 
between AGA and SGA infants after adjustment for gender and gestational age (Table 
5.2). Gain in BMC and BMC/weight was higher in AGA than SGA infants after adjustment 
for gender and gestational age (Table 5.2). Gain in BMC remained higher in AGA than 
SGA infants after additional adjustment for gain in weight and length (β=-0.11, 95%CI 
-0.18;-0.03, p=0.01) and after additional adjustment for gain in weight, length, and bone 
area (β=-0.10, 95%CI -0.18;-0.02, p=0.01). The differences in gain in bone mass between 
AGA and SGA infants were not explained by severity of illness or the type of diet.
aga and sga infants: relative gain in weight, length, and bone mass between 
term age and six months post-term
Relative gain in weight, length, and BA was higher in SGA than AGA infants adjusted for 
gender and gestational age (Table 5.3). After additional adjustment for relative gain in 
weight and length, relative gain in BA was not different between AGA and SGA infants. 
Relative gain in BMC and BMD was not different between AGA and SGA infants adjusted 
for gender and gestational age (Table 5.3).
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figure 5.2. Bone mass accretion in AGA (●) and SGA (■) infants between term age and six months post-term
Values as mean ± SD; AGA: appropriate-for-gestational-age (weight and length ≥-2 SDS); SGA: small-for-
gestational-age (weight and/or length <-2 SDS); BA: bone area; BMC: bone mineral content; BMD: bone mineral 
density. Multivariate regression analyses with natural log transformed parameters and covariates for between-
group differences, adjusted for gender and gestational age; *** P<0.001, ** P<0.01, * P<0.05.
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dIscussIon
This study is the first to demonstrate that incomplete intra-uterine bone mass accretion 
cannot be compensated in the extra-uterine environment in SGA preterm-born infants. 
In analogy with term-born SGA infants [36-38], preterm-born SGA infants have lower 
bone mass accretion during early infancy, independent of body size. Previous studies 
demonstrated lower bone mass in SGA than AGA infants directly after birth. Petersen 
et al. show that preterm-born infants with a birth weight below the 10th percentile have 
lower bone mineral mass at birth than preterm-born AGA infants [36]. The present study 
showed that lower bone mass in SGA preterm-born infants persists into early infancy due 
to lower gain in bone mass until six months post-term, independent of post-term growth.
Previous authors have suggested that, in preterm-born infants, the postnatal growth tra-
jectory modifies bone mass accretion, since weight and length during infancy are positively 
associated with bone mineral content in childhood and adulthood [24, 26-27] and, indeed, 
this association is found in term-born infants [16, 22-24, 39]. However, in our study, the 
lower gain in bone mass in SGA preterm-born infants could not be attributed to smaller 
body size during infancy. Thus, it appears that in preterm-born infants bone mass during 
early infancy is mainly determined by the prenatal growth trajectory. This difference with 
term-born infants may be explained by the fact that preterm-born infants are exposed to the 
extra-uterine environment during the third trimester, when normally 80% of the total intra-
uterine bone mass is attained [1]. The extra-uterine environment during the third trimester 
cannot meet the needs of preterm-born infants, and the bone mineral deficit is further ag-
Table 5.3. Relative gain in weight, length, and bone mass gain in AGA and SGA infants between term age 
and six months post-term
AGA 
(n=63)
SGA 
(n=21)
AGA versus SGA
mean ± SD mean ± SD β 95% CI P
% ΔWeight 134.4 ± 30.6 163.6 ± 25.5 0.17 0.06;0.29 0.004
% ΔLength 36.4 ± 4.5 41.2 ± 6.0 0.11 0.04;0.18 0.002
% ΔBA 98.6 ± 23.8 117.0 ± 21.0 0.16 0.04;0.29 0.012
% ΔBMC 213.4 ± 71.4 253.5 ± 71.2 0.15 -0.03;0.32 n.s.
% ΔBMD 56.9 ± 23.2 61.9 ± 22.4 0.08 -0.20;0.37 n.s.
AGA: appropriate-for-gestational-age (weight and length ≥-2 SDS); SGA: small-for-gestational-age (weight and/
or length <-2 SDS); BA: bone area; BMC: bone mineral content; BMD: bone mineral density; Δ: gain. % ΔWeight: 
relative gain in weight=(Δweight between term age and six months post-term)/weight at term age*100%; other 
parameters were calculated similarly. Multivariate regression analyses with AGA versus SGA as independent 
categorical variable (AGA as reference category) and natural log transformed weight, length, and bone mass 
parameters as dependent variables, adjusted for gender and gestational age. The positive beta coefficient (β) 
indicates higher relative gain in SGA than AGA infants. Only infants with good quality DXA at both term age and 
six months post-term were included in the analyses.
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gravated. Our results suggest that this deficit persists during early infancy. The lower bone 
mass accretion in SGA preterm-born infants could not be attributed to lower gain in skeletal 
size, as measured by bone area [40]. Since a low bone mineral content may reflect either a 
small skeleton (i.e. low bone area) or low bone density [40], this finding implies that SGA 
preterm-born infants in our study have lower bone mass accretion as a result of decreased 
bone density. Tracking of decreased bone mass from infancy to adulthood may explain the 
finding that preterm-born SGA adults have decreased bone mass [7, 21].
In the present study, bone mineral content was lower in SGA infants at term age and 
six months post-term (21.6% and 10.3%, respectively). However, the difference in relative 
gain in BMC was not significantly different. This suggests that SGA preterm-born infants 
in our study do not have a significantly higher bone mass accretion between term age 
and six months post-term to compensate for a lower bone mineral content at term age.
An important factor for bone mass accretion is type of feeding. During infancy, human 
milk results in lower bone mineral content than formula [10-12, 41], and term formula 
results in lower bone mineral content than nutrient-enriched formula in preterm-born 
infants [13-15]. Surprisingly, greater neonatal human milk exposure is associated with 
increased bone mineral content in preterm-born adults at 20 years of age, suggesting 
that the period before term age is sensitive for the effect of human milk on later bone 
mass [7]. Fewtrell et al. speculated that this enhancing effect of human milk on bone 
mass may be explained by the various growth factors and hormones present in human 
milk [7]. In the present study, the type of feeding after term age was not related to the 
lower gain in bone mass in SGA compared to AGA infants during the first six months 
post-term. It might be suggested that the sensitive period for the effect of human milk 
on bone mass exists before but not after term age.
Several characteristics of the study population may have influenced the results of the 
present study. First, SGA infants had a higher mean gestational age than AGA infants 
due to the inclusion criteria of the randomized controlled trial, which were a gestational 
age of 32 weeks or less and/or a birth weight of 1,500 gram or less. However, SGA infants 
had lower bone mass during infancy. Thus, our data suggest that, with regard to bone 
mineralization, SGA infants do not benefit from this longer exposure to the intra-uterine 
environment. This may indicate that the detrimental effect of intra-uterine growth 
restriction on bone mass accretion persists after term age.
Second, the SGA group comprised a higher percentage of boys. This may be a result 
of the inclusion criteria of the randomized trial because gender in combination with 
being SGA or AGA at birth was not taken into account at the moment of inclusion. In the 
present study, all analyses were adjusted for gestational age and gender to exclude any 
influence of these parameters on bone mass and growth.
Furthermore, SGA infants all had short stature at birth and 30% had low birth weight 
as well. This can be explained by the SGA classification, which was based on birth weight 
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as well as birth length. Post-term gain in weight and length was similar in SGA and 
AGA infants, and this resulted in a smaller body size in SGA infants at all time-points. 
Therefore, analyses with bone mass parameters were adjusted for body size to exclude a 
proportionally lower bone mass in SGA infants.
This study had several limitations. An important limitation was that the sample size 
was small, especially after subgroup classification. Another limitation was that size at 
birth was classified based on weight and length, since both are important indicators of 
body size and are related to bone mass. In contrast to several previous studies, a value 
below -2 SDS was used to define small body size and, thus, only the smallest infants were 
included in the SGA group.
In addition, statistical approaches for bone mass analyses vary considerably between 
studies. For statistical analyses, we adjusted for body size and bone area, as described by 
Prentice et al. and as used by Fewtrell et al. for analyses in a preterm-born adult cohort 
[7, 35]. Several studies did not adjust for differences in actual body size when comparing 
bone mass between AGA and SGA infants [36-38]. Therefore, lower bone mass in SGA 
infants in these studies may be explained by smaller body size and not by actual bone 
mass deficit. Nevertheless, our data showed that bone mass was lower in SGA infants, 
independent of body size.
Furthermore, it is difficult to compare the results of our study to those of previous 
studies due to differences in the methodology of bone mass measurement [33]. In 
previous studies, bone mass measurements were performed with different apparatus, 
e.g. single photon absorptiometry versus dual-energy x-ray absorptiometry, and with a 
different model and type of dual-energy x-ray absorptiometry, e.g. Lunar versus Hologic, 
and analyses of bone mass were performed with different software, e.g. Pediatric versus 
Infant Software. For these reasons, comparisons between our study and previous stud-
ies need to be interpreted with caution.
concLusIon
This study suggests that the lack of bone accretion of SGA preterm-born infants cannot 
be compensated during the first six months post-term. Their lower bone mass gain is not 
related either to gain in body or skeletal size or to the type of feeding. Thus, the prenatal 
growth trajectory, and not the postnatal growth trajectory, appears to be the main 
determinant of bone mass accretion in preterm-born infants during the first six months 
post-term. This novel idea that the extra-uterine environment cannot replicate the favor-
able intra-uterine conditions for bone mass accretion emphasizes the importance of the 
intra-uterine environment for sufficient bone mass accretion in preterm-born infants. 
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Furthermore, these findings question the efficacy of postnatal nutritional interventions 
for the improvement of bone mass accretion in SGA preterm-born infants.
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absTracT
objective
To identify growth-related collagen and bone parameters in small-for-gestational-age 
(SGA) and appropriate-for-gestational-age (AGA) preterm infants during the first six 
months post-term. In SGA preterm infants, increased growth and decreased bone acqui-
sition, which we demonstrated previously, may be reflected by these markers.
design
Observational study within a randomized controlled trial.
Patients
Thirty-three SGA (weight, length, or both at birth <-2 SDS) and 98 AGA preterm infants 
(gestational age [median (IQR)]: 30.3 (2.0) versus 31.1 (1.6) weeks; 42.9% versus 72.7% 
boys).
Measurements
Weight (g), length (cm), procollagen type I N-terminal peptide (PINP; μg/l), urinary heli-
cal peptide (UHP; μg/mmol creatinine), and alkaline phosphatase (ALP; U/l) expressed as 
standard deviation scores (SDS) at term age, three and six months post-term.
results
Weight and length gain during the first six months post-term and PINP SDS at term age, 
three months, and six months post-term were higher in SGA compared to AGA infants. 
UHP SDS and ALP SDS were similar in AGA and SGA infants. PINP SDS and UHP SDS at 
term age and PINP SDS at three months post-term were associated with subsequent 
weight and length gain until six months post-term.
conclusions
Accelerated growth in SGA compared to AGA preterm infants is reflected by increased 
collagen type I synthesis during the first six months post-term, suggesting that PINP 
and UHP correspond with growth in preterm infants. An explanation for decreased bone 
acquisition of SGA preterm infants may be that increased collagen type I synthesis is not 
directly followed by increased bone mineralization.
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InTroducTIon
During growth, collagen turnover is abundant and leads to the production of specific 
products that may be used as markers of collagen synthesis and degradation [1]. For 
collagen type I, which is predominantly present in bone matrix, serum procollagen 
type I N-terminal peptide (PINP) is a synthesis marker [1-2] and urinary helical peptide 
(UHP) a degradation marker. Lower collagen type I synthesis markers in cord blood may 
reflect decreased intrauterine growth [3-4] that results in low weight, length, or both at 
birth. Furthermore, they may reflect decreased intrauterine bone formation that results 
in lower bone mineral content (BMC) of small-for-gestational-age (SGA) compared to 
appropriate-for-gestational-age (AGA) preterm infants at birth [5].
Postnatally, preterm infants and in particular those born SGA have increased growth in 
the presence of an adequate nutritional supply. In term infants, collagen type I synthesis 
markers are associated with growth during infancy [6], childhood, and adolescence [7-
12]. In preterm infants, growth, which may also affect bone accretion [13], is reflected 
by increased formation and decreased degradation markers of collagen type I until 
term age (i.e. 40 weeks postmenstrual age) [1, 14-16]. No information on collagen type I 
turnover in relation to growth and bone accretion in preterm infants after term age has 
been published.
Moreover, collagen type I formation and degradation markers may allow a more 
dynamic assessment of bone formation and bone resorption [17]. Recently, we have 
demonstrated lower BMC gain in SGA compared to AGA preterm infants during the first 
six months post-term, independent of growth or gain in skeletal size [18]. The lower BMC 
gain may be attributed to decreased bone mineralization [18], in which case a lower se-
rum alkaline phosphatase (ALP) is expected in SGA preterm infants. On the other hand, 
lower BMC gain may also reflect lower collagen type I deposition in the bone matrix.
The present study aimed to elucidate whether growth and bone accretion of AGA 
and SGA preterm infants are associated with collagen type I formation and degradation 
markers and investigated PINP, ALP, and UHP in relation to growth and BMC in AGA and 
SGA preterm infants between term age and six months post-term. We hypothesized 
that, during the first six months post-term, increased growth in SGA preterm infants was 
associated with higher PINP and lower UHP. Second, we hypothesized that lower gain in 
BMC was explained by lower bone mineralization reflected by lower ALP.
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PaTIenTs and MeThods
Patients
The present study was part of a randomized controlled trial that evaluated the effects 
of postdischarge formula, term formula, and human milk on growth and body composi-
tion in preterm infants, as described previously [18-19]. In short, 152 infants born at a 
gestational age of 32 weeks or less, with a birth weight of 1,500 gram or less, or both 
were included and attended our outpatient clinic at term age (40.3 ± 0.7 weeks post-
menstrual age), three months post-term (53.0 ± 0.5 weeks postmenstrual age), and six 
months post-term (66.0 ± 0.5 weeks postmenstrual age). One-hundred-and-thirty-nine 
infants completed the randomized controlled trial at six months post-term, as described 
previously [18-19]. The present study investigated size at birth, postnatal growth, and 
BMC in relation to serum collagen turnover and bone markers and included 98 AGA and 
33 SGA infants with available data on collagen turnover and bone markers, growth, and 
BMC between term age and six months post-term. Eight preterm infants of the original 
randomized controlled trial were not included because they could not be classified as 
AGA or SGA due to missing data on birth length. This study was conducted according 
to the guidelines laid down in the Declaration of Helsinki, and all procedures involv-
ing patients were approved by the Ethics Committee of VU University Medical Center, 
Amsterdam, The Netherlands. All the parents of the participating infants gave written 
informed consent.
Methods
Gestational age (weeks) at birth was extracted from the infants’ medical records. Weight 
and length were measured at birth, term age, three and six months post-term, as de-
scribed previously [18-19]. At birth and term age, weight and length were expressed as 
standard deviation scores (SDS) based on Swedish references for preterm infants [20]. 
At three and six months post-term, weight and length were expressed as SDS based on 
Dutch references [21]. Infants were classified as AGA if weight and length at birth were 
-2 SDS or above and as SGA if weight, length, or both at birth were below -2 SDS. Gain 
(Δ) in weight SDS and length SDS was calculated for the following intervals: birth-term 
age, birth-three months post-term, birth-six months post-term, term age-three months 
post-term, term age-six months post-term, and three-six months post-term.
PINP, ALP, urine creatinine, and UHP were measured at term age, three and six months 
post-term. PINP (μg/l) was measured at the Endocrine Laboratory of VU University Medi-
cal Center, Amsterdam, The Netherlands by a radioimmunoassay (Orion Diagnostica, 
Espoo, Finland) with an inter-assay variance of 9.0%. ALP (U/l) was measured at the De-
partment of Clinical Chemistry of VU University Medical Center, Amsterdam, The Neth-
erlands by IFCC method (Roche diagnostics, Mannheim, Germany) with an inter-assay 
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variance of 1.9%. Urine creatinine (mmol/l) was analyzed at the Department of Clinical 
Chemistry of VU University Medical Center, Amsterdam, The Netherlands by the Jaffé 
method (Roche diagnostics, Mannheim, Germany) with an inter-assay variance of 2.2%. 
UHP (μg/mmol creatinine) was measured at the University Medical Centre Groningen, 
Groningen, The Netherlands by ELISA (Quidel Corporation, San Diego, CA, USA) with an 
inter-assay variance of 8.8%. Change in PINP, ALP, and UHP was calculated between term 
age and three months post-term and between three and six months post-term. The ratio 
between PINP and UHP was calculated at term age, three and six months post-term, as a 
proxy for the ratio between collagen type I formation and degradation.
BMC (g) was measured at term age and six months post-term by whole-body dual-
energy x-ray absorptiometry (DXA; Hologic QDR4500A, Hologic Inc., Bedford, MA, USA) 
and analyzed with Infant Whole Body Software, version 12.3.3, as described previously 
[18-19]. DXA scan quality was evaluated by one expert radiologist who was blinded for 
the size at birth and the type of feeding of the infants. Incomplete scans and scans with 
severe movement artefacts were excluded. Good quality DXA scans were available from 
82 AGA and 28 SGA preterm infants at term age, 78 AGA and 24 SGA preterm infants at 
six months post-term, and 63 AGA and 21 SGA at both term age and six months post-
term [18].
statistics
The distribution of gender and type of feeding were expressed as frequency and com-
pared between SGA and AGA infants by logistic regression, adjusted for gestational 
age and for gender and gestational age, respectively. Weight SDS and length SDS were 
normally distributed and expressed as mean ± standard deviation (SD). Gestational age 
at birth, PINP, ALP, UHP, PINP/UHP ratio, and BMC were normally distributed after natural 
log transformation and expressed as median (IQR).
Growth, PINP (μg/l), ALP (U/l), UHP (μg/mmol creatinine), and PINP/UHP ratio were 
compared between SGA and AGA infants by linear regression adjusted for gender and 
gestational age. Associations between PINP (μg/l), UHP (μg/mmol creatinine), PINP/UHP 
ratio, growth, and BMC (g) were evaluated by linear regression adjusted for gender and 
gestational age.
PINP, ALP, UHP, and BMC were expressed as internal SDS by gender with AGA infants as 
the reference category to improve the comparison between SGA and AGA infants, as SGA 
infants were more often boys and had a higher gestational age at birth. In addition, these 
internal SDS were used to exclude the influence of gender and being SGA in the associa-
tions. Unfortunately, SDS references were not available for this age group. Differences in 
PINP SDS, ALP SDS, and UHP SDS between SGA and AGA infants as well as associations 
between PINP SDS, UHP SDS, and growth and between PINP SDS, UHP SDS, and BMC SDS 
were analyzed by linear regression, all adjusted for gender and gestational age.
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It was evaluated if type of feeding (postdischarge formula, term formula, or human 
milk) influenced the differences in growth, collagen turnover and bone markers between 
SGA and AGA infants. In addition, it was evaluated if associations between collagen 
turnover markers, growth, and BMC were modified by the type of feeding or by being 
SGA and if there was an interaction between gender, gestational age, and being SGA 
on these associations. Associations between growth intervals and collagen turnover 
markers were adjusted for gain in weight SDS or length SDS in the preceding interval. 
All statistical analyses were performed with SPSS 17.0 for Windows (SPSS Inc., Chicago, 
IL, USA). A P value of less than 0.05 was considered significant.
resuLTs
sga and aga infants: baseline characteristics and growth
Gestational age at birth was higher in SGA compared to AGA infants (31.1 (1.6) weeks 
versus 30.3 (2.0) weeks, P=0.001). SGA infants were more often boys compared to AGA 
infants (72.7% versus 42.9%, P=0.004). The type of feeding did not differ between SGA and 
AGA infants (SGA: 36.4% postdischarge formula; 30.3% term formula, 33.3% human milk; 
AGA: 38.8% postdischarge formula, 26.5% term formula, 34.7% human milk; P≥0.05).
Weight SDS and length SDS were lower in SGA compared to AGA infants at all time-
points (Figure 6.1). Between birth and term age, gain in weight SDS and length SDS was 
similar in SGA and AGA infants (Table 6.1). Between term age and three months post-
term and between term age and six months post-term, gain in length SDS was higher in 
SGA compared to AGA infants (Table 6.1). Between three and six months post-term, gain 
in weight SDS was higher in SGA compared to AGA infants (Table 6.1).The differences in 
growth between SGA and AGA infants were not related to the type of feeding (data not 
shown).
sga and aga infants: collagen turnover and bone markers
PINP (μg/l) and UHP (μg/mmol creatinine) at term age and PINP (μg/l) at three and six 
months post-term were higher in SGA compared to AGA infants; ALP (U/l) at term age, 
three and six months post-term was not different between SGA and AGA infants (Figure 
6.2). Between term age and three months post-term, the decline in PINP (μg/l) and UHP 
(μg/mmol creatinine) and the increase in ALP (U/l) were similar in SGA and AGA infants 
(data not shown). Between three and six months post-term, SGA infants had a greater 
decline in UHP compared to AGA infants (-1016 (712) versus -718 (831) μg/mmol creati-
nine, P=0.036), whereas the decline in PINP (μg/l) and ALP (U/l) was not different (data 
not shown). As a result, SGA infants had higher PINP/UHP ratio at six months post-term 
compared to AGA infants (Figure 6.2).
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A challenge of working with collagen turnover and bone markers is that serum levels 
change with age and differ between boys and girls. Since SGA infants were more often 
boys compared to AGA infants, collagen turnover and bone markers were compared 
using SDS. PINP SDS at term age, three and six months post-term was higher in SGA 
compared to AGA infants, whereas UHP SDS, PINP/UHP ratio SDS, and ALP SDS were 
similar in SGA and AGA infants (Figure 6.3). The differences in collagen turnover and 
bone markers expressed as SDS between SGA and AGA infants were not influenced by 
the type of feeding (data not shown).
figure 6.1. Weight SDS (A) and length SDS (B) in SGA and AGA preterm infants between term age and six 
months post-term
Tukey box plots. SGA: small-for-gestational-age; AGA: appropriate-for-gestational-age; months: months post-
term. Weight SDS and length SDS were compared between SGA and AGA infants by linear regression, adjusted 
for gender and gestational age.
Table 6.1. Gain in weight SDS and length SDS in SGA and AGA preterm infants between birth and six 
months post-term
SGA
(n=33)
AGA
(n=98)
Birth-term age
ΔWeight SDS -0.61 ± 0.74 -0.70 ± 0.68
ΔLength SDS 0.08 ± 1.04 -0.38 ± 1.07
Term age-3 months post-term
ΔWeight SDS 0.82 ± 0.71 0.69 ± 0.77
ΔLength SDS 0.84 ± 0.78** 0.43 ± 0.69
3-6 months post-term
ΔWeight SDS 0.15 ± 0.61* -0.10 ± 0.60
ΔLength SDS 0.44 ± 0.70 0.30 ± 0.58
Term age-6 months post-term
ΔWeight SDS 0.97 ± 1.04 0.59 ± 1.03
ΔLength SDS 1.28 ± 1.04** 0.73 ± 0.87
Values as mean ± SD. SGA: small-for-gestational-age; AGA: appropriate-for-gestational-age; Δ: gain; SDS: 
standard deviation score. Values compared between SGA and AGA preterm infants by linear regression adjusted 
for gender and gestational age; ** P<0.02; * P<0.05.
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Total group: collagen turnover markers in relation to growth
Gain in weight SDS between birth and term age was associated with PINP SDS and with 
PINP/UHP ratio SDS at term age (β=0.13, 95%CI 0.03;0.24, P=0.016; and β=0.16, 95%CI 
0.05;0.27, P=0.004; respectively) but not with UHP SDS at term age. Gain in weight SDS 
and length SDS between birth and three months post-term as well as between birth and 
six months post-term was not associated with PINP SDS, UHP SDS, and the PINP/UHP 
ratio SDS at three and six months post-term, respectively (data not shown).
PINP SDS and UHP SDS at term age were associated with gain in weight SDS and 
length SDS between term age and six months post-term (Table 6.2). PINP/UHP ratio SDS 
at term age was not associated with gain in weight SDS and length SDS between term 
age and six months post-term (Table 6.2). These associations persisted after adjustment 
figure 6.2. PINP (μg/l; A), UHP (μg/mmol creatinine; B), PINP/UHP ratio (C), and ALP (U/l; C) in SGA and 
AGA preterm infants between term age and six months post-term
Tukey boxplots. months: months post-term; SGA: small-for-gestational-age; AGA: appropriate-for-gestational-
age; PINP: procollagen type I N-terminal peptide; UHP: urinary helical peptide; ALP: alkaline phosphatase. 
Markers were compared between SGA and AGA preterm infants by linear regression with natural log 
transformed parameters, adjusted for gender and gestational age.
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for preceding gain in weight SDS or length SDS between birth and term age. In ad-
dition, adjusted for preceding gain in weight SDS between birth and term age, PINP 
SDS at term age was positively associated with gain in weight SDS between term age 
and six months post-term (β=0.17, 95%CI 0.01;0.33, P=0.033). PINP SDS at three months 
post-term was associated with gain in weight SDS and length SDS between three and 
six months post-term, whereas UHP SDS and PINP/UHP ratio SDS were not (Table 6.3). 
These associations persisted after adjustment for preceding gain in weight or length 
SDS between birth and three months post-term.
Similar associations were found between PINP (μg/l), UHP (μg/mmol creatinine), PINP/
UHP ratio, and growth, adjusted for gender and gestational age (data not shown). The 
associations between collagen turnover markers, expressed as absolute values or SDS, 
figure 6.3. PINP SDS (A), UHP SDS (B), PINP/UHP ratio SDS (C), and ALP SDS (D) in SGA and AGA preterm 
infants between term age and six months post-term
Tukey boxplots. SGA: small-for-gestational-age; AGA: appropriate-for-gestational-age; months: months post-
term; PINP: procollagen type I N-terminal peptide; UHP: urinary helical peptide; ALP: alkaline phosphatase. 
Markers were compared between SGA and AGA preterm infants by linear regression, adjusted for gender and 
gestational age.
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and growth were not modified by being SGA at birth or by the type of feeding (data not 
shown). There was no interaction between gender or gestational age and being SGA on 
the associations (data not shown).
Total group: collagen turnover markers in relation to bMc
PINP SDS and UHP SDS at term age were inversely associated with BMC SDS at term 
age (β=-0.30, 95%CI -0.48;-0.11, P=0.004; and β=-0.52, 95%CI -0.71;-0.34, P<0.001; re-
spectively). UHP SDS at term age was inversely associated with BMC SDS at six months 
post-term (β=-0.36, 95%CI -0.57;-0.16, P=0.001), whereas PINP SDS at term age was not. 
PINP SDS at three and six months post-term was not associated with BMC SDS at six 
months post-term. UHP SDS at three and six months post-term was inversely associ-
ated with BMC SDS at six months post-term (β=-0.33, 95%CI -0.52;-0.13, P=0.001; and 
β=-0.34, 95%CI -0.55;-0.13, P=0.002; respectively).
Similar associations were found between PINP (μg/l), UHP (μg/mmol creatinine), and 
BMC (g), adjusted for gender and gestational age (data not shown). The associations 
between collagen turnover markers and BMC, expressed as absolute values or SDS, were 
not modified by being SGA at birth or by the type of feeding (data not shown). There was 
no interaction between gender or gestational age and being SGA on the associations 
(data not shown).
Table 6.2. PINP SDS, UHP SDS, and PINP/UHP ratio SDS at term age in relation to gain in weight SDS and 
length SDS in the total group (n=131) between term age and six months post-term
Term age
PINP SDS UHP SDS PINP/UHP ratio SDS
R β 95% CI R β 95% CI R β 95% CI
Term age-3 months 
post-term
ΔWeight SDS 0.33 0.08 -0.03;0.20 0.32 0.07 -0.05;0.19 0.07 0.10 -0.16;0.36
ΔLength SDS 0.17 0.10 -0.01;0.22 0.21 0.13 0.01;0.25* 0.01 -0.02 -0.29;0.25
3-6 months post-term
ΔWeight SDS 0.05 0.02 -0.07;0.12 0.22 0.12 0.02;0.22** 0.13 -0.24 -0.57;0.10
ΔLength SDS 0.18 0.06 -0.04;0.15 0.21 0.08 -0.03;0.18 0.01 0.01 -0.32;0.34
Term age-6 months 
post-term
ΔWeight SDS 0.26 0.11 -0.05;0.27 0.30 0.19 0.02;0.35* 0.02 -0.02 -0.22;0.17
ΔLength SDS 0.21 0.16 0.01;0.30* 0.27 0.21 0.06;0.36** 0.01 -0.01 -0.22;0.21
PINP: procollagen type I N-terminal peptide (μg/l); UHP: urinary helical peptide (μg/mmol creatinine); R: 
model summary correlation coefficient; β: regression coefficient; 95%CI: 95% confidence interval of regression 
coefficient; Δ: gain in. Associations evaluated by linear regression, adjusted for gender and gestational age;
** P<0.02, * P<0.05.
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dIscussIon
The present study is the first to publish on collagen type I turnover in preterm infants 
after term age in relation to growth and bone accretion and demonstrates that SGA 
preterm infants have higher collagen type I synthesis, reflected by higher PINP levels, 
compared to AGA preterm infants during the first six months post-term. Collagen turn-
over markers as indicators of growth have only been reported in preterm infants until 
term age [1, 14-16]. We have now demonstrated that the collagen turnover markers PINP 
and UHP continue to be markers of growth of preterm infants during the first six months 
post-term.
Furthermore, our findings suggest that higher collagen type I synthesis in SGA com-
pared to AGA preterm infants may reflect faster growth in SGA preterm infants during 
the first six months post-term. In contrast, others demonstrate equal PINP levels in SGA 
and AGA preterm infants until term age [14]. In the present study, the higher collagen 
type I synthesis markers may reflect accelerated growth of SGA preterm infants, similar 
to associations demonstrated in term subjects during infancy [6], childhood and adoles-
cence [7-12]. In more detail, this study adds that PINP is associated with growth between 
three and six months post-term, which might imply that most of the collagen type I 
synthesis that contributes to growth takes place during this interval.
During the first year of life, collagen type I synthesis decreases, which is reflected by a 
decrease in PINP levels [22-23]. This decline may demonstrate a shift from rapid in utero 
and early postnatal growth towards slower growth during infancy [24]. In the present 
study, PINP levels decreased in both SGA and AGA preterm infants during the first six 
months post-term, which suggests a shift towards slower growth. The higher PINP levels 
at six months post-term in SGA compared to AGA infants may imply that preterm SGA 
infants approach this phase of growth deceleration later during infancy.
Table 6.3. PINP SDS, UHP SDS, and PINP/UHP ratio SDS at three months post-term in relation to gain in 
weight SDS and length SDS in the total group (n=131) between three and six months post-term
3 months post-term
PINP SDS UHP SDS PINP/UHP ratio SDS
R β 95% CI R β 95% CI R β 95% CI
3-6 months post-term
ΔWeight SDS 0.30 0.15 0.05;0.25** 0.03 0.02 -0.09;0.12 0.16 0.29 -0.04;0.62§
ΔLength SDS 0.26 0.15 0.05;0.25** 0.21 0.09 -0.02;0.20§ 0.09 0.16 -0.17;0.49
PINP: procollagen type I N-terminal peptide (μg/l); UHP: urinary helical peptide (μg/mmol creatinine); R: 
model summary correlation coefficient; β: regression coefficient; 95%CI: 95% confidence interval of regression 
coefficient; Δ: gain in. Associations evaluated by linear regression, adjusted for gender and gestational age;  
** P<0.01, § P=0.09.
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It may be hypothesized that collagen type I synthesis predominantly results in bone 
growth because collagen type I is mainly deposited in bone matrix [2]. Although, in the 
present study, SGA preterm infants had increased collagen type I synthesis, we demon-
strated recently that the same group of infants has a decreased gain in BMC [18]. BMC is 
determined by skeletal size as well as by bone mineral density [25]. We hypothesize that 
higher collagen type I synthesis of SGA preterm infants may not result in higher gain in 
BMC because there is a lag time before bone mineralization starts, as suggested by a 
previous study in SGA term infants [26]. This hypothesis may be supported by the pres-
ent study that demonstrated that increased collagen type I synthesis in SGA preterm 
infants was not accompanied by increased bone mineralization, as suggested by the 
finding that serum ALP was not increased in SGA preterm infants. ALP has inconsistently 
been associated with BMC [27]. This puts emphasis on adequate postnatal nutritional 
regimens that supply sufficient nutrients to SGA preterm infants, including sufficient 
amino acids for collagen type I synthesis [24] as well as adequate amounts of calcium, 
phosphorus, and vitamin D in order to enhance bone mineralization.
Several characteristics of the study population may be taken into account when the 
results of the present study are interpreted. Being SGA was classified based on birth 
weight and birth length, as both are important indicators of body size and are related 
to bone mass. In contrast to previous studies, only the smallest infants were included 
in the SGA group because weight and length below -2 SDS were used to define small 
body size. Furthermore, SGA preterm infants had a higher gestational age at birth and 
were more often boys. The latter may be due to the fact that gender in combination 
with being SGA was not taken into account during randomization. In order to control 
for the influence of this difference in gestational age and gender, all analyses were ad-
justed for these variables and standard deviation scores were used. For weight SDS and 
length SDS, large reference groups were available. For BMC, collagen turnover and bone 
markers, internal SDS were constructed. In addition, there was no interaction between 
gender, gestational age, and being SGA on the presented results.
The present study had several limitations. The sample size was small, especially after 
subgroup classification. Another limitation was that the original randomized controlled 
trial investigated growth and body composition of preterm infants fed three different 
nutritional regimens after discharge. The distribution of the type of feeding was compa-
rable in SGA and AGA infants and the type of postdischarge nutrition neither influenced 
nor explained the associations between growth, BMC, and collagen turnover and bone 
markers or the differences between SGA and AGA infants. However, the influence of the 
nutritional regimen after discharge cannot be excluded completely.
In conclusion, increased collagen type I synthesis in SGA compared to AGA preterm 
infants is associated with accelerated growth during the first six months post-term, sug-
gesting that PINP and UHP correspond with growth in preterm infants. Furthermore, 
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lower gain in BMC in SGA compared to AGA preterm infants is not a consequence of 
insufficient collagen type I synthesis or increased bone resorption in SGA preterm 
infants. This lower gain in BMC may be attributed to a delay in bone mineralization, as 
suggested by the finding that increased collagen type I synthesis in SGA preterm infants 
is not yet accompanied by increased ALP, which reflects bone mineralization. These 
findings emphasize the importance of an adequate nutritional supply to SGA preterm 
infants, including calcium, phosphorus, and vitamin D, in order to achieve adequate 
bone mineralization during the first half of infancy.
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Purpose
Preterm infants are at risk for suboptimal bone mineralization. Postnatal bone formation 
requires optimal nutritional composition. This study evaluated the effect of isocaloric, 
protein- and mineral-enriched postdischarge formula (PDF), standard term formula 
(TF), and human milk (HM) on gain in bone mineral content (BMC) of preterm infants 
between term age (40 weeks postmenstrual age) and 6 months corrected age (CA).
Methods
Between term age and 6 months CA, 93 preterm infants were randomized to be fed PDF 
(n=52) or TF (n=41) and 46 preterm infants were fed HM. Weight (g) and length (cm) 
were measured at birth, term age, and 6 months CA. BMC (g) was measured by whole-
body dual-energy x-ray absorptiometry at term age and 6 months CA.
results
Gain in BMC (expressed as median with interquartile range) between term age and 6 
months CA was higher in PDF fed infants (102.3 (32.4) g) compared to TF and HM fed 
infants (91.6 (24.5) and 84.5 (33.3) g, respectively), adjusted for gender, gestational age, 
birth weight, and gain in weight and length.
conclusion
Between term age and 6 months CA, isocaloric PDF enhances gain in BMC of preterm 
infants, independent of gain in weight and length. We speculate that higher gain in BMC 
during infancy may improve adult bone mass in preterm infants.
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InTroducTIon
Eighty percent of the total bone mass of a newborn is acquired during the intra-uterine 
third trimester. Since preterm infants are exposed to extra-uterine conditions during the 
third trimester, they are at risk for suboptimal bone mineralization. To achieve adequate 
bone accretion during the extra-uterine third trimester, preterm infants require an opti-
mal composition of nutrient supply after birth [1].
Between birth and term age (40 weeks postmenstrual age), preterm infants fed an 
isocaloric, protein- and mineral-enriched formula reach a higher bone mineral content 
(BMC) compared to preterm infants fed a standard term formula [2]. After term age, 
the effect of a high-caloric, protein- and mineral-enriched formula on BMC has been in-
vestigated but remains controversial. Whereas some studies demonstrate that preterm 
infants fed a high-caloric, protein- and mineral-enriched formula reach a higher BMC 
than infants fed a standard term formula [3-5], other studies did not find a positive effect 
of a high-caloric, enriched formula on BMC after term age [6-7].
As the effect of an isocaloric, protein- and mineral-enriched formula on BMC has been 
demonstrated until term age [2], we hypothesized that protein and minerals added to 
a formula without additional energy enrichment improve bone accretion of preterm 
infants after term age. Therefore, the present study investigated the effects of isocaloric 
postdischarge formula (PDF), standard term formula (TF), and human milk (HM) on bone 
area (BA) and BMC of preterm infants between term age and 6 months corrected age 
(CA).
PaTIenTs and MeThods
The design of the present study and its participants have been described in detail previ-
ously [8]. In short, infants born at a gestational age of 32 weeks or less and/or with a 
birth weight of 1,500 g or less were eligible for the study. Exclusion criteria included 
congenital malformations or conditions known to affect growth or body composition. 
The study was approved by the local ethics committee. Parents of the participating 
children gave written informed consent. 
At term age, formula-fed infants were randomized to PDF (n=52; Table 7.1) or TF (n=41) 
and were fed this diet until 6 months CA. Between birth and term age, preterm infants 
were fed preterm formula (n=62: 39 PDF and 23 TF fed infants) or fortified human milk 
(n=75: 13 PDF, 17 TF, and 45 HM fed infants) and the type of diet could not be classified 
in two infants due to missing data. Sixteen HM fed infants were supplemented with 200 
IU/d vitamin D after human milk fortification was stopped at discharge. Between birth 
and term age, two PDF and two TF fed infants were supplemented with 200 IU/d vitamin 
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D during two or three weeks because they were fed unfortified human milk. Infants did 
not receive any mineral supplements between birth and term age. Two PDF and two TF 
fed infants were supplemented with vitamin D by their parents for unknown reasons 
during the first week after term age. At term age, infants were considered to be HM fed 
(n=46) if they received >80% HM and were supplemented with 200 IU/d of vitamin D. 
If HM was insufficiently available, TF was added to the diet. Between term age and 6 
months CA, the total volume intake (ml/kg/day) was not different between PDF and TF 
fed infants [8]. In the present study, infants did not receive any mineral supplements 
between term age and 6 months CA.
Weight (g) and length (cm) were measured at birth, term age, and six months CA, as 
described previously [8]. Weight and length at birth and term age were expressed as 
standard deviation score (SDS) based on Swedish references of preterm infants [9] and 
weight and length at 6 months CA were expressed as SDS based on Dutch references 
[10]. BA (cm2) and BMC (g) were measured at term age and 6 months CA by whole-body 
dual-energy x-ray absorptiometry (DXA; Hologic QDR4500A, Hologic Inc., Bedford, MA, 
USA) and were analyzed by Infant Whole Body Software version 12.3.3. One expert radi-
ologist evaluated the DXA quality and was blinded for the type of diet. Scans with severe 
movement artifacts and incomplete scans were excluded [11]. Good quality scans were 
available from 116 infants at term age, 106 infants at 6 months CA, and 87 infants at both 
term age and 6 months CA. Gain in weight, length, BA, and BMC between term age and 
6 months CA was calculated.
statistics
The distribution of gender was expressed as a frequency and compared between PDF, 
TF, and HM fed infants by Fisher’s exact test. Postmenstrual age, weight, length, BA, BMC, 
gain in BA, and gain in BMC were normally distributed after log transformation and were 
expressed as median with interquartile range (IQR). Postmenstrual age, adjusted for 
Table 7.1. Composition of study formulasa
Postdischarge formula (PDF)b Term formula (TF)c
Energy (kcal) 67 67
Protein (g) 1.7 1.47
Protein/energy ratio (g/100 kcal) 2.6 2.2
Carbohydrates (g) 7.0 7.2
Fat (g) 3.5 3.5
Calcium (mg) 65 50
Phosphorus (mg) 38 30
Vitamin D (IU) 56 48
a per 100 ml prepared formula; b Friso Prematuur 1®, FrieslandCampina, Leeuwarden, The Netherlands; c Friso 1 
normaal®, FrieslandCampina, Leeuwarden, The Netherlands.
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gender, as well as weight and length, both adjusted for gender and gestational age, 
were compared between PDF, TF, and HM fed infants by linear regression analyses.
BA and BMC were compared between PDF, TF, and HM fed infants by linear regression 
analyses with gender, gestational age, birth weight, and current weight and length as 
covariates. Gain in BA and BMC was compared between PDF, TF, and HM fed infants by 
linear regression analyses with gender, gestational age, birth weight and gain in weight 
and length as covariates. In addition, BMC at term age, BMC at 6 months CA, and gain in 
BMC were adjusted for BA at term age, BA at 6 months CA, and gain in BA, respectively, 
as recommended by Prentice et al. and Mølgaard et al. [12-13]. All analyses were also 
performed with weight and length SDS and these results were similar to those with ab-
solute weight and length. Therefore, only the analyses with absolute weight and length 
are described here. A P value of less than 0.05 was considered significant. All statistical 
analyses were performed using SPSS 17.0 for Windows (SPSS Inc., Chicago, IL, USA).
resuLTs
Postmenstrual age, weight, length, and the distribution of gender were not different 
between PDF, TF, and HM fed infants (Table 7.2). BMC at term age was lower in PDF and 
TF fed infants compared to HM fed infants (Table 7.3). BMC at 6 months CA was higher 
in PDF fed infants compared to TF and HM fed infants (Table 7.3). After adjustment for 
BA, BMC at term age and 6 months CA remained different between PDF and HM fed 
infants. Gain in BMC between term age and 6 months CA was higher in PDF fed infants 
compared to TF and HM fed infants (Table 7.3). However, after adjustment for gain in 
BA, gain in BMC was no longer different between PDF and TF fed infants but remained 
higher in PDF fed infants compared to HM fed infants. Gain in BMC was not different 
between TF and HM fed infants (Table 7.3).
All HM fed infants received fortified human milk, whereas PDF and TF fed infants 
received either preterm formula or fortified human milk between birth and term age. 
BMC at term age, BMC at 6 months CA, and gain in BMC was similar in PDF and TF fed 
infants that were fed preterm formula compared to those fed fortified human milk 
between birth and term age (data not shown). There was no interaction between the 
diet between birth and term age and the diet between term age and 6 months CA on 
bone mass parameters. In addition, there was no interaction between gender and diet 
on bone mass parameters.
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Table 7.2. Growth parameters between birth and 6 months corrected age in PDF, TF, and HM fed infants
PDF 
(n=52)
TF
 (n=41)
HM
(n=46)
Boysa (%) 51.9 56.1 45.7
Birth
PMA (weeks) 30.7 (1.5) 30.9 (2.3) 30.0 (1.9)
Weight (g) 1344 (483) 1394 (262) 1345 (605)
Length (cm) 38.0 (4.0) 38.3 (3.0) 38.0 (3.5)
Term age
PMA (weeks) 40.6 (1.1) 40.3 (0.9) 40.6 (0.7)
Weight (g) 3173 (699) 3090 (603) 3158 (734)
Length (cm) 49 (3.0) 48.5 (3.0) 48.3 (2.6)
6 months CA
PMA (weeks) 66.1 (1.0) 66.1 (1.0) 66.3 (1.0)
Weight (g) 7380 (1511) 7460 (1430) 7150 (1729)
Length (cm) 67.0 (2.5) 66.5 (4.8) 66.3 (4.0)
Values as median (IQR), unless specified otherwise. PDF: postdischarge formula; TF: term formula; HM: human 
milk; PMA: postmenstrual age; CA: corrected age. Linear regression analyses for comparisons between PDF, TF, 
and HM fed infants. No significant differences between PDF, TF, and HM fed infants. a Frequency (%).
Table 7.3. Bone area and bone mineral content in PDF, TF, and HM fed infants between term age and 6 
months corrected age
PDF TF HM
n median (IQR) n median (IQR) n median (IQR)
Term age
BA (cm2) 43 309.7 (73.9)* 36 300.4 (67.2)# 37 314.8 (57.2)
BMC (g) 43 43.8 (20.4)‡ 36 47.3 (12.7)# 37 48.5 (16.7)
6 months CA
BA (cm2) 42 632.3 (97.3) 30 597.8 (88.3) 34 601.4 (95.8)
BMC (g) 42 150.5 (42.5)*,+ 30 134.2 (35.1) 34 132.6 (33.4)
Term age-6 months CA
ΔBA (cm2) 36 306.2 (81.4) 25 300.6 (95.4) 26 317.1 (41.8)
ΔBMC (g) 36 102.3 (32.4)*,+ 25 91.6 (24.5) 26 84.5 (33.3)
PDF: postdischarge formula; TF: term formula; HM: human milk; BA: bone area; BMC: bone mineral content; 
CA: corrected age; Δ: gain. Linear regression analyses for differences between PDF, TF, and HM fed infants were 
adjusted for gender, gestational age, birth weight, and (gain in) weight and length; * PDF versus TF, P<0.05; + PDF 
versus HM, P<0.01; ‡ PDF versus HM, P<0.05; # TF versus HM, P<0.05.
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dIscussIon
This study demonstrates that PDF fed infants have the highest gain in BMC between 
term age and 6 months CA, independent of gain in weight and length. Several studies 
demonstrate a beneficial effect of various high-caloric postdischarge formulae on BMC 
of preterm infants during infancy [3-4]. Nonetheless, the isocaloric PDF used in the pres-
ent study also improves the BMC of preterm infants during early infancy.
In the present study, gain in BMC was higher in PDF fed infants compared to HM fed 
infants. In contrast to previous studies that found lower bone mineralization in infants 
fed human milk compared to infants fed standard term formula [14-18], gain in BMC was 
not different between HM and TF fed infants in the present study. This may be explained 
by a different composition and a different volume intake of the TF used in the present 
study compared to the standard term formula used in previous studies [14-18]. Another 
explanation may be that, in the present study, HM fed infants were fed TF if HM was 
insufficiently available, which occurred especially after 3 months CA. This may result in a 
comparable gain in BMC of HM and TF fed infants.
BMC is the product of BA and bone density. Therefore, low BMC may reflect either a 
small skeleton (i.e. low BA) or low bone density [13]. In the present study, the higher 
gain in BMC of PDF fed infants compared to TF fed infants was explained by a difference 
in gain in BA. This may imply that PDF fed infants have a higher gain in BMC as a result 
of a difference in skeletal size. A difference in skeletal size was not the explanation for 
higher gain in BMC in PDF fed infants compared to HM fed infants, since the gain in BMC 
remained higher in PDF fed infants after adjustment for gain in BA. In other words, this 
may imply that PDF fed infants have a higher gain in BMC compared to HM fed infants 
due to a higher gain in bone density. Both findings support our hypothesis that PDF 
enhances bone mineralization of preterm infants during early infancy.
Gain in BMC during early infancy may be very important for future bone health. Low 
BMC in infancy may persist into adulthood and result in lower adult bone mass [19-21], 
leading to a higher risk of osteoporosis in later life [22]. Therefore, it can be expected 
that increased gain in BMC in preterm infants as a result of nutritional intervention dur-
ing early infancy is important for adult peak bone mass.
In conclusion, an isocaloric, protein- and mineral-enriched PDF between term age and 
6 months CA enhances gain in BMC of preterm infants. We speculate that higher gain 
in BMC as a result of isocaloric PDF may be beneficial to attain higher adult peak bone 
mass in preterm infants.
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Post-term dietary-induced changes in DHA and 
AA status relate to gains in weight, length, 
and head circumference in preterm infants
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Preterms need supplementation with docosahexaenoic (DHA) and arachidonic (AA) 
acids to prevent steep postnatal declines. Associations between growth and erythro-
cyte (RBC) DHA and AA were studied in 139 preterms (51% male, gestational age 30.3 
± 1.5 weeks, birth weight 1341 ± 288 g) fed human milk with breast milk fortifier or 
preterm formula until term age followed by postdischarge formula (PDF; n=52, 0.4% 
DHA, 0.4% AA), term formula (TF; n=41, 0.2% DHA, 0.2% AA), or human milk (HM; n=46). 
At six months corrected age, PDF resulted in higher RBC-DHA than TF and HM, while 
RBC-AA was higher than TF but similar to HM. There were no between-group differences 
in growth between term age and six months corrected age. RBC-DHA related positively 
with gain in weight and length and negatively with gain in head circumference. RBC-AA 
related positively with gain in head circumference and negatively with gain in weight 
and length. In conclusion, PDF with higher DHA and AA than TF may promote postnatal 
growth of preterms.
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InTroducTIon
Long-chain polyunsaturated fatty acids (LC-PUFAs), notably docosahexaenoic (DHA) 
and arachidonic (AA) acids, are important for central nervous system development [1-3], 
growth, and body composition [4]. Especially in very low birth weight infants, biosynthe-
sis of LC-PUFA from alpha-linolenic and linoleic acid is insufficient to prevent postnatal 
decline of DHA and AA, which might adversely affect growth and development [5-7]. 
Meta-analyses of randomized controlled trials have, however, not shown better growth 
by LC-PUFA supplementation, neither in term nor in preterm infants [8-10].
Preterm infants have lower LC-PUFA stores at birth compared to term infants [5, 11-13], 
since they lack part of the rapid LC-PUFA accretion of the last trimester of pregnancy [3, 
14-15]. Insufficient dietary supply of LC-PUFA between birth and term age causes a steep 
decrease of LC-PUFA status in preterm infants. This LC-PUFA gap is not observed in term 
infants [5, 16]. The colostrum of preterm delivering mothers contains higher DHA and 
AA than milk from mothers delivering at term [17-18]. This apparent advantage vanishes 
rapidly with advancing lactation and is unable to fill the LC-PUFA gap [19]. For DHA this 
may in part be caused by the low DHA status of mothers living in Western countries [20], 
which adversely affects both the DHA status of preterm infants at birth and the ability to 
fill the imminent DHA gap after birth by feeding the mother’s own milk.
Guidelines for LC-PUFA content of infant formula are based on the LC-PUFA content of 
milk from Western mothers [21-22]. The European Society of Paediatric Gastroenterology, 
Hepatology and Nutrition (ESPGHAN) recommends 0.25-0.45 g% DHA and 0.38-0.64 g% 
AA for in-hospital preterm formula [23-25], but there are no specific recommendations 
for the LC-PUFA content of formula for preterm infants after discharge.
We aimed to prevent the imminent low LC-PUFA status of preterm infants by feeding 
a DHA and AA enriched postdischarge formula between term age and six months cor-
rected age. Furthermore, we aimed to study the relation between red blood cell (RBC) 
DHA, AA, and eicosapentaenoic acid (EPA) concentrations and postnatal growth.
PaTIenTs and MeThods
study design
The present study and its participants have been described previously [26]. In short, 
infants born at gestational ages of 32 weeks or less and/or with birth weights of 1,500 
g or less were included in a randomized controlled trial, which evaluated the effect of 
postdischarge formula (PDF), term formula (TF), and human milk (HM) between term 
age and six months corrected age on growth and body composition. Until term age, 
infants received human milk with standard breast milk fortifier or preterm formula. The 
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estimated LC-PUFA content of the preterm formula was 0.4-0.5 g% for DHA and 0.5-0.6 
g% for AA (Friso Prematuur, FrieslandCampina, Leeuwarden, The Netherlands; Nenatal 
start, Nutricia, Zoetermeer, The Netherlands). Infants were considered HM-fed if, at term 
age, they received predominantly human milk. If HM was insufficient, additional term 
formula was provided until six months corrected age. PDF contained the same quantity 
of energy, lower levels of carbohydrates, and higher levels of protein, DHA, AA, and 
some minerals and vitamins compared to TF (Table 8.1). Both TF and PDF were supplied 
by FrieslandCampina, Leeuwarden, The Netherlands. Of the 152 infants included in this 
study, 139 completed the study at six months corrected age. Informed consent from the 
parents and ethics committee approval were obtained.
Methods
Weight, length, and head circumference were measured at birth and term age and at 
three and six months corrected age. At birth and term age, weight, length, and head 
circumference were expressed as standard deviation score (SDS) based on Swedish ref-
erences for preterm infants [27]. At three and six months corrected age, weight, length, 
and head circumference were expressed as SDS based on Dutch references [28].
At term age and at three and six months corrected age, EDTA-anticoagulated venous 
blood samples for RBC-fatty acid analysis were collected at least 2.5 h after feeding. 
Blood samples were immediately cooled in melting ice. Within 2 h after collection, 
Table 8.1. Composition of study formulaea
Formula content Preterm formula (PTF)b Postdischarge formula (PDF) Term formula (TF)
Energy (kcal) 80 67 67
Protein (g) 2.2-2.5 1.7 1.4
Protein/energy ratio (g/100 kcal) 2.75-3.1 2.6 2.2
Carbohydrates (g) 7.6-8.2 7.0 7.2
Fat (g) 4.3-4.4 3.5 3.5
 Linoleic acid (mg) 490-560 415 422
 α-Linolenic acid (mg) 69-80 59 63
 Docosahexaenoic acid (mg) 18-20 (0.4-0.5%)c 14 (0.4%)c 7 (0.2%)c
 Arachidonic acid (mg) 20-26 (0.5-0.6%)c 14 (0.4%)c 7 (0.2%)c
 Eicosapentaenoic acid (mg) 0-3.9 (0-0.09%)c 3.9 (0.09%)c -
Calcium (mg) 100-120 65 50
Phosphorus (mg) 55-66 38 30
Vitamin D (µg) 2.4-3.0 1.4 1.2
Iron (mg) 0.78-1.4 1.00 0.78
a Data are for 100 ml prepared formula; b For PTF the ranges of composition is shown for Friso Prematuur 
(FrieslandCampina, Leeuwarden, The Netherlands) and Nenatal start (Nutritica, Zoetermeer, The Netherlands);  
c Percentage of total fat.
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plasma and buffy coat were removed. The RBC were washed three times with isotonic 
saline. The RBC were finally suspended to a hematocrit of about 50%. Two hundred µL 
of this suspension was stored at -20oC in a teflon-sealable tube containing 2 mL metha-
nol-6 M HCl (5:1 v/v), 1 mg butylated hydroxytoluene (antioxidant) and internal standard 
(50 µg 17:0 in 100 µL methanol). Samples were transported in dry ice to the University 
Medical Center Groningen (The Netherlands) for RBC-fatty acid composition analysis. 
The ready-to-transmethylate mixture was heated to 90oC for 4 h. Fatty acid methyl esters 
were extracted into hexane and profiled by capillary gas chromatography and flame 
ionization detection, as described previously [29]. RBC-fatty acid composition was cal-
culated from the peak areas and expressed as g% (fatty acid composition) or g/g (fatty 
acid ratios). The within-run and day-to-day precision for the RBC-fatty acid analysis has 
been described before [29]. Of the 139 infants that completed the study at six months 
corrected age, RBC-fatty acid analyses were available from 115 infants at term age, 128 
infants at three months, and 114 infants at six months corrected age.
Between term age and six months corrected age, parents recorded their child’s intake 
of the preceding week in a diary once a week. These diaries provided information about 
type and amount of enteral intake and any supplements and were used to calculate total 
milk volumes (ml/kg/day). Human milk fed infants were usually breastfed and therefore 
the exact total milk intake was unknown. In formula fed infants, protein intake (g/kg/
day) and DHA, EPA, and AA intakes (mg/kg/day) between term age and six months cor-
rected age were calculated based on total milk volumes and composition of the study 
formulae as described in Table 8.1. Nutrient intake, especially LC-PUFA intake, of the 
mother during pregnancy and lactation was unknown.
statistics
All statistical analyses were performed with SPSS 17.0 for Windows (SPSS Inc., Chicago, 
IL, USA). RBC-fatty acid data were expressed as mean ± standard deviation (SD). After 
natural logarithmic transformation, RBC-EPA levels at term age and three months cor-
rected age were normally distributed. All other parameters were normally distributed.
Regression analyses were used to evaluate between-group differences in gestational 
age at birth and between-group differences in weight, length, head circumference and 
RBC-fatty acids at term age and at three and six months corrected age. Between-group 
differences in RBC-fatty acids at three and six months corrected age were corrected for 
RBC-fatty acids at term age. Generalized estimating equations were used to evaluate 
within-group longitudinal changes in growth and RBC-fatty acids and the relation 
between growth and change in RBC-fatty acids between term age and six months cor-
rected age. P values of less than 0.05 were considered significant.
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resuLTs
anthropometry and dietary intake
There were no between-group differences in gestational age or anthropometric charac-
teristics (Table 8.2). Between term age and six months corrected age, total milk volume 
intakes (ml/kg/day) were not significantly different between PDF and TF-fed infants. 
Consequently, PDF-fed infants had significantly higher DHA, EPA, and AA intakes (mg/
kg/day) compared to TF-fed infants (data not shown).
between-group differences in rbc-fatty acids
Gestational age and gender did not influence RBC-DHA, EPA, and AA at term age and at 
three and six months corrected age (data not shown). At term age, HM-fed infants had 
lower RBC-DHA and DHA/AA ratio and similar RBC-AA and EPA compared to formula-fed 
infants (Table 8.3).
At three months corrected age, PDF-fed infants had higher RBC-DHA, EPA, and DHA/
AA ratio compared to TF and HM-fed infants. Furthermore, PDF-fed infants had higher 
RBC-AA compared to TF-fed infants and lower AA compared to HM-fed infants. HM-fed 
infants had higher RBC-AA compared to TF-fed infants (Table 8.3). After correction for 
RBC-AA and EPA at term age, the differences in RBC-AA and EPA at three months cor-
rected age between PDF and HM-fed infants were no longer significant.
At six months corrected age, PDF-fed infants had higher RBC-DHA, AA, EPA, and DHA/
AA ratio compared to TF-fed infants and higher RBC-DHA, EPA, and DHA/AA ratio com-
pared to HM-fed infants. At six months corrected age, RBC-AA was similar in PDF and 
Table 8.2. Characteristics of the study population
Characteristics PDF 
(n=52)
TF 
(n=41)
HM 
(n=46)
Boysa 27/52 = 51.9% 23/41 = 56.1% 21/46 = 45.7%
First born childa 33/52 = 63.5% 25/41 = 61.0% 36/46 = 78.3%
At birthb
Gestational age (week) 30.5 ± 1.4 30.5 ± 1.4 30.0 ± 1.6
Weight (g) 1344 ± 304 1377 ± 210 1304 ± 330
Length (cm) 38.2 ± 3.0 38.2 ± 2.6 37.7 ± 3.1
Head circumference (cm) 27.8 ± 1.9 28.0 ± 1.7 27.4 ± 2.0
At term ageb
Postmenstrual age (week) 40.7 ± 0.7 40.4 ± 0.6 40.6 ± 0.9
Weight (g) 3137 ± 511 3193 ± 489 3138 ± 513
Length (cm) 48.7 ± 2.3 48.7 ± 2.1 48.2 ± 2.5
Head circumference (cm) 35.9 ± 1.2 35.8 ± 1.5 35.6 ± 1.5
PDF: postdischarge formula; TF: term formula; HM: human milk. a Frequency (%); b mean ± SD.
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HM-fed infants (Table 8.3). These differences remained significant after correction for 
RBC-DHA, AA, and EPA at term age.
within-group longitudinal changes in rbc-fatty acids
In PDF and HM-fed infants, RBC-DHA increased between term age and three months 
as well as between three and six months corrected age. In TF-fed infants, RBC-DHA 
increased only between three and six months corrected age. In PDF, TF, and HM-fed 
infants, RBC-AA decreased between term age and three months corrected age. HM-fed 
infants showed a further decrease of RBC-AA between three and six months corrected 
age. In PDF, TF, and HM-fed infants RBC-DHA/AA ratio increased between term age and 
three months as well as between three and six months corrected age (Figure 8.1).
between-group differences in growth
At term age and at three and six months corrected age, there were no significant dif-
ferences in weight, length, and head circumference SDS between PDF, TF, and HM-fed 
infants (Figure 8.2).
within-group longitudinal changes in growth
In PDF, TF, and HM-fed infants, the main changes in weight, length and head circumfer-
ence SDS occurred between term age and three months corrected age. In PDF, TF, and 
HM fed infants, weight and length SDS increased and head circumference SDS decreased 
between term age and three months corrected age (Figure 8.2).
Table 8.3. RBC-AA, DHA, and EPA (g%) and the DHA/AA ratio (g/g) at term age, three months and six 
months corrected age
Fatty acid (ratio) Age PDF TF HM PDF vs TFa PDF vs HMa TF vs HMa
AA Term age 13.74 ± 0.89 13.86 ± 0.93 14.06 ± 1.17 n.s. n.s. n.s.
3 months 12.99 ± 1.20 12.53 ± 0.64 13.57 ± 1.06 0.039 0.008 <0.001
6 months 13.12 ± 0.98 12.50 ± 0.63 13.15 ± 0.90 0.002 n.s. 0.001
DHA Term age 4.71 ± 0.70 4.59 ± 0.76 4.08 ± 0.55 n.s. <0.001 0.003
3 months 5.73 ± 0.73 4.70 ± 0.49 4.43 ± 0.78 <0.001 <0.001 n.s.
6 months 6.01 ± 0.67 4.96 ± 0.54 4.74 ± 0.67 <0.001 <0.001 n.s.
EPA Term age 0.34 ± 0.05 0.32 ± 0.06 0.33 ± 0.13 n.s. n.s. n.s.
3 months 0.37 ± 0.05 0.30 ± 0.04 0.32 ± 0.11 <0.001 <0.001 n.s.
6 months 0.38 ± 0.04 0.30 ± 0.05 0.30 ± 0.07 <0.001 <0.001 n.s.
DHA/AA ratio Term age 0.34 ± 0.05 0.33 ± 0.06 0.29 ± 0.04 n.s. <0.001 <0.001
3 months 0.44 ± 0.05 0.38 ± 0.04 0.33 ± 0.06 <0.001 <0.001 <0.001
6 months 0.46 ± 0.05 0.40 ± 0.04 0.36 ± 0.06 <0.001 <0.001 0.005
Values as mean ± SD. n.s. : not significant; PDF: postdischarge formula; TF: term formula; HM: human milk; AA: 
arachidonic acid; DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid. a P-value, significance level P<0.05.
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figure 8.1. RBC-DHA, AA, and EPA (g%) and the DHA/AA ratio (g/g) at term age, three and six months 
corrected age for PDF, TF, and HM-fed preterm infants
RBC: red blood cell; DHA: docosahexaenoic acid; AA: arachidonic acid; EPA: eicosapentaenoic acid; PDF: 
postdischarge formula; TF: term formula; HM: human milk. Similar letters indicate a significant change in time, 
P<0.05.
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figure 8.2. Weight, length, and head circumference SDS at term age, three and six months corrected age 
for PDF, TF, and HM-fed preterm infants
PDF: postdischarge formula; TF: term formula; HM: human milk. Similar letters indicate a significant change in 
time, P<0.05.
Monique binnenwerk.indd   116 06-01-14   13:13
117
8
LC-PUFAs and postdischarge formula
relation between rbc-fatty acid changes and growth
For all infants, the changes in RBC-DHA were positively associated with gain in weight 
and length and negatively with gain in head circumference between term age and six 
months corrected age. Similarly, for all infants, the changes in RBC-AA were positively as-
sociated with gain in head circumference and negatively with gain in weight and length. 
Changes in the RBC-DHA/AA ratios were positively associated with gain in weight and 
length and negatively with gain in head circumference between term age and six 
months corrected age. Changes in RBC-EPA showed no associations with gain in weight, 
length, or head circumference between term age and six months corrected age (Table 
8.4). All of the above significant associations remained significant after adjustment for 
protein intake in formula fed infants.
dIscussIon
AA is an important regulator of fetal growth, but during the third trimester of pregnancy, 
DHA becomes increasingly more important [2, 6]. Preterm infants lack fetal DHA and AA 
accretion during the last trimester [3, 14-15], resulting in lower DHA and AA at birth and 
a lower nadir in DHA and AA compared to infants born at term. For that reason, adequate 
dietary LC-PUFA intake might be essential for preterm infants to prevent low postnatal 
LC-PUFA status and concomitant negative effects on growth and central nervous system 
development.
This randomized controlled trial with three post-term feeding regimens differing in 
DHA and AA intakes failed to show the influence of these LC-PUFAs on the growth of 
preterm infants. However, in contrast to several previous studies, we found associa-
tions between the LC-PUFAs in RBC and postnatal growth until six months post-term. 
Until now, AA and DHA supplementation of preterm formulae has been associated 
with increased growth up to two months post-term, but these associations disappear 
Table 8.4. Associations between the changes in RBC-DHA, AA, and EPA (g%) and the DHA/AA ratio (g/g) 
and postnatal growth between term age and six months corrected age
Weight SDS
0-6 months
Length SDS
0-6 months
Head circumference SDS
 0-6 months
β1 β2 β1 β2 β1 β2
DHA (g%) 0-6 months 0.27** 0.16* 0.42** 0.29** -0.15** -0.13*
AA (g%) 0-6 months -0.28** -0.17** -0.23** -0.11* 0.15** 0.15**
EPA (g%) 0-6 months 0.07 0.33 0.33 0.71 -0.83 -1.04
DHA/AA (g/g) ratio 0-6 months 4.53** 2.87** 5.91** 4.07** -2.53** -2.41**
DHA: docosahexaenoic acid; AA: arachidonic acid; EPA: eicosapentaenoic acid. β1: unadjusted; β2: adjusted for 
protein intake; ** P< 0.001; * P< 0.05.
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thereafter [9, 30]. In our analyses, we have taken into account that protein intake is an 
important determinant of growth, but the current associations remained significant 
after adjustment for protein intake between term age and six months post-term.
Supplementation studies with DHA and EPA, without AA, have been shown to cause a 
decline of RBC-AA in preterm infants during the first half of infancy, especially between 
birth and term age. This might be caused by immature AA synthesis capacity postnatally 
or by the competition of dietary EPA with AA for incorporation into phospholipids [7]. 
Decreased RBC-AA has been associated with decreased gain in weight, length, and head 
circumference during the first year in preterm infants [31]. This might suggest that EPA 
supplementation has a negative effect on postnatal growth. However, in this study, we 
found no associations between changes in RBC-EPA and gain in weight, length, and 
head circumference between term age and six months post-term.
A postnatal AA decline might theoretically be prevented in several ways. The linoleic 
acid intake could be decreased to diminish the competition of the high linoleic acid 
content of milk with the available AA for incorporation into phospholipids [32]. Second, 
DHA intake could be decreased to prevent competition with AA, but, in preterm infants, 
the DHA status is already endangered. Finally, the AA intake could be increased, which 
seems the most practical. To achieve an AA status similar to term breast fed infants, 
preterm infants need to reach a RBC-AA of 15 g% at three months post-term [33]. In the 
present study, PDF-fed infants had an RBC-AA closer to this possible target than TF-fed 
infants (about 13 g%, Table 8.3). To meanwhile guarantee sufficient DHA status, preterm 
infants may also need to be supplemented with additional DHA to prevent unfavorable 
competition of a higher AA intake with the available DHA [34]. What target should be 
aimed at is currently unknown, but an adequate supply of DHA to e.g. brain becomes 
increasingly more important from the end of pregnancy and especially after delivery 
because of the rapid DHA accumulation [2, 6]. In contrast to AA, DHA status is highly 
dependent on DHA intake, notably from fish. Two reference points for postnatal infant 
RBC-DHA status have recently emerged from the study of mothers with lifetime stable 
dietary habits. Mothers with an RBC-DHA status of 6 g% at the end of pregnancy deliver 
infants with an RBC-DHA of 6 g% at term birth and the infant RBC-DHA will remain at 
6 g% after three months exclusive breastfeeding. Second, infants of lactating mothers 
with an RBC-DHA of 8 g% at the end of pregnancy will increase their RBC-DHA from 7 g% 
at term birth to 8 g% after three months breastfeeding [33].
In our study, PDF-fed infants reached this 6 g% RBC-DHA reference point for term 
infant postnatal equilibrium [33] from about three months post-term, whereas TF and 
even HM-fed infants did not. The 8 g% RBC-DHA reference point, at which the lactating 
mother is in equilibrium during lactation [33], can only be reached if the PDF contains 
higher DHA or if additional DHA will be provided via the preterm formula. We conclude 
that the current feeding regimen almost reached term infant RBC-AA targets and also 
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reached the reference point of term infant RBC-DHA equilibrium. It is possible that feed-
ing regimens with higher AA and DHA concentrations in notably preterm formula will 
cause an AA status closer to the term infant RBC-AA target of 15 g% and a higher DHA. 
We speculate that the resulting higher AA and DHA status may jointly improve growth 
of a lean body mass that is in need of LC-PUFA.
Early aggressive feeding protocols, notably those aiming at increased caloric intake, 
may lead to increased growth of very low birth weight infants that is nevertheless asso-
ciated with increased risk of disease later in life, such as diabetes [35-36], cardiovascular 
disease [37-38], and obesity [39-40]. Without increased growth during infancy, preterm 
infants might have lower risk of the metabolic syndrome and associated cardiovascular 
disease in later life but may exhibit inappropriate brain growth and adverse neurodevel-
opmental outcome [41-42]. This study demonstrates that an increased AA intake with 
a balanced DHA/AA ratio was associated with enhanced gain in head circumference. 
Head growth and concomitant gain in brain volume is crucial for central nervous system 
development. We reported previously that the infants receiving the current feeding 
regimen with PDF had lower fat mass corrected for body size at six months corrected 
age compared to infants fed TF or HM [26]. Whether the current feeding regimen with 
PDF also promotes the growth of lean body mass in later life and causes a higher lean 
body mass/fat mass ratio with concomitant lower chance of the metabolic syndrome is 
currently unknown and should be the subject of further investigation.
The main limitation in the interpretation of the current results is in its emphasis on 
associations between RBC LC-PUFA and growth, which are not necessarily causal. No 
differences emerged from the randomized design. It must, however, be emphasized that 
most of the randomized studies with LC-PUFA are negative, while associations have con-
sistently been found [43]. Several suggestions explaining this discrepancy have been 
made [43]. Second, the number of subjects was small. Third, HM-fed infants were fed 
(almost) exclusively with HM at randomization, but the number of exclusively HM-fed 
infants declined thereafter, in particular after three months. When HM was insufficient, 
TF was given. Therefore, comparisons between HM- and TF-fed infants should be inter-
preted with caution. Fourth, RBC-fatty acids were not measured at birth or at any time 
between birth and term age. Therefore, we cannot correct the RBC-fatty acid contents at 
term age for values at birth. Preterm infants born at lower gestational age are expected 
to have lower LC-PUFA stores, but we found no influence of gestational age at birth on 
RBC-fatty acids at term age. We have no explanation for this finding. Apparently, the 
dietary postnatal environment has a larger influence on LC-PUFA status at term age than 
gestational age and LC-PUFA status at birth.
In conclusion, at six months post-term, PDF-fed infants had RBC-AA levels that were 
higher than TF-fed infants but similar to HM-fed infants. At six months post-term, the 
RBC-DHA contents of PDF-fed infants exceeded those of TF and HM-fed infants to reach 
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the 6 g% reference point of RBC-DHA equilibrium for term HM-fed infants. There were no 
between-group differences in growth. Higher RBC-DHA was associated with increased 
gain in weight and length, and higher RBC-AA was associated with increased gain in 
head circumference between term age and six months post-term. Our data suggest that 
feeding preterm infants with a postdischarge formula with 0.4% DHA and 0.4% AA is 
superior for growth compared with a term formula with 0.2 % DHA and 0.2% AA.
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Higher vitamin D intake in preterm infants fed  
an isocaloric, protein- and mineral-enriched 
postdischarge formula is associated 
with increased bone accretion
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absTracT
During the first half of infancy, bone accretion of preterm infants fed an isocaloric, pro-
tein- and mineral-enriched postdischarge formula (PDF) is higher compared with those 
fed term formula (TF) or human milk (HM). This may be related to higher protein, calcium, 
phosphorus, and vitamin D intakes. This study investigated serum calcium, phosphate, 
and 25-hydroxyvitamin D [25(OH)D] in relation to bone mineral content (BMC) in PDF, 
TF, and HM fed preterm infants between term age (40 wk postmenstrual age) and 6 mo 
corrected age (CA). Between term age and 6 mo CA, 52 preterm infants were fed PDF 
(per 100 ml: 67 kcal, 1.7 g protein, 65 mg calcium, 38 mg phosphorus, 56 IU vitamin D), 
41 were fed TF (per 100 ml: 67 kcal, 1.47 g protein, 50 mg calcium, 30 mg phosphorus, 
48 IU vitamin D) and 46 were fed HM. Serum calcium, phosphorus, and 25(OH)D were 
measured at term age and at 3 and 6 mo CA. BMC (g) was measured by whole-body 
dual-energy x-ray absorptiometry at term age and 6 mo CA. Between term age and 6 
mo CA, intakes of calcium, phosphorus, and vitamin D were significantly higher in PDF 
compared with TF fed infants, and PDF fed infants reached significantly higher serum 
25(OH)D at 6 mo CA (103 ± 24.3 vs. 92.8 ± 15.5 nmol/L, P=0.003). Between term age and 
6 mo CA, increases in serum 25(OH)D were associated with an increase in BMC (β=0.001, 
95%CI 0.00-0.003, P=0.046). In conclusion, during the first 6 mo post-term, higher vita-
min D intake and greater increase in serum 25(OH)D concentration in PDF fed preterm 
infants were associated with increased bone accretion.
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InTroducTIon
More than two thirds of the calcium, vitamin D, and bone accretion takes place during 
the third trimester of pregnancy [1-3]. Vitamin D accretion depends on the maternal 
vitamin D status [4]. Postnatally, in addition to the availability of dietary protein, calcium, 
and phosphate, the vitamin D status of the infant becomes very important for postnatal 
bone accretion [5]. The vitamin D status of the infant is related to maternal vitamin D sta-
tus during pregnancy, dietary vitamin D intake, and 1,25-dihydroxyvitamin D synthesis 
[2, 4], which is already operative during intrauterine life and starts within 24 h after birth 
in infants born as early as 28 wk gestational age [6].
In term infants, vitamin D stores are depleted within the first 8 postnatal weeks [6] due 
to insufficient dietary vitamin D intake, especially in breast fed term infants. In preterm 
infants, vitamin D stores are lower at birth and, moreover, during early extrauterine life, 
dietary vitamin D supply is frequently lower than during the intrauterine third trimester 
[7]. As a consequence, vitamin D deficiency may develop, which results in secondary 
hyperparathyroidism with increased calcium resorption from the bone to maintain 
serum calcium concentrations [8].
In addition to bone-related effects, several studies demonstrate that a low maternal 
and concomitant low infant vitamin D status are associated with other conditions, such 
as type 1 diabetes in childhood [9], allergic diseases [10], and impaired neurocognitive 
development [11-12]. Furthermore, a low vitamin D status affects the immune system, 
such as the first line of defense in the intestine, which needs an adequate vitamin D sta-
tus for the synthesis of the antimicrobial peptide cathelicidin [13]. This may contribute 
to increased (respiratory) infections in infants with a low vitamin D status during the first 
months of life [13-15].
Recently, we demonstrated that bone accretion during the first 6 mo post-term is 
higher in preterm infants fed an isocaloric, protein- and mineral-enriched postdischarge 
formula (PDF) compared with those fed a standard term formula (TF) or human milk 
(HM) [16]. PDF fed preterm infants may have higher availability of dietary protein, 
calcium, phosphorus, and vitamin D for bone accretion. However, controversy remains 
whether an improved vitamin D status is related to increased bone accretion of preterm 
infants. Some state that vitamin D status may only play a minor role in the presence 
of adequate calcium and phosphorus intake [17], whereas others demonstrate that 
vitamin D status is associated with bone accretion during infancy [18-19] and childhood 
[20]. The present study investigated serum calcium, phosphate, parathyroid hormone 
(PTH), and 25-hydroxyvitamin D [25(OH)D], a good marker of vitamin D status [4, 6, 8], in 
relation to bone accretion in preterm infants fed PDF, TF, and HM between term age (40 
wk postmenstrual age) and 6 mo corrected age (CA).
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PaTIenTs and MeThods
Details of this study have been described previously [16, 21]. In short, 139 infants born at 
a gestational age ≤32 wk and/or with a birth weight ≤1,500 g were included. This study 
was conducted according to the guidelines laid down in the Declaration of Helsinki and 
all procedures involving patients were approved by the Ethics Committee of VU Univer-
sity Medical Center, Amsterdam, The Netherlands. Parents of the participating children 
gave written informed consent.
Between birth and term age, infants were fed fortified human milk (13 PDF, 17 TF, and 
45 HM fed infants) or preterm formula (39 PDF and 23 TF fed infants) (Table 9.1). The 
type of feeding between birth and term age could not be determined in 2 infants due to 
missing data. Breast milk fortifier provided 64.9 mg calcium, 42.7 mg phosphorus, and 
200 IU vitamin D/100 mL HM. According to the recommendations in The Netherlands 
between 2003 and 2006, preterm infants fed >50% HM were supplemented with breast 
milk fortifier or with 200 IU/d vitamin D when human milk fortification was discontinued 
at discharge. Preterm infants fed >50% formula, either preterm formula, PDF, or TF, were 
not supplemented with vitamin D. Of the infants fed human milk between birth and term 
age, 20 infants (2 PDF, 2 TF, and 16 HM fed infants) were supplemented with 200 IU/d 
vitamin D when HM fortification was discontinued after discharge. None of the infants 
fed preterm formula between birth and term age were supplemented with vitamin D.
At term age, formula-fed infants were randomized to PDF (n=52) or TF (n=41) and 
were fed this formula until 6 mo CA (Table 9.1). Infants were considered to be HM fed 
(n=46) if they received >80% HM at term age and these infants were supplemented 
with 200 IU/d vitamin D. If HM was insufficiently available, TF was added to the diet. 
Infants did not receive enteral calcium or phosphorus supplementation at any time. In 
contrast to the Dutch recommendations described above, 2 PDF and 2 TF fed infants 
Table 9.1. Nutritional composition of study formulas
Per 100 mL
Preterm formula1 Postdischarge formula (PDF)2 Term formula (TF)3
Energy (kcal) 80 67 67
Protein (g) 2.2-2.5 1.7 1.47
Protein/energy ratio (g/100 kcal) 2.75-3.1 2.6 2.2
Carbohydrates (g) 7.6-8.2 7.0 7.2
Fat (g) 4.3-4.4 3.5 3.5
Calcium (mg) 100-120 65 50
Phosphorus (mg) 55-66 38 30
Vitamin D (IU) 96-120 56 48
1 Range of composition for Friso Prematuur (FrieslandCampina) and Nenatal Start (Nutricia); 2 Friso Prematuur 1 
(FrieslandCampina); 3 Friso 1 Normaal (FrieslandCampina).
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were supplemented with vitamin D by their parents for unknown reasons during the 
first week after term age [2 PDF fed infants received 62.4 IU/(kg•d) and 2 TF fed infants 
received 25.6 and 78.8 IU/(kg•d) vitamin D].
Between birth and discharge, data on parenteral and enteral intake (mL/d) and weight 
(g) were extracted from infants’ medical records by a single person. Between discharge 
and 6 mo CA, parents recorded in a diary their infant’s weight (g), formula intake (mL/d), 
vitamin D supplements, and any changes in their infant’s diet (per day between discharge 
and term age and 1d/wk between term age and 6 mo CA). In formula (preterm formula, 
PDF, and TF) fed infants, intakes of calcium [mg/(kg•d)], phosphorus [mg/(kg•d)], and 
vitamin D [IU/(kg•d)], and vitamin D per day (IU/d) between birth and 6 mo CA were 
calculated for each week on the basis of the infant’s weight, the volume intake (mL/d) of 
formula, and the nutritional composition of the formula. In HM fed infants, the vitamin 
D intake [IU/(kg•d)] and the vitamin D intake per day (IU/d) between birth and term age 
were calculated on the basis of the infant’s weight, the volume intake (mL/d) of HM, the 
vitamin D content of breast milk fortifier, and the vitamin D intake from supplements. 
Between birth and term age, HM fed infants were fed expressed HM and, therefore, their 
volume intake was known. In contrast, between term age and 6 mo CA, HM-fed infants 
were breastfed and their exact intake was unknown. In addition, parents of HM fed in-
fants did not record vitamin D supplementation consistently in the parental diaries, and 
some HM fed infants were additionally fed TF. As a consequence, the vitamin D intake of 
HM fed infants between term age and 6 mo CA could not be calculated.
Gestational age at birth was extracted from infants’ medical records. At birth, term 
age, 3 and 6 mo CA, weight was measured to the nearest gram with a digital scale, length 
was measured to the nearest 0.1 cm with a length board, and head circumference was 
measured to the nearest 0.1 cm with a non-stretchable measuring tape, as described 
previously [21]. Weight, length, and head circumference were expressed as z-scores at 
birth and term age [22] and at 3 and 6 mo CA [23]. Ethnicity was based on paternal 
and maternal ethnicity and was classified as white if both parents were white and as 
nonwhite if one or both parents were of nonwhite race/ethnicity.
At term age, 3 and 6 mo CA, serum total calcium (mmol/L) and phosphate (mmol/L) 
were measured by colorimetric assay (Modular analytics, Roche diagnostics, Mannheim, 
Germany) with an inter-assay variance of 2.5 and 2.6%, respectively. At similar time-
points, PTH (pmol/L) was measured by luminescent immunometric assay (Nichols 
Institute Diagnostics, San Juan Capistrano, USA) with an inter-assay variance of 10% 
and 25(OH)D (nmol/L) was measured by a competitive binding protein assay (Diasorin, 
Stillwater, Minnesota, USA) with an inter-assay variance of 10%. Between term age and 
6 mo CA, change in serum total calcium, phosphate, PTH, and 25(OH)D was calculated. 
Vitamin D deficiency was defined as serum 25(OH)D <30 nmol/L, vitamin D insufficiency 
as serum 25(OH)D <50 nmol/L, and high vitamin D concentrations as serum 25(OH)D 
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>150 nmol/L [3, 8, 24-25]. Because endogenous vitamin D synthesis in Amsterdam (lati-
tude: 52.4o north) ceases between October and April [26], season of birth was defined as 
winter (November through April) or summer (May through October).
At term age and at 6 mo CA, bone area (cm2) and bone mineral content (BMC; g) were 
measured by whole-body DXA (Hologic QDR4500A, Hologic, Inc.) and analyzed by Infant 
Whole Body Software version 12.3.3 (Hologic). The quality of the DXA was evaluated by 
1 expert radiologist who was blinded for the type of feeding. Scans with severe move-
ment artifacts and incomplete scans were excluded [27]. Good-quality DXA scans were 
available from 116 infants at term age (43 PDF, 36 TF, and 37 HM fed infants), 106 infants 
at 6 mo CA (42 PDF, 30 TF, and 34 HM fed infants), and 87 infants at both term age and 6 
mo CA (36 PDF, 25 TF, and 26 HM fed infants), as described previously [16]. Gain in BMC 
between term age and 6 mo CA was calculated.
Statistical analyses were performed using SPSS 17.0 for Windows (SPSS Inc.). The distri-
bution of sex, ethnicity, season of birth, vitamin D deficiency and insufficiency, and high 
vitamin D concentrations were expressed as frequencies and were compared between 
PDF, TF, and HM fed infants by χ2 test. Gestational age at birth, vitamin D intake per day 
(IU/d), serum PTH, and BMC were normally distributed after ln transformation and were 
expressed as medians (IQR). Weight, length, and head circumference z-scores; intakes of 
calcium, phosphorus, and vitamin D; and concentrations of serum calcium, phosphate, 
and 25(OH)D were normally distributed and expressed as means ± SDs.
Gestational age at birth, growth, serum calcium, serum phosphate, serum PTH, and 
serum 25(OH)D were compared between PDF, TF, and HM fed infants by linear regression 
adjusted for sex and gestational age (analysis with gestational age was only adjusted for 
sex). Analyses with serum 25(OH)D were adjusted for season of birth and ethnicity. Bone 
area and BMC were compared between PDF, TF, and HM fed infants by linear regression 
adjusted for sex, gestational age, birth weight, and actual weight and length. Intakes of 
calcium [mg/(kg•d)], phosphorus [mg/(kg•d)], and vitamin D [IU/(kg•d)], and vitamin D 
per day (IU/d) between term age and 6 mo CA were compared between PDF and TF fed 
infants by linear regression adjusted for sex and gestational age. Associations between 
BMC and serum calcium, serum PTH, and serum 25(OH)D as well as between gain in 
BMC and change in serum PTH and change in serum 25(OH)D were evaluated by linear 
regression; we also evaluated whether type of feeding (PDF, TF, or HM), season of birth, 
ethnicity, or sex modified these associations. A P value <0.05 was considered significant.
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resuLTs
Pdf, Tf, and hM fed infants
Infant characteristics at birth and growth variables between birth and 6 mo CA were 
not different among PDF, TF, and HM fed infants [Table 9.2 and Supplemental Table 9.1 
(Appendix B)]. Between birth and term age, the mean intakes of calcium, phosphorus, 
and vitamin D were similar in PDF and TF fed infants who were fed preterm formula 
[calcium: 110 ± 24.9 vs. 108 ± 24.7 mg/(kg•d); phosphorus: 57.7 ± 11.5 vs. 56.9 ± 12.1 mg/
(kg•d); vitamin D: 222 ± 42.4 vs. 221 ± 47.2 IU/(kg•d); all P≥0.05]. Between birth and term 
age, the mean vitamin D intake was similar in PDF, TF, and HM fed infants fed fortified 
HM [233 ± 43.7 vs. 247 ± 37.8 vs. 228 ± 50.7 IU/(kg•d), respectively; P≥0.05]. Between 
term age and 6 mo CA, the mean intakes of calcium, phosphorus, and vitamin D were 
significantly higher in PDF compared with TF fed infants [calcium: 100 ± 10.9 vs. 77.2 ± 
6.9 mg/(kg•d); phosphorus 58.3 ± 6.3 vs. 46.1 ± 4.0 mg/(kg•d); vitamin D: 86.8 ± 9.6 vs. 
74.4 ± 6.8 IU/(kg•d); all P<0.001]. Between term age and 6 mo CA, the vitamin D intake 
per day (IU/d) was significantly higher in PDF compared with TF fed infants [values 
indicate median (IQR); 445 (72.8) vs. 380 (60.8) IU/d, P<0.001].
25(oh)d and PTh in Pdf, Tf, and hM fed infants
The frequency of vitamin D deficiency [serum 25(OH)D <30 nmol/L] at term age and 
of vitamin D insufficiency [serum 25(OH)D <50 nmol/L] at term age and 3 mo CA were 
similar in PDF, TF, and HM fed infants (vitamin D deficiency at term age: 7.7, 0, and 2.3%, 
respectively; vitamin D insufficiency at term age: 13.5, 10, and 9.1%, respectively; and 
vitamin D insufficiency at 3 mo: 2, 2.4, and 0%, respectively; all P≥ 0.05). None of the 
infants was vitamin D deficient or insufficient at 6 mo CA. The frequency of high serum 
25(OH)D (>150 nmol/L) was significantly higher in TF compared with PDF and HM fed 
infants at term age and similar at 3 and 6 mo CA (term age: 10% vs. 1.9% and 0%; respec-
tively; P<0.05; 3 mo: 0% and 0% vs. 0%, P≥0.05; 6 mo: 0% vs. 3.9% and 0%, P≥0.05). PDF 
Table 9.2. Infant characteristics at birth1
PDF 
(n=52)
TF 
(n=41)
HM 
(n=46)
n Value n Value n Value
Boys (%) 27 51.9 23 56.1 21 45.7
White (%) 34 65.4 32 78 34 73.9
Season of birth (%)
 winter 25 48.1 29 70.7 26 56.5
 summer 27 51.9 12 29.3 20 43.5
Gestational age at birth (wk) 52 30.7 (1.5) 41 30.9 (2.3) 46 30.0 (1.9)
1 Values as frequencies or medians (IQR). HM: human milk; PDF: postdischarge formula; TF: term formula.
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fed infants had slightly lower serum 25(OH)D at term age and significantly higher serum 
25(OH)D at 6 mo CA compared with TF and HM fed infants (Table 9.3). Between term 
age and 6 mo CA, PDF fed infants had a significantly greater increase in serum 25(OH)D 
compared with TF and HM fed infants [change in 25(OH)D: 18.4 ± 33.1 vs. -4.2 ± 35.7 and 
4.5 ± 33.6 nmol/L, respectively; P<0.05].
Although the frequency of vitamin D deficiency was similar in PDF, TF, and HM infants 
at term age, PDF and TF fed infants had significantly higher serum PTH compared with 
HM fed infants at term age, but this difference disappeared thereafter (Table 9.3). Be-
tween term age and 6 mo CA, PDF and TF fed infants had a significantly greater decrease 
in serum PTH compared with HM fed infants [change in PTH: -3.17 (4.99) and -2.44 (3.55) 
vs. 0.01 (3.55) pmol/L, P<0.01].
Table 9.3. Serum total calcium, phosphate, PTH, 25(OH)D, BA, and BMC between term age and 6 mo CA in 
preterm infants fed PDF, TF, and HM1
PDF 
(n=52)
TF 
(n=41)
HM 
(n=46)
n Value n Value n Value
Term age
Calcium (mmol/L) 52 2.56 ± 0.10 41 2.54 ± 0.09 46 2.55 ± 0.10
Phosphate (mmol/L) 52 2.17 ± 0.17a 41 2.20 ± 0.16a 46 2.05 ± 0.29b
PTH (pmol/L) 49 5.40 (5.55)a 38 4.86 ( 3.93)a 36 2.41 ( 3.66)b
25(OH)D (nmol/L) 52 85.2 ± 31.9 40 97.2 ± 37.9 44 90.5 ± 28.1
BA (cm2) 43 310 (73.9)a 36 300 (67.2)b 37 315 (57.2)a
BMC (g) 42 43.8 (20.4) 30 47.3 (12.7) 34 48.5 (16.7)
3 mo CA
Calcium (mmol/L) 51 2.66 ± 0.09a 41 2.61 ± 0.11b 46 2.67 ± 0.09a
Phosphate (mmol/L) 51 2.22 ± 0.14a 41 2.18 ± 0.15a 46 2.06 ± 0.22b
PTH (pmol/L) 47 2.96 (1.89) 41 2.87 (2.01) 45 2.50 (2.13)
25(OH)D2 (nmol/L) 50 95.0 ± 21.9 41 89.3 ± 20.9 46 87.1 ± 17.8
6 mo CA
Calcium (mmol/L) 52 2.67 ± 0.09 41 2.66 ± 0.09 46 2.66 ± 0.07
Phosphate (mmol/L) 52 2.06 ± 0.14 41 2.06 ± 0.12 46 2.06 ± 0.17
PTH (pmol/L) 47 2.23 (1.33) 41 2.08 (1.30) 43 2.65 (1.70)
25(OH)D2 (nmol/L) 51 103 ± 24.3a 41 92.8 ± 15.5b 45 95.6 ± 18.9a
BA (cm2) 43 632 (97.3)a 36 598 (88.3)a 37 601 (95.8) b
BMC (g) 42 151 (42.5)a 30 134 (35.1)b 34 133 (33.4)b
1 Values are means ± SD or median (IQR) and show comparison between PDF, TF, and HM fed infants by linear 
regression adjusted for sex and gestational age [and 25(OH)D for season of birth and ethnicity]. Labeled means 
or medians in a row without a common letter differ, P<0.05.
BA: bone area; BMC: bone mineral content; CA: corrected age; HM: human milk; PDF: postdischarge formula; PTH: 
parathyroid hormone; TF: term formula; 25(OH)D: 25-hydroxyvitamin D. 
2 PDF versus HM, P=0.06.
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serum calcium, PTh, and 25(oh)d in relation to bone mass
At term age, serum total calcium and 25(OH)D were positively associated and serum 
PTH was negatively associated with BMC (Table 9.4). At 3 and 6 mo CA, serum 25(OH)D 
was positively associated and serum PTH was negatively associated with BMC at 6 mo 
CA (Table 9.4). 
Table 9.4. Serum total calcium, serum PTH, and serum 25(OH)D in relation to bone mineral content (BMC) 
in preterm infants between term age and 6 mo CA1
BMC2 (g) 
Term age 6 mo CA
n β (95% CI) n β (95% CI)
Term age
Calcium (mmol/L) 116 0.88** (0.43;1.32) 106 0.27 (-0.08;0.61)
PTH2 (pmol/L) 103 -0.15** (-0.21;-0.09) 92 0.01 (-0.04;0.06)
25OHD (nmol/L) 114 0.003** (0.002;0.005) 103 0.00 (0.00;0.001)
3 mo CA
Calcium (mmol/L) N/A 105 0.17 (-0.16;0.51)
PTH2 (pmol/L) N/A 101 -0.06* (-0.12;0.00)
25OHD (nmol/L) N/A 104 0.002* (0.00;0.003)
6 mo CA
Calcium (mmol/L) N/A 106 0.36 (-0.01;0.73)
PTH2 (pmol/L) N/A 101 -0.13** (-0.20;-0.07)
25OHD (nmol/L) N/A 105 0.001† (0.00;0.003)
1 Associations by linear regression; * P<0.05; ** P<0.001; †P=0.083. BMC: bone mineral content; CA: corrected age; 
N/A: not applicable; PTH: parathyroid hormone; 25(OH)D: 25-hydroxyvitamin D. 
2 ln transformed 
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figure 9.1. Change in serum 25(OH)D (A) and change in serum PTH (B) in relation to gain in BMC in 
preterm infants between term age and 6 mo corrected age
BMC: bone mineral content; PTH: parathyroid hormone; 25(OH)D: 25-hydroxyvitamin D.
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Between term age and 6 mo CA, change in serum 25(OH)D was positively associated 
and change in serum PTH was negatively associated with gain in BMC (Figure 9.1). There 
was no effect modification of type of feeding, season of birth (winter/summer), ethnicity 
(white/nonwhite), or sex on the associations between serum total calcium, serum PTH, 
serum 25(OH)D, and BMC.
dIscussIon
The present study demonstrates that higher vitamin D intake with an isocaloric, pro-
tein- and mineral-enriched PDF leads to a greater increase in serum 25(OH)D in preterm 
infants during the first 6 mo post-term. The greater increase in serum 25(OH)D in PDF fed 
preterm infants that results in higher serum 25(OH)D at 6 mo CA may be compensatory 
for the slightly lower 25(OH)D at term age. Change in serum 25(OH)D was positively 
associated with gain in BMC during the first 6 mo post-term. This may reflect that a 
greater increase in 25(OH)D enhances calcium absorption and availability for bone 
mineralization and may suggest that, in addition to dietary calcium, phosphorus, and 
protein availability, a higher vitamin D intake and greater increase in serum 25(OH)D 
contribute to higher bone accretion of PDF fed infants [16]. In addition, we hypothesize 
that the negative association between change in serum PTH and gain in BMC may imply 
that calcium resorption from bone is decreased in PDF fed infants with higher bone 
accretion. However, the higher dietary calcium, phosphorus, and protein intakes from 
PDF may also have an important role for the enhancement of bone accretion of preterm 
infants. It has been hypothesized that a higher bone mass during infancy may track to 
adulthood [16] and that higher adult bone mass, in turn, is associated with a lower risk 
of osteoporosis in later life [28].
PDF fed infants reached the recommended intake of 400 IU/d vitamin D during the 
first 6 mo post-term, whereas TF fed infants had a vitamin D intake slightly below 400 
IU/d. This vitamin D intake is in accordance with the current guidelines on vitamin D 
supplementation for term infants, as recommended by the Institute of Medicine, the 
American Association of Pediatrics, the Pediatric Endocrine Society, and the Dutch Health 
Council [3, 8, 29-30] as well as in accordance with the current guidelines on vitamin D 
requirements for preterm infants after discharge [31], but is far below the 800-1000 IU/d 
vitamin D for preterm infants as recommended by the European Society of Paediatric 
Gastroenterology Hepatology and Nutrition [32]. However, the vitamin D intake from 
the formula used in the present study is sufficient to prevent vitamin D deficiency in 
preterm infants at 6 mo CA. Furthermore, PDF fed infants may already benefit from their 
higher vitamin D intake, as suggested by higher bone accretion [16]. This might suggest 
that if the current Dutch and American advice on vitamin D supplementation [3, 8, 29-
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30] is combined with the higher vitamin D intake from PDF, preterm infants may reach 
even higher bone accretion during the first 6 mo post-term. On the other hand, these 
preterm infants may be at risk of serum 25(OH)D concentrations >150 nmol/L (60 ng/L), 
which have been associated with acute toxicity mostly related to hypercalcemia and 
growth retardation [25]. In the present study, the higher vitamin D intake from PDF did 
not lead to serum 25(OH)D concentrations >150 nmol/L (60 ng/L) at 6 mo CA.
On the other hand, during the first year of life, the vitamin D status of preterm infants 
is influenced by rapid growth and it has been suggested that vitamin D dosage should 
be adjusted for the actual body weight of the infant [33-34]. A recent study in healthy 
term infants demonstrates that a vitamin D intake close to 100 IU per kg body weight per 
day is sufficient to prevent vitamin D deficiency [33]. In the present study, the vitamin 
D intake per kilogram body weight per day was closer to the advised 100 IU/(kg•d) in 
PDF fed infants than in TF fed preterm infants and PDF fed infants had a low frequency 
of vitamin D deficiency at 3 and 6 mo CA. This may suggest that PDF approximates an 
adequate amount of vitamin D intake in preterm infants during the first 6 mo post-term.
The question remains whether the observed bone accretion in preterm infants in our 
study depends on vitamin D status. It has been suggested that vitamin D plays a minor 
role in bone accretion when adequate dietary calcium and phosphorus are available 
[17] because these nutrients are mandatory to achieve sufficient bone accretion. Never-
theless, in line with previous studies during infancy [18-19] and childhood [20], serum 
25(OH)D was clearly associated with bone accretion, whereas calcium and phosphorus 
were not. Furthermore, in the present study, the frequency of vitamin D deficiency was 
low and serum calcium, phosphate, and PTH were within normal range (normal range 
of serum calcium: 2.10-2.60 mmol/L; phosphate: 1.10-2.10 mmol/L; and PTH: <8 pmol/L; 
respectively [35]). Because serum 25(OH)D was associated with bone accretion and 
there was a low frequency of vitamin D deficiency, it seems likely that vitamin D may 
play an important role in bone accretion in preterm infants.
A limitation of the present study was that the randomized controlled trial was de-
signed and powered to evaluate the effect of postdischarge nutrition on growth and 
body composition between term age and 6 mo CA [21]. The study was not designed to 
test causal relations, thus, only associations can be demonstrated. Therefore, the results 
of the present study need to be interpreted with caution.
Another limitation may be that calcium, phosphorus, and vitamin D absorption from 
infant formula may vary considerably. The absorption of calcium from formula varies 
between 35 and 60% [1], while the absorption of phosphate is >90%. However, calcium 
salts within the infant formula may precipitate [1], which decreases intestinal calcium 
absorption. The absorption of vitamin D from infant formula may be complicated, since 
vitamin D is a fat-soluble vitamin and may adhere to the surface of feeding bottles [36]. 
Furthermore, in the present study, it was difficult to determine the vitamin D intake of 
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HM fed infants because the exact volume intake of HM fed infants was unknown and 
information on maternal vitamin D status or supplementation was not available. In 
addition, parents of HM fed infants did not consistently record the amount of vitamin 
D supplements administered in the diaries, and in a number of cases it can only be as-
sumed that these infants received 200 IU/d vitamin D as recommended at the time.
Moreover, the vitamin D status of infants is not only determined by their dietary 
vitamin D intake. Maternal vitamin D status during pregnancy has a major influence 
on infant vitamin D status in early life [2, 4, 37-38] as well as on bone accretion during 
infancy [39-41] and childhood [42]. In addition, sunlight exposure [2, 8, 20], which is 
related to season of birth [18, 38, 43], skin pigmentation, and geographic location [6], 
may influence the vitamin D status of infants. However, the effect of vitamin D intake 
from formula on vitamin D status in infants may be dominant over the effect of sunlight 
exposure and, in turn, of geographic location [17]. Unfortunately, in the present study, 
no data were available on maternal vitamin D status or on infant vitamin D status before 
term age.
In addition, serum total calcium and not ionized calcium was measured at term age 
and at 3 and 6 mo CA. Serum total calcium may have a wide range due to variations in 
serum albumin and the state of hydration and can change without affecting the ionized 
calcium concentration. On the other hand, ionized calcium concentration can change 
without affecting the serum total calcium concentration.
Furthermore, the current guidelines vary with regard to the target 25(OH)D recom-
mended for infants. The American Association of Pediatrics recommends a target 25(OH)
D >50 nmol/L for term and preterm infants [29, 31], whereas the Endocrine Society 
recommends a target 25(OH)D >75 nmol/L for the overall population [8]. In line with the 
guidelines of the American Association of Pediatrics, vitamin D sufficiency was defined 
as serum 25(OH)D >50 nmol/L in the present study.
In conclusion, with the nutritional regimen of the present study, the additional vitamin 
D intake from an isocaloric, protein- and mineral-enriched PDF, which is in accordance 
with current recommendations of 400 IU/d vitamin D [3, 8, 29-30] and which ap-
proximates the advised 100 IU/(kg•d) vitamin D for term infants [33], results in a greater 
increase in serum 25(OH)D. This increase in serum 25(OH)D may, in addition to dietary 
protein, calcium, and phosphorus availability [44], contribute to increased bone accre-
tion compared with standard TF or HM [16]. Furthermore, in addition to an isocaloric, 
protein- and mineral-enriched PDF, higher vitamin D supplementation, as advised with 
the current guidelines [3, 8, 29-30, 32], may improve bone accretion even further.
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Iron deficiency and anemia in iron-fortified 
formula and human milk fed preterm 
infants until six months post-term
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absTracT
Purpose
An iron intake of >2 mg/kg/d is recommended for preterm infants. We hypothesized 
that human milk (HM) fed preterm infants require iron supplementation after discharge, 
whereas iron-fortified formulae (IFF; 0.8-1.0 mg iron/100 ml) may provide sufficient 
dietary iron until six months post-term.
Methods
At term age, three and six months post-term, ferritin (μg/l) was measured in 92 IFF-fed 
infants (gestational age [median (interquartile range)] 30.7 (1.4) weeks, birth weight 
1,375 (338) gram) and 46 HM-fed infants (gestational age 30.0 (1.7) weeks, birth weight 
1,400 (571) gram). Iron intake (mg/kg/d) between term age and six months post-term 
was calculated.
results
Iron was supplemented to 71.7% of the HM-fed infants and 83.7% of IFF-fed infants 
between term age and three months post-term and to 13% of HM-fed infants and 0% 
of IFF-fed infants between three and six months post-term. IFF-fed infants had an iron 
intake from supplements and formula of 2.66 (1.22) mg/kg/d between term age and 
three months post-term and 1.19 (0.32) mg/kg/d between three and six months post-
term. At three and six months post-term, the incidence of ferritin <12 μg/l was higher 
in HM- compared to IFF-fed infants (23.8% versus 7.8% and 26.3% versus 9.5%, P<0.02).
conclusion
This observational study demonstrates that ferritin <12 μg/l is more prevalent in HM-fed 
infants until six months post-term. This may be due to early cessation of additional iron 
supplementation. We speculate that additional iron supplementation is not necessary in 
preterm infants fed IFF (0.8-1.0 mg iron/100 ml), as they achieve ferritin ≥12 μg/l without 
additional iron supplements between three and six months post-term.
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Iron deficiency
InTroducTIon
Preterm infants lack the rapid fetal iron accretion during the third trimester of pregnancy 
[1-2]. In addition, frequent blood sampling and rapid postnatal growth exacerbate the 
depletion of body iron stores after birth [1, 3]. As a result, iron deficiency, defined as 
decreased ferritin (<12 μg/l), develops in 25-85% of preterm infants, which is mostly 
due to inadequate dietary iron intake during the first year [4-6]. Other markers of iron 
deficiency are decreased mean corpuscular volume (MCV <90 fl) and increased red 
cell distribution width (RDW >14.5%). Iron deficiency is associated with poor growth 
and reduced brain development [2, 7-8]. However, there is inconclusive but plausible 
evidence that enteral iron supplementation of preterm and low birth weight infants is 
beneficial for growth and neurodevelopment [9-12]. Nevertheless, an elemental iron 
intake of 2-4 mg/kg/d is recommended for preterm infants between 6 weeks and 12 
months postnatal age [11, 13-14].
Several studies show that enteral iron supplementation results in a slight improve-
ment of hemoglobin and ferritin after eight weeks postnatal age [4-5, 9]. It has been 
suggested that iron-fortified formulae (IFF) are sufficient to prevent iron deficiency. 
However, in current practice, preterm infants fed these formulae frequently receive 
additional enteral iron supplementation, which may have adverse effects due to iron 
overload [15]. On the other hand, enteral iron supplementation is important for human 
milk (HM) fed preterm infants because HM has a low iron content (0.5 mg/L) [9].
We hypothesized that HM-fed preterm infants require enteral iron supplementation to 
achieve an iron intake >2 mg/kg/d, whereas preterm infants fed IFF that provide an iron 
intake >2 mg/kg/d do not require additional enteral iron supplementation to prevent 
iron deficiency. With the IFF used in this study a volume intake of 200 ml/kg/d results in 
an iron intake of approximately 2 mg/kg/d. The present study evaluated the iron intake 
of IFF- and HM-fed preterm infants and its effect on the incidence of iron deficiency 
between term age (40 weeks postmenstrual age) and six months post-term.
subjecTs and MeThods
subjects
This study was part of a randomized controlled trial that evaluated the effects of an iso-
caloric, protein- and mineral-enriched postdischarge formula compared to a standard 
term formula and human milk as a control group on growth and body composition of 
preterm infants between term age and six months post-term, as described previously 
[16]. Growth and body composition during the first six months post-term were the pri-
mary outcomes of the randomized controlled trial. Signs of anemia and iron deficiency 
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were secondary outcomes of the randomized controlled trial. In short, 152 infants with 
a gestational age of 32 weeks or less and/or a birth weight of 1,500 gram or less were in-
cluded shortly after birth (Figure 10.1). Between birth and term age, 80 infants were fed 
human milk with breast milk fortifier, which did not contain iron, and 75 infants were fed 
preterm formula (Friso Prematuur®, FrieslandCampina, Amersfoort, The Netherlands; 0.8 
mg iron/100 ml or Nenatal start®, Nutricia, Zoetermeer, The Netherlands; 0.9 mg iron/100 
ml). The type of feeding between birth and term age could not be determined in two 
postdischarge formula, four standard term formula, and one human milk fed infant due 
to missing data. Between term age and six months post-term, 102 formula-fed infants 
were randomized to postdischarge formula (n=54; Friso Prematuur 1®, FrieslandCampi-
na, Amersfoort, The Netherlands; 1.0 mg iron/100 ml) or standard term formula (n=48; 
Friso Normaal 1®, FrieslandCampina, Amersfoort, The Netherlands; 0.8 mg iron/100 ml). 
Without randomization, 50 preterm infants that received predominantly (>80%) HM at 
term age were considered to be HM-fed. If HM was insufficiently available in this control 
group at some point between term age and six months post-term, standard term formula 
was added to the diet after parents consulted the coordinating investigator (E.M.A). At 
INCLUDED:
152 preterm infants 
(GA ≤32 wk and/or BW ≤1,500 g)
102 formula fed infants
50 human milk (HM)
(no iron)
152 preterm infants
4 did not follow study protocol2 did not follow study protocol 7 did not follow study protocol
1 no data on iron intake
54 postdischarge formula (PDF)
(1.0 mg iron/100 ml)
48 standard term formula (TF)
(0.8 mg iron/100 ml)
BIRTH
TERM AGE 50 human milk fed infants
46 HM fed infants 
included in analyses
52 PDF fed infants 
included in analyses
6 MONTHS 
POST-TERM
40 TF fed infants 
included in analyses
RANDOMIZATION NO RANDOMIZATION
65 Preterm formulaa
(0.8-0.9 mg iron/100 ml)
80 Fortified human milkb
(no iron)
7 missing data 
(1 TF and 1 HM)
Enteral iron supplementation
43 term age-3 months post-term
none 3-6 months post-term
Enteral iron supplementation
34 term age-3 months post-termc
none 3-6 months post-term
Enteral iron supplementation
33 term age-3 months post-termd
6  between 3-6 months post-term
figure 10.1. Flowchart of subject inclusion and randomization of the randomized controlled trial
BW: birth weight; GA: gestational age; HM: human milk; PDF: postdischarge formula; TF: term formula. a 39 PDF- 
and 26 TF-fed infants; b 13 PDF-, 18 TF-, and 49 HM-fed infants; c data on iron supplementation were missing in 1 
TF-fed infant; d data on iron supplementation were missing in 3 HM-fed infants.
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six months post-term, 138 preterm infants completed the study (Figure 10.1). Between 
term age and three months post-term, 28, 3, and 15 HM-fed infants were fed 75-100%, 
50-75%, and <50% HM, respectively. Between three and six months post-term, 13, 7, and 
9 HM-fed infants were fed 75-100%, 50-75%, and <50% HM, respectively. The remainder 
of the diet consisted of standard term formula (0.8 mg iron/100 ml).
The present observational study combined data on iron intake and the incidence of 
iron deficiency and anemia of 52 postdischarge formula, 40 standard term formula, and 
46 HM-fed preterm infants during the first six months post-term. Infants attended the 
outpatient clinic of VU University Medical Center, Amsterdam, The Netherlands at term 
age (40.3 ± 0.7 weeks postmenstrual age), three months post-term (53.0 ± 0.5 weeks 
postmenstrual age), and six months post-term (66.0 ± 0.5 weeks postmenstrual age) 
for anthropometry and blood samples. The study protocol was approved by the local 
ethics committee and the study was conducted according to the guidelines laid down 
in the Declaration of Helsinki. All parents of the included infants gave written informed 
consent.
Methods
Gestational age at birth and the number and volume (ml) of erythrocyte transfusions 
during the study period were extracted from medical records. Weight (g), length (cm), 
and head circumference (cm) were measured at birth, term age, three months post-
term, and six months post-term, as described previously [16]. To adjust for gender and 
postmenstrual age, weight, length, and head circumference were expressed as standard 
deviation score (SDS) based on Swedish references for preterm infants at birth and term 
age and based on Dutch references at three and six months post-term [17-18].
Between birth and discharge, details on enteral and parenteral intake were collected 
from the infant’s medical record by one single person. Between discharge and six months 
post-term, parents recorded their child’s intake in a diary (daily until term age and 
weekly after term age). The medical records and parental diaries provided information 
on type and amount of intake (ml) and on dosage and frequency of iron supplements. 
In general, the local pediatricians were discouraged to prescribe iron supplementation 
to IFF-fed infants, but they were free to follow their local routine. Unfortunately, no 
nationwide guidelines regarding iron supplementation in very low birth weight infants 
existed at that time, and in many cases no justification or rationale for the enteral iron 
supplementation could be given other than the finding of a rather low hemoglobin. In 
all infants, the intake of elemental iron (mg/kg/d) from iron supplements was calculated 
for each postnatal week. In the IFF-fed infants, the total intake of elemental iron (mg/
kg/d) for each postnatal week was calculated based on the total volume intake (ml/kg/d) 
and the iron content of the formulae and on the intake of any iron supplements. The 
median iron intake from supplements (all infants) and the median total iron intake (IFF-
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fed infants) were calculated for the following intervals: birth-term age, term age-three 
months post-term, three-six months post-term.
It was routine clinical practice to measure hemoglobin on the first day of life. At 
term age, three and six months post-term, venous blood samples were collected for 
the analysis of hemoglobin, hematocrit, mean corpuscular volume (MCV), red cell dis-
tribution width (RDW), serum ferritin, and C-reactive protein (CRP). Hemoglobin (g/l) 
was measured by colorimetry (Cell-Dyn Sapphire, Abbott Diagnostics, IL, USA) with an 
inter-assay variance of 1.6%. Hematocrit (l/l) and MCV (fl) were measured by impedance 
and optical flow cell measurement (Cell-Dyn Sapphire, Abbott Diagnostics, IL, USA) 
with an inter-assay variance of 2.6% and 1.6%, respectively. RDW (%) was measured by 
SE-9000 (Sysmex, Kobe, Japan). Ferritin was measured by an electrochemiluminescence 
immunoassay (Modular E, Roche diagnostics, Mannheim, Germany) with and inter-assay 
variance of 4.2%. CRP (mg/l) was measured by an immunoturbidimetric assay (CRPLX, 
Roche Diagnostics, Mannheim, Germany) with an inter-assay variance of 2.7%. All mea-
surements were performed at the Department of Clinical Chemistry of VU University 
Medical Center, Amsterdam, The Netherlands.
Criteria that were considered indicative of iron deficiency were: serum-ferritin <12 
μg/l [19], MCV <80 fl, and/or RDW >14.5%. Low ferritin was considered the most reliable 
indicator of iron deficiency, as it is inversely associated with iron absorption in infants 
and it reflects decreased iron stores that result in iron deficiency [11, 20]. Since ferritin 
is an acute phase reactant, ferritin was excluded from the analyses if CRP was ≥5 mg/l. 
Anemia was defined as hemoglobin <94.9 g/l and/or hematocrit <0.32 l/l.
statistics
Distribution of gender, number of transfusions, number of infants receiving iron 
supplementation, and number of infants with signs of iron deficiency and anemia were 
expressed as frequencies and compared between IFF- and HM-fed infants by chi-square 
test. Hemoglobin at birth, total transfusion volume before term age, and weight, length, 
and head circumference SDS at birth, term age, three and six months post-term were 
normally distributed. Gestational age and weight (g), length (cm), and head circumfer-
ence (cm) at birth, term age, three and six months post-term were normally distributed 
after natural log transformation. For consistency, hemoglobin at birth, total transfusion 
volume, gestational age, and growth parameters were expressed as median with inter-
quartile range (IQR) and compared between IFF- and HM-fed infants by linear regression 
adjusted for gender and gestational age.
The dosage of oral iron supplements and parameters of iron deficiency and anemia 
were not normally distributed. These parameters were expressed as median with IQR 
and were compared between IFF- and HM-fed infants by non-parametric Kruskall-Wallis 
and post-hoc Mann-Whitney test with Bonferroni correction (P<0.017 was considered 
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significant). The change in parameters of iron deficiency and anemia between time-
points was evaluated by Wilcoxon signed rank test. The correlation between ferritin at 
different time-points was evaluated by the non-parametric Spearman’s rho (rs). A P value 
of less than 0.05 was considered significant. All statistical analyses were performed in 
SPSS 17.0 for Windows (SPSS Inc., Chicago, IL, USA).
Table 10.1. Iron-fortified formula (IFF) and human milk (HM) fed infants
Iron-fortified formula (n=92)
PDF 
(n=52)
TF 
(n=40)
HM 
(n=46)
n n n
Birth
Malea (%) 27 51.9 23 57.5 21 45.7
Gestational age (weeks) 52 30.7 (1.5) 40 30.8 (2.4) 46 30.0 (1.93)
Weight (g) 52 1344 (483) 40 1390 (261) 46 1345 (605)
Length (cm) 50 38.0 (4.0) 35 38 (3.0) 45 38.0 (3.5)
Head circumference(cm) 50 27.9 (2.5) 37 28.0 (2.0) 46 28.0 (2.8)
Hemoglobin (g/l) 52 169.9 (33.8) 38 165.8 (48.3) 46 165.8 (27.4)
Birth-term age
Erythrocyte transfusiona (%) 28 53.8 19 47.5 31 67.4
Erythrocyte transfusion (ml) 28 72.0 (52.0) 19 50.0 (65.0) 31 51.0 (56.0)
Term age
Weight (g) 52 3173 (699) 40 3090 (584) 46 3158 (734)
Length (cm) 52 49.0 (3.0) 40 48.5 (3.0) 46 48.3 (2.6)
Head circumference (cm) 52 35.9 (1.4) 40 35.8 (1.6) 46 35.8 (2.3)
3 months post-term
Weight (g) 52 5573 (1410) 40 5495 (1240) 46 5508 (1210)
Length (cm) 52 59.0 (3.8) 40 59.0 (4.4) 46 58.8 (3.5)
Head circumference (cm) 52 40.7 (2.1) 40 40.8 (1.0) 46 40.8 (2.2)
6 months post-term
Weight (g) 52 7380 (1511) 40 7428 (1442) 46 7150 (1729)
Length (cm) 51 67.0 (2.5) 40 66.5 (4.4) 46 66.3 (4.0)
Head circumference (cm) 52 43.8 (1.6) 40 43.7 (1.8) 46 44.1 (2.0)
Values as median (IQR) and between-group comparisons by linear regression adjusted for gender and 
gestational age, unless specified otherwise. a Frequency (%) and between-group comparisons by chi-square 
test. There were no significant between-group differences. HM: human milk; IFF: iron-fortified formula; PDF: 
postdischarge formula; TF: term formula. 
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resuLTs
erythrocyte transfusions and growth
Hemoglobin levels at birth and the frequency and volume of erythrocyte transfusions 
given before discharge were not different between IFF- and HM-fed infants (Table 10.1). 
Growth between birth and six months post-term was comparable between IFF- and HM-
fed infants (Table 10.1 and Figure 10.2).
Iron intake
The total iron intake (i.e. from formula and supplements) was higher in preterm infants 
fed postdischarge formula (1.0 mg iron/100 ml) compared to those fed standard term 
formula (0.8 mg iron/100 ml) between term age and six months post-term [2.07 (0.87) 
versus 1.75 (0.52) mg/kg/d; P<0.05]. Even though the total iron intake was higher, 
parameters of anemia and iron deficiency were not different between infants fed post-
discharge formula and standard term formula (Table 10.2). Therefore, only comparisons 
between IFF-fed infants (fed postdischarge formula or term formula between term age 
and six months post-term) and HM-fed infants are further described here.
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figure 10.2. Weight SDS, length SDS, and head circumference SDS in IFF- and HM-fed preterm infants 
between birth and six months post-term
Values as median with interquartile range (bars) in postdischarge formula (●), standard term formula (■), and 
HM-fed infants (▲). Weight, length, and head circumference SDS were compared between groups by linear 
regression adjusted for gender and gestational age and there were no significant differences.
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In this study, 79.7% of the infants received iron supplements between term age and 
three months post-term (71.7% of the HM-fed infants and 83.7% of the IFF-fed infants). 
Most infants received iron supplements within one month after term age. In iron supple-
mented infants, the dosage of iron supplementation was higher in HM- compared to 
IFF-fed infants between birth and term age as well as between term age and three 
months post-term [birth-term age: 2.78 (0.94) versus 2.16 (1.43) mg/kg/d; and term age-
three months post-term: 2.51 (0.85) versus 2.26 (0.81) mg/kg/d; respectively; all P<0.05] 
(Figure 10.3). Between three and six months post-term, none of the IFF-fed infants and 
six HM-fed infants received iron supplements [HM-fed infants: 1.91 (1.42) mg/kg/d].
Table 10.2. Parameters of iron deficiency and anemia in iron-fortified formula (IFF) and human milk (HM) 
fed infants between term age and six months post-term
Iron-fortified formulae (n=92)
PDF 
(n=52)
TF 
(n=40)
HM 
(n=46)
Pa
n n n
Hemoglobin(g/l)
Term age 52 96.6 (9.7)* 40 96.6 (19.3)* 46 94.9 (14.5)* n.s.
3 months post-term 52 115.9 (8.1)# 40 115.9 (12.9)‡ 46 114.3 (16.1)‡ n.s.
6 months post-term 52 120.8 (12.9) 40 119.1 (11.3) 46 117.5 (9.6) n.s.
Hematocrit (l/l)
Term age 52 0.29 (0.03)* 40 0.28 (0.05)* 45 0.29 (0.05)* n.s.
3 months post-term 52 0.34 (0.03)# 40 0.35 (0.04)# 46 0.34 (0.05)‡ n.s.
6 months post-term 52 0.36 (0.04) 40 0.36 (0.03) 46 0.35 (0.03) n.s.
MCV (fl)
Term age 52 87 (5)* 40 88 (5)* 45 86 (6)* n.s.
3 months post-term 52 79 (5)‡ 40 79 (4) 46 77 (5)‡ <0.017
6 months post-term 52 78 (5) 40 78 (4) 46 77 (6) <0.017
RDW (%)
Term age 51 14.4 (2.3)* 40 14.9 (2.1)* 44 14.5 (1.5)* n.s.
3 months post-term 52 12.9 (1.5) 40 13.1 (1.6)‡ 45 13.1 (2.5) n.s.
6 months post-term 52 12.5 (1.9) 39 12.3 (1.4) 46 13.5 (2.6) <0.01
Ferritinb (μg/l)
Term age 46 44.3 (63.0)* 32 38.6 (79.9)$ 44 52.6 (61.1)* n.s.
3 months post-term 45 21.1 (20.1) 32 18.9 (15.0) 42 21.1 (23.0)‡ n.s.
6 months post-term 40 21.5 (19.2) 34 18.4 (8.9) 38 15.0 (9.2) <0.01
Values as median (IQR). a Between group comparisons by Kruskal-Wallis test and post-hoc Mann-Whitney test; 
Bonferroni correction, P<0.017 considered significant. b If CRP < 5 mg/L. Between time-points, values were 
compared by Wilcoxon signed rank test; * P<0.001 between term age and 3 months post-term; $ P<0.05 between 
term age and 3 months post-term; # P<0.001 between 3 and 6 months post-term; ‡ P<0.05 between 3 and 6 
months post-term. HM: human milk; IFF: iron-fortified formula; PDF: postdischarge formula; TF: standard term 
formula; n.s.: not significant.
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IFF-fed infants had a total iron intake (i.e. iron intake from formula and supplements) 
above 2 mg/kg/d between term age and three months post-term (Table 10.3). HM-fed 
infants that were fed additional IFF had a total iron intake below 2 mg/kg/d between 
birth and six months post-term (Table 10.3).
Parameters of iron deficiency and anemia
Between term age and three months post-term, hemoglobin and hematocrit increased 
and MCV, RDW, and ferritin decreased in HM and IFF-fed infants (Table 10.2). Between 
three and six months post-term, hemoglobin and hematocrit increased in HM- and IFF-
fed infants, while ferritin decreased in HM-fed infants and RDW decreased in IFF-fed in-
fants (Table 10.2). Ferritin at term age correlated positively with ferritin at three months 
post-term (rs=0.27, P<0.01); ferritin at three months post-term correlated positively with 
ferritin at six months post-term (rs=0.33, P<0.01).
  





 

 






 





  
 
  
  
  


  
figure 10.3. Median dosage (mg/kg/d) of oral iron supplements in iron-fortified formula (IFF) and human 
milk (HM) fed infants between birth and six months post-term
IFF: iron-fortified formula; HM: human milk. 77 IFF and 33 HM fed infants included between term age and three 
months post-term; no IFF and 6 HM fed infants included between three and six months post-term. Dosage of 
iron supplements (mg/kg/d) per week was compared between IFF- and HM-fed infants by Mann-Whitney test; * 
P<0.05.
Table 10.3. Total iron intake in iron-fortified formula (IFF) and human milk (HM) fed infants that received 
additional iron-fortified formula between birth and six months post-term
Total daily iron intakea
(mg/kg/d)
IFFb HMc IFF versus HMd
n median (IQR) n median (IQR) P
Birth-term age 88 1.19 (0.92) 43 0.82 (1.1) <0.001
Term age-3 months post-term 91 2.66 (1.22) 19 1.42 (0.36) <0.001
3-6 months post-term 90 1.19 (0.32) 33 1.04 (0.19) 0.001
a Based on iron intake from IFF and from enteral iron supplements; b preterm formula between birth and term 
age; postdischarge formula and standard term formula between term age and six months post-term; c only HM-
fed infants that were fed additional iron-fortified formula were included; d between group values were compared 
by Mann-Whitney test. IFF: iron-fortified formula; HM: human milk.
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At three months post-term, the incidence of ferritin <12 μg/l and RDW >14.5% was 
higher in HM- compared to IFF-fed infants (Table 10.4). At six months post-term, the 
incidence of ferritin <12 μg/l and RDW >14.5% was higher in HM- compared to IFF-fed 
infants (Table 10.4). At six months post-term, the incidence of hemoglobin <94.9 g/l and 
hematocrit <0.32 l/l was not different between HM- and IFF fed infants (Table 10.4).
If only infants with ferritin <12 μg/l were considered, the incidence of hemoglobin 
<94.9 g/l, hematocrit <0.32 l/l, or both was similar in HM- and IFF-fed infants at term age 
and higher in HM-fed infants at three months post-term compared to IFF-fed infants 
(term age: 80% versus 88.9%; P≥0.05; and three months post-term: 60% versus 0%; 
P<0.02; respectively). At six months post-term, none of the infants with ferritin <12 μg/l, 
fed either IFF or HM, had hemoglobin <94.9 g/l, hematocrit <0.32 l/l, or both.
Table 10.4. Anemia and iron deficiency in iron-fortified formula (IFF) and human milk (HM) fed infants 
between term age and six months post-term
IFF
(n=92)
HM 
(n=46)
IFF versus HMa
% % OR 95%CI P
Hemoglobin <94.9 g/l Term age 43.5 50 n.s.
3 months post-term 1.1 4.3 n.s.
6 months post-term 0.0 2.2 n.s.
Hematocrit <0.32 l/l Term ageb 82.6 82.2 n.s.
3 months post-term 6.5 26.1 0.15 0.05-0.46 0.001
6 months post-term 2.2 2.2 n.s.
MCV <80 fl Term ageb 4.3 4.4 n.s.
3 months post-term 59.8 78.3 0.39 0.17-0.92 0.031
6 months post-term 67.4 80.4 n.s.
RDW >14.5% Term agec 52.7 48.9 n.s.
3 months post-termb 9.8 26.7 0.25 0.09-0.68 0.006
6 months post-termd 9.9 32.6 0.19 0.07-0.50 0.001
Ferritin <12 μg/l Term agee 11.5 11.4 n.s.
3 months post-termf 7.8 23.8 0.22 0.07-0.68 0.009
6 months post-termg 9.5 26.3 0.27 0.09-0.79 0.017
Values as frequencies (%); a compared between IFF- and HM-fed infants by logistic regression adjusted for gender 
and gestational age; b 45 HM-fed infants; c 91 IFF-fed infants and 45 HM-fed infants; d 91 IFF-fed infants; e 78 IFF-
fed infants and 44 HM-fed infants; f 77 IFF-fed infants and 42 HM-fed infants; g 74 IFF-fed infants and 38 HM-fed 
infants. HM: human milk; IFF: iron-fortified formula; n.s.: not significant.
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dIscussIon
In the present study, the incidence of decreased ferritin (<12 μg/l) or increased RDW 
(>14.5%), suggestive of iron deficiency, at three and six months post-term was higher 
in HM- compared to IFF-fed preterm infants. In addition, we observed that the number 
of HM-fed infants receiving additional iron supplements decreased during the first six 
months post-term. Some HM-fed infants were fed additional TF (0.8 mg iron/100 ml) 
because HM was insufficiently available. However, the additional intake of this iron-
fortified formula did not increase their iron intake above 2 mg/kg/d (Table 10.3). If iron 
supplements were prescribed to HM-fed infants, the dosage was in accordance with the 
current guidelines that recommend 2-4 mg/kg/d elemental iron supplementation in pre-
term infants during the first 12 postnatal months [11, 13-14]. The decreased frequency 
of iron supplementation and the resultant higher incidence of iron deficiency in HM-fed 
preterm infants probably reflects the standard pediatric practice in The Netherlands 
between 2003 and 2006, when a rather low hemoglobin was often used as the only 
indicator for the initiation of iron supplementation. In addition, the higher incidence of 
iron deficiency in HM-fed infants in the present study was not explained by lower birth 
weight or faster postnatal growth, which are both associated with a higher risk of iron 
deficiency [21-23]. 
Controversy exists about the exact amount of iron required in infant formulae for 
preterm infants, partly because iron absorption from infant formulae is problematic 
and iron fortification of formulae may be associated with gastrointestinal symptoms [9]. 
Formulae with 0.5-0.9 mg iron/100 ml lead to serum ferritin <10μg/L in 2.5% of preterm 
infants before two months post-term and in 14.3% of preterm infants between two and 
six months post-term [24]. In contrast, we demonstrated a lower incidence of ferritin 
<12 μg/l in preterm infants fed formulae with 0.8-1.0 mg iron/100 ml between three 
and six months post-term, when only a few IFF-fed infants received iron supplements. 
With the IFF (0.8-1.0 mg iron/100 ml) used in this study, preterm infants need a volume 
intake of at least 200 ml/kg/d of IFF to approximate the recommended minimal iron 
intake of 2 mg/kg/d [11, 13-14]. Remarkably, the preterm infants in our study had a total 
iron intake below the recommended minimal intake of 2 mg/kg/d [11, 13-14]. Therefore, 
we speculate that infant formulae with an iron concentration of 0.8-1.0 mg/100 ml may 
prevent iron deficiency between three and six months post-term and that routine iron 
supplementation in preterm infants fed such iron-fortified formulae appears to be un-
necessary. The participating pediatricians were not restricting the prescription of iron 
supplements, even though they were requested to restrict iron supplementation. For 
that reason, it is not possible to make a firm statement on the necessary iron concentra-
tion in postdischarge formulae during the first three months post-term. However, since 
no differences were found in parameters of iron deficiency and anemia between the 
Monique binnenwerk.indd   152 06-01-14   13:13
153
10
Iron deficiency
formulae with 0.8 and 1.0 mg iron/100 ml, the lower concentration seems to be sufficient 
during the first three months post-term under the circumstances of the present study.
This study demonstrates that a serum ferritin <12 μg/l is found in IFF- and HM-fed 
infants without signs of anemia (defined as hemoglobin <94.9 g/l, hematocrit <0.32 l/l, 
or both). At three months post-term, 60% of the HM-fed infants with ferritin <12 μg/l 
were anemic, whereas at six months post-term, none of the infants with ferritin <12 
μg/l, fed either IFF or HM, were anemic. This might suggest that a biochemical marker, 
such as ferritin [20], is preferred for the diagnosis of iron deficiency and the initiation 
of iron supplementation in preterm infants. However, it should be taken into account 
that ferritin is an acute-phase reactant and an infection marker [for instance C-reactive 
protein (CRP)] should be measured to exclude a false-negative diagnosis of iron suf-
ficiency. In addition, ferritin can be disturbed by several other conditions. For example, 
ferritin may be elevated as a result of liver or kidney disease and it may be decreased 
due to malabsorption syndromes [25]. If blood samples are grossly hemolytic, serum 
ferritin can be increased by 60% in these samples due to the release of intracellular fer-
ritin [25]. Furthermore, ferritin may track between term age and six months post-term, 
as suggested by the positive correlations between time-points in the present study. This 
might imply that ferritin can be used for the early identification of preterm infants that 
are at risk of iron deficiency at three or six months post-term and may be amendable to 
early iron supplementation.
In conclusion, this observational study shows that ferritin <12 μg/l is more prevalent 
in HM- than IFF-fed infants until six months post-term. We might speculate that this 
may be due to (too) early cessation of iron supplementation in HM-fed preterm infants, 
which may reflect the standard pediatric practice in The Netherlands in 2003-2006. In 
addition, we speculate that additional iron supplements may not be necessary in infants 
fed IFF with 0.8-1.0 mg iron/100 ml, as these infants achieve ferritin levels above 12 μg/l 
without additional iron supplementation between three and six months post-term, 
which is defined as the cut off value for iron deficiency [19]. Future research may in-
vestigate if initiation and continuation of enteral iron supplements during the first six 
months post-term prevent ferritin <12 μg/l in HM-fed infants. Furthermore, it may clarify 
if IFF with 0.8-1.0 mg iron/100 ml is sufficient to prevent iron deficiency during the first 
six months post-term if no additional iron supplementation is initiated. 
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General discussion
The last three decades, the incidence and survival of preterm infants increased worldwide 
[1-3]. In The Netherlands, the incidence of very preterm birth (<32 weeks gestational age) 
increased from 0.63% in 1983 [4-5] to 1.5% in 2008 [3], while mortality rates decreased 
from 30% in 1983 [4-6] to 16% in 2008 [3]. Increased survival of preterm infants can be 
attributed to regionalization of perinatal care [5, 7], to improved obstetric care [6-8], and 
to improved neonatal care [8-9]. This improved survival results in an increased incidence 
of long-term morbidity [7]. Consequently, the focus of research in preterm infants shifted 
towards improving growth and long-term morbidity. In subsequent investigations, the 
quantity and quality of prenatal and postnatal growth, which might be influenced by 
postnatal nutritional interventions, have been related to several long-term outcomes, 
such as neurodevelopment, metabolic problems, and cardiovascular disease [10]. In this 
thesis, studies that aimed to investigate the effects of prenatal growth, early postnatal 
growth, and postdischarge nutrition on growth, body composition, and bone accretion 
of preterm infants during the first six months post-term were described. In this chapter, 
the results obtained by these studies are discussed and these may contribute to neces-
sary recommendations for preterm infants with regard to nutrition and growth for the 
coming future.
ParT I. PrenaTaL and PosTnaTaL growTh of PreTerM InfanTs
Postnatal growth regulation of preterm infants
There is increasing evidence that postnatal growth of preterm infants is, among other 
factors, regulated by IGF-I, insulin, and nutrition, similar to the regulation of fetal growth 
during the second half of pregnancy [11]. Several studies that focused on the role of 
IGF-I, insulin, and nutrition in postnatal growth of term infants demonstrate that growth 
depends on nutrition during the first half of infancy and on growth hormone (GH) 
thereafter [12]. This thesis demonstrated that IGF-I and insulin are important for growth 
regulation of preterm infants during the first half of infancy [Chapter 3]. The hepatic 
production of IGF-I is increased by the nutrient supply and its resultant insulin secretion 
[13]. This indicates that growth is enhanced through higher IGF-I and insulin secretion 
that is achieved by nutrition. In Chapter 3, the associations between serum IGF-I and 
insulin might suggest that growth regulation of preterm infants is nutrition dependent 
at least until three months post-term, since it has been stated that these hormones are 
regulated by the nutrient supply [13]. Between three and six months post-term, a shift 
towards GH dependency occurs that, in contrast to the first three months post-term, 
may not be strongly affected by nutritional intake [11]. This finding may support previ-
ous studies suggesting that the critical window for nutritional interventions to affect 
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long-term growth and body composition of preterm infants may be early in life, in 
particular during the first three months of life [14-18].
As opposed to the aforementioned relation between IGF-I and nutrient supply, con-
troversy exists on the associations between nutrient intake, in particular protein intake, 
and IGF-I during infancy. Some studies show that IGF-I is related to nutrient intake 
in preterm infants before term age [19] and in term infants during late infancy [20], 
whereas others did not find any association in term infants [21]. In this thesis, nutrient 
intake was not directly associated with insulin or IGF-I concentrations during the first 
half of infancy [Chapter 3]. This contradicts the previous suggestion that growth regula-
tion of preterm infants is nutrition dependent during the first six months post-term. It 
may be hypothesized that the postnatal growth pattern and its regulating hormones are 
determined prenatally. Another explanation may be that, in the present study, preterm 
infants had such cumulative nutritional deficits that a positive effect on growth could 
not be reached. These cumulative nutritional deficits frequently develop early in life as a 
result of a mismatch between increased nutritional demands due to postnatal morbidity 
and limited feeding possibilities in preterm infants. It may be hypothesized that these 
nutritional deficits need to be corrected before nutrient intake can affect IGF-I and 
insulin secretion and function. Therefore, we can only suggest that with the post-term 
nutritional regimen used in the randomized controlled trial nutrient intake does not 
influence IGF-I or insulin during the first half of infancy [Chapter 3].
Intrauterine and extrauterine growth restriction (Iugr and eugr): growth, 
body composition and bone accretion
Preterm infants that are small-for-gestational-age (SGA) at birth may have either 
experienced intrauterine growth restriction (IUGR) due to fetal, maternal, or placental 
morbidity or may be genetically small [22]. SGA preterm infants with IUGR can dem-
onstrate accelerated growth during infancy, defined as upward centile crossing (>0.67 
SDS) on a growth reference chart, to achieve their genetic growth potential, whereas 
SGA preterm infants that are genetically small do not. In addition, extrauterine growth 
restriction (EUGR) before term age (early EUGR), as a result of a mismatch between nu-
tritional demand and supply, is also associated with accelerated growth during infancy. 
Accelerated growth during infancy is associated with an increased risk of metabolic 
and cardiovascular disease in later life. Furthermore, decreased intrauterine growth in 
preterm infants with IUGR and decreased early postnatal growth in preterm infants with 
early EUGR do not only result in a lower weight and length but also in lower bone mass, 
which needs to be compensated during the phase of increased growth. This indicates 
that the prenatal and early postnatal growth trajectories are important for growth, body 
composition, and bone accretion that are achieved during the first half of infancy and 
may, among other factors, be determined by the fetal and postnatal nutrient supply.
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Similar to Roggero et al. [23], this thesis showed that SGA preterm infants and preterm 
infants with early EUGR remained smaller during the first six months post-term, despite 
increased relative growth and higher energy and macronutrient intake [Chapter 4]. With 
respect to body composition, this thesis demonstrated that the higher relative weight 
gain of SGA preterm infants and preterm infants with early EUGR consisted of higher 
gain in lean mass and lower gain in fat mass, resulting in a lower percent body fat during 
the first six months post-term. The increased relative growth of SGA preterm infants and 
preterm infants with early EUGR suggests that they did not achieve their full genetic 
growth potential during the intrauterine and early extrauterine period. Surprisingly, as 
mentioned before, this accelerated growth was not accompanied by increased adiposity 
in these infants, which may favor their metabolic health in the coming future [24]. For 
now, it is only speculative whether these infants are also at lower risk of cardiovascular 
and metabolic disease in later life.
The SGA classification used in this thesis is based on birth weight and birth length, 
which are indirect markers of the prenatal growth trajectory [25], and relates the size of 
the infant to the general population. It does not reflect the actual intrauterine growth 
pattern and cannot differentiate between SGA preterm infants with IUGR and SGA pre-
term infants that are genetically small. Serial ultrasonographic evaluation of intrauterine 
growth is the only method than can be used to differentiate SGA preterm infants with 
IUGR from SGA preterm infants that are genetically small.
An explanation for the lack of adiposity in SGA preterm infants and preterm infants 
with early EUGR may be that the restoration of fat mass takes longer than the study 
period of the randomized controlled trial and might require a higher energy intake 
compared to lean mass restoration [26]. Moreover, it is possible that fat mass of these 
infants further increases after the study period due to nutritional intervention. Other 
studies show that fat accumulation of preterm infants during the first two years of life 
[27-28] may track to increased adiposity at adult age [29-30] and that this is associated 
with risk of cardiovascular disease in later life [31]. Therefore, the optimal nutritional 
requirements of SGA preterm infants and preterm infants with early EUGR during the 
first half of infancy to achieve an adequate body composition without excessive fat mass 
have to be elucidated.
Increased relative growth of SGA preterm infants was accompanied by increased 
collagen type I synthesis during the first six months post-term [Chapter 6], which may 
indicate an increase in skeletal size. In SGA preterm infants, gain in bone area (BA) was 
indeed slightly but not significantly higher [Chapter 5], which may suggest that these 
infants have increased bone matrix formation that leads to increased skeletal size 
[32-33]. However, increased collagen type I synthesis was not accompanied by higher 
gain in bone mineral content (BMC) in SGA preterm infants during the first six months 
post-term [Chapter 5 and 6]. This indicates that, although bone matrix formation is 
Monique binnenwerk.indd   161 06-01-14   13:13
162 Chapter 11
increased, deposition of mineral in the bone matrix is diminished and/or delayed. It 
may be hypothesized that SGA preterm infants benefit from increased protein, calcium, 
phosphorus, and vitamin D intake to improve bone accretion and mineralization during 
the first six months post-term. As lower bone mass of SGA preterm infants at birth [34] 
and at term age [35] is a risk factor for osteoporosis in later life [36-39], it is important to 
stimulate the postnatal bone accretion with nutritional interventions, as supported by 
previous studies in preterm subjects [40-42].
The smaller body size, lower fat deposition, and lower bone accretion during the first 
half of infancy in SGA preterm infants and preterm infants with early EUGR may imply that 
the prenatal and early postnatal trajectory are dominant over any postnatal nutritional 
intervention during the first half of infancy. On the other hand, it emphasizes the need 
for an adequate nutrient supply. Although it has been stated that enriched formulae and 
human milk fortification are effective strategies to address nutritional deficits and poor 
growth of preterm infants early after discharge [43], the exact nutritional intake that is re-
quired is unknown and the current nutritional guidelines are not adapted to the growth 
pattern until term age [44]. Furthermore, special interest should be addressed to the 
nutritional intake before term age to prevent that cumulative nutritional deficits develop 
in early life. To date, however, these early nutritional deficits cannot be fully prevented 
[43], which emphasizes the need for specialized enriched nutrition after term age.
ParT II. PosTdIscharge nuTrITIon
Nutrition is important for postnatal growth, body composition, and bone accretion. 
Preterm infants remain smaller [45-48] and have a suboptimal bone mass [49-52] 
throughout infancy, childhood, and adolescence compared to term infants. This may be 
a consequence of inadequate growth and bone accretion due to cumulative nutritional 
deficits before term age. These nutritional deficits underline the importance of an ad-
equate nutritional regimen after term age, which may be achieved with postdischarge 
formula. Since the first publication on postdischarge formula in 1992 by Lucas et al. 
[53], several studies report that postdischarge formulae enriched with energy, protein, 
and minerals enhance growth [53-59] and bone accretion [58, 60-61] of preterm infants 
during the first year of life. Therefore, specialized postdischarge formula is now recom-
mended for all preterm infants, if human milk is not available [44, 62].
The effect of postdischarge formula on growth and body composition
The debate continues on the effect of postdischarge formulae on growth and body 
composition of preterm infants. Some studies on postdischarge formulae with a high 
energy (>72 kcal/100 ml) and a high protein content (>1.7 g/100 ml) show no clear 
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benefit on growth and body composition [23, 63-65], whereas others report increased 
fat accretion during the first year of life [58, 66], which may be directly related to the 
higher energy intake [67-68]. The present study used a postdischarge formula (PDF) 
that was isocaloric but high in protein, minerals, vitamin D, and LC-PUFAs [Chapter 2], in 
accordance with ESPGHAN guidelines for postdischarge formulae [44]. This PDF resulted 
in similar growth, lower fat deposition, and higher bone accretion during the first six 
months post-term compared to standard term formula [Chapter 2, 7, 8]. In more detail, 
the higher protein availability from this isocaloric PDF may explain the similar growth 
with lower fat deposition [Chapter 2]. It may be hypothesized that this reduced infant 
fat accumulation tracks to adulthood [31, 69] and so reduces the risk of cardiovascular 
and metabolic diseases.
Growth of preterm infants fed the isocaloric PDF used in the present study may be 
further promoted by long-chain polyunsaturated fatty acids (LC-PUFAs). Preterm infants 
have a lower docosahexaenoic acid (DHA) and arachidonic acid (AA) status at birth and 
require an adequate dietary LC-PUFA intake to prevent postnatal deficits, which have 
been associated with adverse effects on growth and central nervous system develop-
ment. Previous studies in preterm infants report that DHA and AA supplementation 
of preterm formula enhances growth up to two months postnatal age [70] but not 
thereafter [71-72]. We found that higher RBC-DHA was associated with increased gain 
in weight and length and decreased gain in head circumference and that higher RBC-
AA was associated with increased gain in head circumference and decreased gain in 
weight and length [Chapter 8]. Increased head growth within 2 standard deviations of 
the mean may prevent an adverse neurodevelopmental outcome [73-74]. Moreover, the 
results described in this thesis suggests that the dietary supply of DHA and AA from PDF, 
resulting in a DHA and AA status within the range of the targets of human milk fed term 
infants, is associated with balanced growth of preterm infants [Chapter 8].
The effect of postdischarge formula on bone accretion
The combined higher protein, calcium, phosphorus, and vitamin D intake from PDF 
may attribute to higher collagen type I synthesis [75-76] and bone accretion [77] due to 
higher bone matrix formation combined with higher bone mineralization. In this thesis, 
the higher gain in bone mineral content of PDF compared to TF fed preterm infants 
was explained by the slightly higher increase in skeletal size in PDF fed preterm infants, 
whereas the difference with HM fed preterm infants was explained by higher bone 
mineral deposition in PDF fed preterm infants [Chapter 7]. Furthermore, higher vitamin 
D intake from PDF resulted in a higher increase in serum 25-hydroxyvitamin D concentra-
tions, which was related to a higher increase in bone mineral content [Chapter 9]. It may 
be speculated that since a higher infant bone mineral content may track to adulthood 
[36-37], PDF fed preterm infants may have a lower risk of osteoporosis in later life [39]. 
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Nevertheless, although the results of the randomized controlled trial suggest that an 
isocaloric, high-protein, mineral-enriched postdischarge formula improves quality of 
growth as well as bone accretion of preterm infants during the first six months post-term, 
there is an urgent need to investigate these long-term effects in the coming future.
Postdischarge nutrition and iron
Another micronutrient that is important for preterm infants is iron. Iron deficiency has 
been related to anemia, growth faltering, adverse neurodevelopmental outcome, and 
an impaired immune status [78-80]. As iron deficiency is frequently not accompanied by 
anemia, a biochemical marker of iron deficiency, such as ferritin [81], should be preferred 
over hemoglobin and hematocrit as an indicator of iron deficiency [Chapter 10]. In this 
thesis, we demonstrated that, at six months post-term, the incidence of iron deficiency 
(ferritin <12 μg/l) was higher in preterm infants fed human milk compared to those fed 
iron-fortified formulae [PDF (1.0 mg iron/100 ml) and TF (0.8 mg iron/100 ml)] [Chapter 
10]. This may be explained by the finding that the number of human milk fed infants 
that were iron supplemented decreased rapidly during the first six months post-term, 
especially after three months post-term. The decision on iron supplementation may 
reflect the pediatric practice in The Netherlands during the study period, which was not 
in line with the current Dutch recommendations of 2-3 mg/kg/d iron supplementation 
between two and six to twelve months of age in preterm infants fed human milk, if 
their birth weight is below 2,000 gram [82-83]. Furthermore, it was stated that preterm 
infants fed iron-fortified formulae do not need additional enteral iron supplementation 
[82-83]. The finding that human milk fed preterm infants were poorly supplemented 
with iron during the first six months of life may underline that the importance of iron 
supplementation in these infants needs to be brought to the attention of pediatricians 
in The Netherlands.
Preterm infants fed iron-fortified formulae with 0.8-1.0 mg iron/100 ml may not need 
additional iron supplementation, as also suggested by the Dutch guidelines on iron sup-
plementation [82-83]. In the present study, these infants achieve ferritin concentrations 
above 12 μg/l between three and six months post-term without additional iron supple-
mentation, which implies that the iron intake from the iron-fortified formulae prevents 
iron deficiency between three and six months post-term [Chapter 10]. However, many 
iron-fortified formula fed preterm infants in our study were iron supplemented between 
term age and three months post-term and, therefore, we cannot state that iron-fortified 
formulae also prevent iron deficiency between term age and three months post-term.
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MeThodoLogIcaL consIderaTIons
This thesis was based on a randomized controlled trial that was designed to evaluate the 
effects of postdischarge nutrition on growth, body composition, and nutritional status 
of preterm infants during the first six months post-term. Although all analyses presented 
in this thesis were adjusted for the type of diet (i.e. PDF, TF, or HM), influence of the 
type of diet on the demonstrated associations cannot be excluded. In addition, only as-
sociations and no causal relations can be established. Unfortunately, body composition, 
laboratory parameters, and bone parameters were not measured at birth.
This thesis presents differences in growth, body composition, and bone accretion be-
tween SGA preterm infants, AGA preterm infants, and preterm infants with early EUGR. 
These analyses were based on post-hoc analyses, as they were not part of the original 
randomized controlled trial. This should be taken into account when the results of these 
analyses are interpreted.
Controversy exists on which growth references should be used to define ‘normal’ 
or ‘adequate’ growth of preterm infants. Growth references are based on intrauterine 
growth reflected by size at birth [84], on postnatal growth of term infants [85], or on 
postnatal growth of preterm infants [86]. Growth references that are based on cross-sec-
tional birth data reflect the intrauterine condition of a reference population that cannot 
be compared to preterm infants [22, 86]. Growth references that are based on postnatal 
growth of term infants require adjustment for prematurity, although postnatal growth 
of term infants cannot be compared to that of preterm infants [86]. Furthermore, growth 
references that are based on postnatal growth of preterm infants [86] imminently reflect 
postnatal growth restriction of preterm infants [22]. Although individualized growth ref-
erences based on the in utero growth pattern are preferred to evaluate postnatal growth 
of preterm infants [22], these references require ultrasonographic measurements of fetal 
growth. The present study used growth references based on cross-sectional birth data 
of preterm infants until term age [84] and growth references based on growth of Dutch 
term infants thereafter, adjusted for postmenstrual age [85].
The present study used dual-energy x-ray absorptiometry (DXA) to determine body 
composition and bone accretion, which is sensitive to movement artifacts. Therefore, an 
experienced research nurse ensured the adequate position of the infants. It is difficult 
to compare DXA measurements of the present study to that measured in previous stud-
ies. Previous studies used different methods (e.g. air displacement plethysmography 
(PEAPOD), bioelectrical impedance analysis, single-photon absorptiometry, or DXA), or 
a different DXA model (e.g. Hologic or Lunar), type, or software [87]. As a consequence, 
comparisons of body composition and bone accretion between the present study and 
previous studies need to be interpreted with caution.
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generaL concLusIons
This thesis shows that the prenatal and early postnatal trajectory are important for 
growth, body composition, and bone accretion of preterm infants, with an important 
growth regulating role for the endocrine factors IGF-I and insulin during the first half of 
infancy. Preterm infants born SGA or those with early EUGR remain smaller with lower 
fat mass and bone mass, despite higher nutritional intake during the first six months 
post-term, and these infants may benefit from even higher nutritional intakes to attain a 
fat mass and bone mass similar to AGA preterm infants. On the other hand, with respect 
to fat mass, it might be hypothesized that the lower fat accumulation in SGA preterm 
infants and preterm infants with early EUGR may be appropriate for their body size.
In addition, this thesis demonstrates that preterm infants benefit from an isocaloric, 
protein- and mineral-enriched postdischarge formula with regard to their quantity 
and quality of growth, bone accretion, and vitamin D status during the first six months 
post-term. In particular, preterm infants may benefit from this postdischarge formula 
because it is not energy-enriched and results in lower fat accumulation, which may be 
associated with a lower risk of adiposity and concomitant metabolic and cardiovascular 
consequences in later life.
Finally, iron deficiency is more common in preterm infants fed human milk compared 
to those fed iron-fortified formulae during the first half of infancy. This may be related to 
the lower frequency of iron supplementation in human milk fed preterm infants. Dutch 
guidelines on iron supplementation for preterm infants, similar to those described by 
Lafeber et al. [83], are required for the daily pediatric practice. In addition, the findings 
of this thesis may indicate that iron-fortified formulae prevent iron deficiency between 
three and six months post-term.
fuTure research
In the present study, preterm infants frequently experienced nutritional deficits before 
term age. Future studies should aim to improve the nutritional intake between birth 
and term age in order to reduce nutritional deficits and growth faltering before term 
age. This may be achieved by high protein administration early after birth [88-90]. We 
hypothesize that with an optimal nutritional regimen before term age, preterm infants 
may benefit even more from postdischarge formula because the higher nutrient sup-
ply from postdischarge formula is no longer needed to compensate for the nutritional 
deficits that developed before term age and can be fully utilized to improve growth, 
body composition, and bone accretion after term age. However, the effect of higher 
nutritional intake before term age as well as the additional effect of postdischarge 
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formula after term age on the quality and quantity of growth need to be investigated. 
These increased nutritional intakes may result in accelerated growth, in particular in 
SGA preterm infants and preterm infants with some degree of early EUGR, followed by 
metabolic and cardiovascular consequences in later life.
Overall, although postdischarge formula has short-term benefits during infancy, the 
long-term outcomes with respect to growth, body composition, bone accretion and 
cardio-metabolic consequences in preterm infants fed this formula need to be further 
investigated. A follow-up study of the randomized controlled trial described in this 
thesis (STEP 2) is currently in progress and evaluates growth, body composition, bone 
accretion, and metabolic health during childhood of preterm infants fed postdischarge 
formula, standard term formula, or human milk. Based on the benefits of the isocaloric, 
protein- and mineral-enriched postdischarge formula for body composition and bone 
accretion during the first half of infancy, it was hypothesized that preterm infants fed 
this formula have less fat mass, higher bone mineralization, lower blood pressure, and 
better metabolic health at 7 years of age compared to preterm infants fed standard term 
formula. Based on this hypothesis, growth, body composition and bone mass (both 
measured by DXA), blood pressure, and several biochemical parameters (e.g. insulin, 
glucose, IGF-I, cholesterol, and 25-hydroxyvitamin D) are evaluated in participants of 
the STEP at 7 years.
Moreover, it was hypothesized that less fat mass during childhood may lead to less adi-
posity during adulthood, which may decrease the risk of metabolic and cardiovascular 
consequences, such as diabetes, hypertension, and cardiovascular disease. To address 
this hypothesis, another follow-up study of the STEP cohort needs to be conducted at 
adult age. This study is expected to yield important results with respect to the long-
term metabolic and cardiovascular effects of the early intervention with postdischarge 
formula and these may contribute to the establishment of optimal nutritional manage-
ment of preterm infants in early life.
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During the extrauterine third trimester, preterm infants develop nutritional deficits as 
postnatal morbidity increases nutritional demands, which are not reached because of 
limited feeding possibilities. Consequently, many preterm infants experience extrauter-
ine growth restriction (EUGR) followed by accelerated growth. Nutritional deficits may 
also lead to decreased bone accretion, micronutrient deficiencies, and neurodevelop-
mental impairment. The quantity and quality of prenatal and postnatal growth of pre-
term infants are important with respect to metabolic and cardiovascular consequences 
in later life. In-hospital feeding regimens aim to prevent cumulative postnatal nutri-
tional deficits in preterm infants. To date, however, in-hospital regimens cannot fully 
prevent cumulative nutritional deficits or EUGR in preterm infants. Therefore, specialized 
postdischarge nutrition has a key role in the nutritional management of preterm infants 
after discharge to improve growth and bone accretion and to limit fat accumulation, 
which is associated with long-term cardiovascular and metabolic consequences. The 
background of this thesis is further addressed in chapter 1.
This thesis is based on a single-blinded randomized controlled trial in 152 preterm 
infants that compared the effects of an isocaloric, protein- and mineral enriched 
postdischarge formula (PDF), a standard term formula (TF), and human milk (HM) on 
growth, body composition, bone accretion, and micronutrient status between term age 
and six months corrected age (CA). chapter 2 describes the study design and the main 
results of the randomized controlled trial. In short, preterm infants fed PDF had higher 
protein intake and similar growth with less fat accumulation compared to those fed TF 
during the first half of infancy. This thesis evaluates the effects of prenatal growth, early 
postnatal growth, and postdischarge nutrition on growth, body composition, and bone 
accretion of preterm infants during the first half of infancy, as stated in chapter 2.
The first part of this thesis focuses on postnatal growth regulation and on the effects of 
prenatal growth and early postnatal growth on body composition and bone accretion 
of preterm infants. chapter 3 demonstrates that insulin-like growth factor type I (IGF-I) 
and insulin are important for growth regulation of preterm infants during the first six 
months post-term, independent of nutritional intake. In addition, the lack of association 
between IGF-I and insulin at six months CA suggests that growth regulation shifts to-
wards growth hormone (GH) dependency at six months CA due to a gradual maturation 
of the GH/IGF-I axis.
Prenatal growth and early postnatal growth are important for body composition and 
bone accretion. chapter 4 reports that small-for-gestational-age (SGA) preterm infants 
and preterm infants with EUGR before term age (early EUGR) remained smaller and had 
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a lower percentage of body fat during the first six months post-term, despite increased 
relative growth and higher energy and macronutrient intakes. It might be hypothesized 
that accelerated infant growth without increased adiposity favors later metabolic health. 
However, the optimal nutritional requirements of preterm infants needed to achieve 
accelerated growth without excessive fat deposition have to be elucidated.
chapter 5 describes that SGA preterm infants had lower gain in bone mineral content 
(BMC) during the first six months post-term, independent of gain in body size. In addi-
tion, chapter 6 shows that SGA preterm infants had higher collagen type I synthesis 
during the first half of infancy, which may reflect increased relative growth. Although 
collagen type I is predominantly found in bone matrix, higher collagen type I synthesis 
did not lead to increased gain in BMC in SGA preterm infants. This may be explained 
by insufficient bone mineralization. Since the lower bone mass of SGA preterm infants 
is a risk factor for osteoporosis, it is important to focus on nutritional interventions, for 
example with calcium, phosphorus, and vitamin D, that may stimulate bone accretion 
in these infants.
The second part of this thesis focuses on the effects of postdischarge nutrition on bone 
accretion, growth, and micronutrient status. chapter 7 describes that PDF enhanced 
gain in BMC of preterm infants during the first six months post-term, independent of 
gain in weight and length. Higher BMC of preterm infants during infancy, as a result of 
PDF, may track to higher adult bone mass, which decreases the risk of osteoporosis in 
later life.
chapter 8 relates growth of preterm infants to long-chain polyunsaturated fatty acid 
(LC-PUFA) levels, namely docosahexaenoic acid (DHA) and arachidonic acid (AA). During 
the first six months post-term, PDF fed preterm infants had higher red blood cell (RBC) 
DHA and AA concentrations. RBC-DHA was positively associated with gain in weight 
and length and negatively with gain in head circumference. RBC-AA was positively 
associated with gain in head circumference and negatively with gain in weight and 
length. These findings suggest that the dietary supply of DHA and AA by PDF, which was 
within the targets of term infants fed human milk, may be related to balanced growth 
of preterm infants.
chapter 9 shows that, in preterm infants, higher vitamin D intake with an isocaloric, 
protein- and mineral-enriched PDF resulted in a greater increase in serum 25-hydroxyvi-
tamin D during the first six months post-term. Increase in serum 25-hydroxyvitamin D 
was positively associated with gain in BMC. This may suggest that, in addition to the 
availability of dietary protein, calcium, and phosphorus, higher vitamin D intake contrib-
utes to increased bone accretion in PDF fed preterm infants.
chapter 10 demonstrates that iron deficiency was more frequent in preterm infants 
fed HM compared to those fed iron-fortified formula at three and six months CA. This 
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may be due to early cessation of additional iron supplementation in HM fed preterm 
infants. This might suggest that the importance of iron supplementation for HM fed 
preterm infants during the first half of infancy needs to be brought to the attention of 
Dutch pediatricians. In accordance with Dutch guidelines, iron-fortified formula appears 
to suffice to prevent iron deficiency between three and six months CA.
chapter 11 discusses the growth regulating role of the endocrine factors IGF-I and 
insulin as well as prenatal growth and early postnatal growth in relation to growth, body 
composition, and bone accretion of preterm infants during the first half of infancy. In ad-
dition, this chapter discusses the benefits of an isocaloric, protein- and mineral-enriched 
PDF with regard to quantity and quality of growth, bone accretion, LC-PUFA status, and 
vitamin D status during the first six months post-term. Finally, the implications of the 
incidence of iron deficiency of preterm infants fed HM and iron-fortified formulae with 
regard to iron supplementation are discussed. Several suggestions for future research 
are described with a special interest in the nutritional intake between birth and term 
age and the long-term outcomes of preterm infants fed the isocaloric, protein- and 
mineral-enriched PDF described in this thesis.
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In vergelijking met op tijd geboren kinderen groeien te vroeg geboren kinderen (prema-
turen) na de geboorte minder goed. Dit wordt deels verklaard door de beperkte moge-
lijkheden om direct na de geboorte voldoende voedingsstoffen toe te dienen. Bovendien 
is de vraag naar voedingsstoffen dan juist verhoogd als gevolg van problemen die met 
de vroeggeboorte samenhangen, zoals infecties en ademhalingsproblemen. Hierdoor 
ontwikkelen veel prematuren direct na de geboorte een groeivertraging (extra-uteriene 
groeirestrictie), die vaak gevolgd wordt door een fase van versnelde groei na de uitge-
rekende (a terme) datum. Tot de gevolgen van het tekort aan voedingsstoffen behoren 
ook een vermindering van de botaanmaak, een tekort aan micronutriënten (vitamines 
en mineralen) en stoornissen in de ontwikkeling. De gevolgen van het groeipatroon 
in de prenatale en postnatale fase (d.w.z. de fase voor en na de geboorte) kunnen zich 
uitstrekken tot op volwassen leeftijd. Groeivertraging en een ongunstige lichaamssa-
menstelling met veel vetmassa zijn bij prematuur geboren mensen geassocieerd met 
het ontwikkelen van het metabool syndroom en cardiovasculaire aandoeningen. Het 
is daarom van belang om al heel vroeg, tijdens de postnatale zorg in het ziekenhuis, 
een tekort aan essentiële voedingsstoffen te voorkomen. Echter, tot op heden kunnen 
deze tekorten evenals de genoemde groeivertraging na de geboorte tijdens de zieken-
huisopname niet worden voorkomen. Daarom heeft aangepaste voeding na ontslag 
(‘postdischarge’ voeding) een speciale plaats in het voedingsbeleid voor prematuren. 
Deze voeding wordt gegeven om de groei, de lichaamssamenstelling en de botaanmaak 
zodanig te verbeteren dat de kans op cardiovasculaire en metabole gevolgen op de 
lange termijn zoveel mogelijk wordt beperkt. De achtergrond van dit proefschrift wordt 
verder besproken in hoofdstuk 1.
In dit proefschrift worden in deel I de gevolgen van prenatale groei (d.w.z. groei voor de 
geboorte), vroeg postnatale groei (d.w.z. groei tussen de geboorte en de uitgerekende 
datum) beschreven. In deel 2 worden de effecten van ’postdischarge’ voeding op de 
groei, de lichaamssamenstelling en de botaanmaak van prematuren gedurende het 
eerste half jaar bestudeerd.
Dit proefschrift is gebaseerd op een gerandomiseerd voedingsonderzoek uitgevoerd bij 
152 prematuren. Deze prematuren werden na een zwangerschapsduur van 32 weken of 
minder geboren en/of hadden een geboortegewicht van 1500 gram of minder. Tussen 
de a terme leeftijd (d.w.z. de verwachte geboortedatum) en de gecorrigeerde leeftijd 
(d.w.z. de leeftijd gerekend vanaf de verwachte geboortedatum) van zes maanden wer-
den deze prematuren met een ‘postdischarge’ voeding, met een standaard voeding voor 
op tijd geboren zuigelingen of met moedermelk gevoed. De ‘postdischarge’ voeding 
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bevatte evenveel calorieën maar meer eiwitten en mineralen dan de standaard voeding 
voor op tijd geboren zuigelingen. Bij dit onderzoek werden de groei, de lichaamssamen-
stelling en de botaanmaak van deze prematuren tijdens het eerste half jaar vergeleken.
hoofdstuk 2 beschrijft de studieopzet en de belangrijkste resultaten van het geran-
domiseerde onderzoek. Het belangrijkste feit uit de analyse was de bevestiging dat 
prematuren die ‘postdischarge’ voeding kregen tijdens het eerste half jaar inderdaad 
een hogere eiwitinname hadden. Deze prematuren lieten een vergelijkbare groei zien 
maar met minder vettoename dan prematuren die standaard voeding kregen.
Het eerste deel van dit proefschrift richt zich op de gevolgen van prenatale en postnatale 
groei van prematuren. 
In hoofdstuk 3 wordt het belang van insulin-like growth factor type I (IGF-I) en insu-
line voor de groeiregulatie van prematuren tot zes maanden gecorrigeerde leeftijd 
beschreven. Deze regulatie was niet gerelateerd aan het type voeding. Er was op de 
a terme leeftijd en op de gecorrigeerde leeftijd van drie maanden een verband tussen 
IGF-I en insuline onderling. Later, op de gecorrigeerde leeftijd van zes maanden, werd 
dit verband tussen IGF-I en insuline niet meer gevonden. Mogelijk duidt dit op een 
afnemend belang van insuline en een toenemend belang van groeihormoon (GH) voor 
de groeiregulatie middels IGF-I. 
In hoofdstuk 4 wordt aangetoond dat prematuren die small-for-gestational-age gebo-
ren zijn (SGA; d.w.z. te klein voor de zwangerschapsduur) en prematuren met vroege 
extra-uteriene groei restrictie (vroege EUGR; d.w.z. met een groeivertraging tussen de 
geboorte en de a terme leeftijd) een relatief hogere groeisnelheid hebben. Deze SGA 
prematuren en prematuren met vroege EUGR hadden een hogere inname van energie, 
eiwitten, koolhydraten en vetten maar bleven desondanks kleiner dan de andere kinde-
ren. Tevens hadden zij een lager vetpercentage gedurende het eerste half jaar. Voor de 
latere gezondheid is een snelle groei, die niet gepaard gaat met aanwas van vetweef-
sel, wellicht gunstig. Echter, de optimale samenstelling van voeding voor prematuren, 
die resulteert in een snelle groei zonder vetaanwas, is op dit moment helaas nog niet 
bekend.
In hoofdstuk 5 wordt beschreven dat SGA prematuren tussen de a terme leeftijd en de 
gecorrigeerde leeftijd van zes maanden een lagere botaanmaak [uitgedrukt als toename 
van bone mineral content (BMC)] hadden. Deze lagere botaanmaak werd niet verklaard 
doordat SGA prematuren kleiner waren.
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Aansluitend toont hoofdstuk 6 dat de collageen type I aanmaak van SGA prematuren 
hoger was dan die van de andere kinderen gedurende het eerste half jaar. Deze ver-
hoogde aanmaak is mogelijk een teken van snelle groei. Echter, de verhoogde aanmaak 
van collageen type I, dat vooral voorkomt in de botmatrix, was bij SGA prematuren 
niet geassocieerd met een verhoogde aanmaak van botweefsel. Deze discrepantie zou 
verklaard kunnen worden door onvoldoende botmineralisatie. Aangezien onvoldoende 
aanmaak van botweefsel een risicofactor is voor het ontwikkelen van osteoporose op 
volwassen leeftijd, hebben juist deze kinderen mogelijk baat bij voedingsinterventies 
die gericht zijn op de stimulatie van botaanmaak. Hierbij kan worden gedacht aan sup-
pletie van extra calcium, fosfaat en vitamine D.
Het tweede deel van dit proefschrift richt zich op de effecten van ‘postdischarge’ voeding op 
de botaanmaak, de groei en voldoende aanwezigheid van micronutriënten. 
In hoofdstuk 7 wordt beschreven dat de ‘postdischarge’ voeding de botaanmaak 
(uitgedrukt als de toename van BMC) van prematuren tussen de a terme leeftijd en zes 
maanden gecorrigeerde leeftijd verbeterde. Deze verbetering was onafhankelijk van de 
toename in gewicht en lengte. Deze toename van BMC bij prematuren heeft mogelijk 
een gunstig effect op de botmassa op volwassen leeftijd. Dit laatste zou kunnen leiden 
tot een verminderd risico op osteoporose op latere leeftijd.
In hoofdstuk 8 wordt de relatie tussen de groei van prematuren en de inname van 
de lange keten meervoudig onverzadigde vetzuren gelegd. De ‘postdischarge’ voeding 
bevatte het omega-3 vetzuur docosahexeenzuur (DHA) en het omega-6 vetzuur arachi-
donzuur (AA). Bij prematuren die ‘postdischarge’ voeding kregen, werden gedurende 
het eerste half jaar hogere waarden van DHA en AA gevonden in de rode bloedcellen 
(RBC waarde). Er werd een positief verband gevonden tussen de RBC waarde van DHA 
en de toename in gewicht en lengte. Eenzelfde verband werd gevonden tussen de RBC 
waarde van AA en de toename in schedelomtrek. Voorts bleek er een negatief verband 
te bestaan tussen de RBC waarde van DHA en de toename in schedelomtrek evenals 
tussen de RBC waarde van AA en de toename in gewicht en lengte. Het aanbod van DHA 
en AA uit ‘postdischarge’ voeding leidde tot bloedwaarden van DHA en AA die goed ver-
gelijkbaar waren met de bloedwaarden van op tijd geboren kinderen die moedermelk 
krijgen. Deze bloedwaarden van prematuren zijn mogelijk van belang voor voldoende 
groei.
In hoofdstuk 9 wordt aangetoond dat kinderen in de ‘postdischarge’ voeding groep 
tijdens het eerste half jaar een hogere vitamine D inname en een grotere toename van 
serum 25-hydroxyvitamine D (een maat voor de vitamine D status) hadden dan kinderen 
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uit de andere voedingsgroepen. Er was een positieve associatie tussen de toename van 
serum 25-hydroxyvitamine D en de toename van BMC. Het is waarschijnlijk dat vitamine 
D, naast eiwit, calcium en fosfaat, bijdraagt aan de hogere botaanmaak van prematuren 
die ‘postdischarge’ voeding krijgen.
In hoofdstuk 10 wordt beschreven dat ijzertekort op de gecorrigeerde leeftijd van 
drie en zes maanden vaker voorkwam bij prematuren die moedermelk kregen dan bij 
prematuren die ijzer verrijkte kunstvoeding, zoals ‘postdischarge’ voeding of standaard 
voeding, kregen. Dit wordt mogelijk verklaard doordat de ijzersuppletie bij prematuren 
die moedermelk kregen ruim voor de gecorrigeerde leeftijd van drie maanden werd 
gestaakt. Dit terwijl ijzersuppletie voor deze kinderen de enige bron van ijzervoorzie-
ning is. Overeenkomstig de Nederlandse richtlijnen lijkt ijzer verrijkte kunstvoeding 
voldoende om bij prematuren een ijzertekort tussen de gecorrigeerde leeftijd van drie 
en zes maanden te voorkomen.
hoofdstuk 11 geeft een overzicht van de onderwerpen en conclusies van dit proef-
schrift. Prenatale groei en vroeg postnatale groei zijn belangrijk voor de groei, de 
lichaamssamenstelling en de botaanmaak van prematuren gedurende het eerste half 
jaar. In deze periode is IGF-I van belang voor de regulatie van groei. 
De ‘postdischarge’ voeding, die gebruikt werd in dit onderzoek, leidt tot een hogere 
inname van eiwitten, lange keten vetzuren (DHA en AA), vitamines (vitamine D), en 
mineralen. Al deze factoren zijn van invloed op de groeimogelijkheden, op de ontwik-
keling van de lichaamsamenstelling en op de botaanmaak van prematuren gedurende 
de eerste zes maanden na de uitgerekende datum. Ten slotte worden de implicaties van 
ijzersuppletie voor de ijzervoorraad van prematuren, die moedermelk en ijzer verrijkte 
kunstvoeding krijgen, aan de orde gesteld. De resultaten suggereren dat prematuren 
die moedermelk krijgen in ieder geval gedurende het eerste half jaar ijzersuppletie 
nodig hebben, terwijl prematuren die ijzer verrijkte kunstvoeding krijgen dit niet nodig 
hebben.
Dit hoofdstuk sluit af met aanbevelingen voor toekomstig onderzoek. Nieuw onder-
zoek zal zich moeten richten op een optimaal voedingsbeleid voor prematuren tussen de 
geboorte en de a terme leeftijd. Daarnaast is het van belang dat onderzoek plaatsvindt 
naar de lange termijn effecten van ‘postdischarge’ voeding, zoals die gebruikt is in het 
gerandomiseerde onderzoek waarop dit proefschrift is gebaseerd. Er wordt kort inzage 
gegeven in de methodieken waarmee thans dit lange termijn onderzoek plaatsvindt op 
7-jarige leeftijd.
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Composition of the study formulae
Postdischarge formula (PDF) Term formula (TF)
Volume (ml/kg/d) 175 175
Protein (g) 1.7 1.47
 Arginine (mg) 70 -
 Taurine (mg) 4.6 4.6
Fat (g) 3.5 3.55
 C8 – C10 (mg) 324 -
 LA (mg) 415 422
 ALA (mg) 59 63
 GLA (mg) 11.5 -
 DHA (mg) 14.0 6.7
 AA (mg) 14.0 6.7
Carbohydrates 7.0 7.23
 Lactose (g) 6.6 7.0
 Saccharose (g) - -
 GOS (g) 0.14 0.24
 Maltodextrin (g) 0.16 0.26
Energy (kcal) 67 67
Na (mg) 25 20
K (mg) 68 67
Cl (mg) 43 40
Ca (mg) 65 50
Mg (mg) 6.14 6.0
P (mg) 38 30
Fe (mg) 1.0 0.8
Cu (μg) 65 50
Mn (μg) 34 33.5
Zn (mg) 0.64 0.6
I (μg) 17 7.4
Vitamin A (μg) 65 58
Beta-carotene (μg) 52 41
Vitamin D (μg) 1.4 1.2
Vitamin E (μg) 2.6 1.3
Vitamin K (μg) 6.35 5.1
Vitamin B1 (μg) 51 44
Vitamin B2 (μg) 115 90
Niacin (μg) 1920 777
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Postdischarge formula (PDF) Term formula (TF)
Vitamin B6 (μg) 77 39.5
Vitamin B12 (μg) 0.29 0.16
Folic acid (μg) 30 11
Pantothenic acid (μg) 500 224
Biotin (μg) 2.05 1.14
Vitamin C (μg) 17 9.4
Choline (mg) 14 14
Carnitine (mg) 2.3 1.9
Osmolality (mOsmol/L) 270 280
All values are per 100 ml of prepared formula, except for volume (ml/kg/d).
AA: arachidonic acid; ALA: alpha linolenic acid; DHA: docosahexaenoic acid; GLA: gamma linolenic acid; GOS: 
galactooligosaccharides; LA: linoleic acid.
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supplemental Table 9.1. Weight, length, and head circumference z-scores between birth and six months 
corrected age (CA) in preterm infants fed postdischarge formula (PDF), term formula (TF), and human milk 
(HM)1
Birth Term age 3 months CA 6 months CA
n Value n Value n Value n Value
Weight (z-score)
PDF 52 -0.43 ± 0.96 52 -1.11 ± 1.24 52 -0.39 ± 1.31 52 -0.38 ± 1.10
TF 41 -0.32 ± 0.82 41 -0.91 ± 1.06 41 -0.16 ± 1.20 41 -0.21 ± 1.24
HM 46 -0.32 ± 1.13 46 -1.04 ± 1.27 46 -0.32 ± 1.35 46 -0.43 ± 1.24
Length (z-score)
PDF 50 -0.93 ± 1.17 52 -1.11 ± 1.31 52 -0.62 ± 1.04 51 -0.18 ± 0.91
TF 41 -1.03 ± 1.06 41 -1.03 ± 1.09 41 -0.41 ± 1.19 41 -0.19 ± 1.26
HM 46 -0.77 ± 1.37 46 -1.32 ± 1.36 46 -0.77 ± 1.20 46 -0.48 ± 1.14
HC (z-score)
PDF 50 -0.35 ± 1.02 52 0.74 ± 0.80 52 0.35 ± 0.88 52 0.26 ± 0.89
TF 41 -0.14 ± 0.92 41 0.73 ± 1.0 41 0.47 ± 0.96 41 0.34 ± 1.14
HM 46 -0.11 ± 1.37 46 0.61 ± 1.05 46 0.32 ± 1.01 46 0.33 ± 1.06
1 Values as mean ± SD. HC: head circumference; HM: human milk; PDF: postdischarge formula; TF: term formula. 
Compared between PDF, TF, and HM fed infants by linear regression adjusted for gender and gestational age; no 
significant differences between groups.
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abbrevIaTIons
AA arachidonic acid
AGA appropriate-for-gestational-age
AGA GR- appropriate-for-gestational-age without growth restriction at term age
AGA GR+ appropriate-for-gestational-age with growth restriction at term age
ALA  alpha-linolenic acid
ALP alkaline phosphatase
BA bone area
BMC bone mineral content
BMD bone mineral density
CA corrected age
CRP C-reactive protein
DoHaD developmental origins of adult health and disease
DXA dual-energy x-ray absorptiometry
DHA docosahexaenoic acid
Early EUGR extrauterine growth restriction before term age
EPA eicosapentaenoic acid
ESPGHAN European Society of Paediatric Gastroenterology Hepatology and Nutrition
EUGR extrauterine growth restriction
FM fat mass
GH growth hormone
GLA  gamma-linolenic acid
GOS galacto-oligosaccharides
HM human milk
IFF iron-fortified formula
IGF insulin-like growth factor
IGF-I insulin-like growth factor type I
IGF-II insulin-like growth factor type II
IQR interquartile range
IUGR intrauterine growth restriction
LC-PUFA long-chain polyunsaturated fatty acid
LA linoleic acid
LM lean mass
MCV mean corpuscular volume
Mo month(s)
PDF postdischarge formula
PEAPOD air displacement plethysmography
PINP procollagen type I N-terminal peptide
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PMA postmenstrual age
PTF preterm formula
PTH parathyroid hormone
RBC red blood cell
RDW red cell distribution width
SD standard deviation
SDS standard deviation score
SGA small-for-gestational-age
STEP Study Towards the Effects of Postdischarge nutrition
TF standard term formula
UHP urinary helical peptide
VLBW very low birth weight (<1500 g)
Wk week(s)
25(OH)D 25-hydroxyvitamin D
%FM percentage fat mass
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“Go confidently in the direction of your dreams. Life the life you have imagined.”
Henry David Thoureau
Promoveren, onderzoek doen en het schrijven van dit proefschrift kon ik niet alleen. De 
afgelopen drie jaar hebben veel mensen bijgedragen aan de totstandkoming van dit 
proefschrift en aan de uitvoering van het vervolgonderzoek van de STEP (de STEP 2). 
Ik ben dankbaar dat ik met plezier aan dit proefschrift heb mogen werken en veel heb 
mogen leren van de mensen met wie ik heb samengewerkt. Een aantal mensen wil ik in 
het bijzonder bedanken.
Allereerst ben ik veel dank verschuldigd aan de ouders en hun kinderen die aan de STEP 
hebben deelgenomen. Zonder jullie was het onderzoek waarop mijn proefschrift is ge-
baseerd niet mogelijk geweest! Bovendien is het fantastisch om te zien dat jullie bereid 
zijn om ook voor de STEP 2, het vervolgonderzoek op 7-jarige leeftijd, naar Amsterdam 
te komen. Zo kunnen ook de lange termijn gevolgen van de ‘postdischarge’ voeding 
onderzocht worden en leveren jullie wederom een ontzettend belangrijke bijdrage aan 
de zorg voor prematuren.
Mijn dank gaat uit naar mijn promotor en copromotoren, prof. dr. H.N. Lafeber, dr. M.M. 
van Weissenbruch en dr. J. Rotteveel. Beste Harrie, bedankt voor het vertrouwen in mij 
als onderzoeker. Jouw optimisme en jouw enthousiasme over het onderzoek waardeer 
ik zeer. Toen ik als medisch student meehielp op de polikliniek bij de STEP had ik niet 
gedacht dat ik jaren later zelf zou promoveren op dit onderzoek. Beste Mirjam, heel 
erg bedankt voor jouw betrokkenheid en bijdrage aan dit proefschrift. Jouw positief 
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